FedInvent™ Patent Applications
Application Details for Thursday, June 09, 2022
This page was updated on Thursday, June 09, 2022 at 05:43 PM GMT
Department of Health and Human Services (HHS)
| US 20220174962 | Webb et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CORNELL UNIVERSITY (Ithaca, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | James Webb (Ithaca, New York); Jing Chen (Ithaca, New York); Minglin Ma (Ithaca, New York) |
| ABSTRACT | A composition for detoxifying insect pollinators from one or more organophosphate pesticides, the composition containing microparticles comprising: (i) a phosphotriesterase; (ii) nanoparticles; and (iii) a surface active agent. Also disclosed herein is an aqueous suspension comprising the above-described detoxifying microparticles in an external aqueous medium, which may also contain an insect pollinator attractant. Also described herein is a method for detoxifying insect pollinators of one or more organophosphate pesticides, the method comprising placing the detoxifying aqueous suspension in a location accessible to the insect pollinators to permit the insect pollinators to ingest the detoxifying aqueous suspension, wherein the detoxifying aqueous suspension comprises microparticles, as described above, suspended in an external aqueous medium, typically also including an insect pollinator attractant in the external aqueous medium. |
| FILED | Tuesday, December 07, 2021 |
| APPL NO | 17/544375 |
| CURRENT CPC | Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators A01N 25/04 (20130101) A01N 25/08 (20130101) A01N 63/50 (20200101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220174963 | BLOOMQUIST, III et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Florida Research Foundation, Inc. (Gainesville, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jeffrey R. BLOOMQUIST, III (Micanopy, Florida); Edmund NORRIS (Gainesville, Florida) |
| ABSTRACT | Described herein are compositions, methods, and kits relating to insecticides. In additional embodiments according to the present disclosure, kits comprising administration devices and methods of such are also described. In embodiments according to the present disclosure, compositions and methods are described herein that comprise essential oils or plant essential oils, for example fir oil or fir needle oil, as a synergistic insecticide additive. |
| FILED | Thursday, March 26, 2020 |
| APPL NO | 17/442853 |
| CURRENT CPC | Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators A01N 43/50 (20130101) A01N 43/56 (20130101) A01N 43/78 (20130101) A01N 43/88 (20130101) A01N 53/00 (20130101) A01N 57/12 (20130101) A01N 65/06 (20130101) Original (OR) Class Biocidal, Pest Repellant, Pest Attractant or Plant Growth Regulatory Activity of Chemical Compounds or Preparations A01P 7/04 (20210801) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175006 | LONGO et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF SOUTHERN CALIFORNIA (LOS ANGELES, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Valter D. LONGO (Playa del Rey, California); Annunziata Nancy CRUPI (Los Angeles, California) |
| ABSTRACT | A dietary composition and method for treating a subject that is in need of muscle regeneration and/or maintenance and improvement of muscle mass and strength. The method includes a step of administering an FMD to a subject that is in need of muscle regeneration and/or maintenance and improvement of muscle mass and strength for a first time period. |
| FILED | Friday, December 03, 2021 |
| APPL NO | 17/541558 |
| CURRENT CPC | Coffee; Tea; Their Substitutes; Manufacture, Preparation, or Infusion Thereof A23F 3/163 (20130101) Foods, Foodstuffs, or Non-alcoholic Beverages, Not Covered by Subclasses A23B - A23J; Their Preparation or Treatment, e.g Cooking, Modification of Nutritive Qualities, Physical Treatment; Preservation of Foods or Foodstuffs, in General A23L 2/60 (20130101) A23L 7/126 (20160801) A23L 19/03 (20160801) A23L 23/00 (20160801) A23L 25/00 (20160801) A23L 33/16 (20160801) A23L 33/30 (20160801) Original (OR) Class A23L 33/155 (20160801) Indexing Scheme Relating to Foods, Foodstuffs or Non-alcoholic Beverages A23V 2002/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175007 | LONGO et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF SOUTHERN CALIFORNIA (Los Angeles, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Valter D. LONGO (Playa del Rey, California); Roberta BUONO (Newport Beach, California) |
| ABSTRACT | A method for improving immune profile and function in adults and elderly is provided. The method includes a step of providing or administering a ketogenic fasting mimicking diet to a normal subject or a subject in need of immune profile and function improvement. |
| FILED | Wednesday, December 08, 2021 |
| APPL NO | 17/545490 |
| CURRENT CPC | Coffee; Tea; Their Substitutes; Manufacture, Preparation, or Infusion Thereof A23F 3/163 (20130101) Foods, Foodstuffs, or Non-alcoholic Beverages, Not Covered by Subclasses A23B - A23J; Their Preparation or Treatment, e.g Cooking, Modification of Nutritive Qualities, Physical Treatment; Preservation of Foods or Foodstuffs, in General A23L 2/60 (20130101) A23L 7/126 (20160801) A23L 19/03 (20160801) A23L 23/00 (20160801) A23L 25/00 (20160801) A23L 33/16 (20160801) A23L 33/30 (20160801) Original (OR) Class A23L 33/155 (20160801) Indexing Scheme Relating to Foods, Foodstuffs or Non-alcoholic Beverages A23V 2002/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175253 | Verkhusha et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Albert Einstein College of Medicine (Bronx, New York); Washington University (St. Louis, Missouri) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Vladislav V. Verkhusha (St. Louis, Missouri); Andrii A. Kaberniuk (St. Louis, Missouri); Lihong Wang (St. Louis, Missouri); Junjie Yao (St. Louis, Missouri); Lei Li (St. Louis, Missouri) |
| ABSTRACT | Reversibly switchable photoacoustic tomography (RS-PAT), a photoacoustic technique with enhanced sensitivity and resolution, is disclosed. RS-PAT utilizes a subtractive process for the formation of a photoacoustic image of a region containing a plurality of switchable photoacoustic probes. In various aspects, the photoacoustic detection in RS-PAT imaging occurs minimally twice: a first image obtained when the photoacoustic probe is in active (absorbing or ON) state and a second image obtained when the photoacoustic probe is in an inactive (less-absorbing or OFF) state. Subtraction of the second image from the first image is used to obtain the RS-PAT image. |
| FILED | Wednesday, November 10, 2021 |
| APPL NO | 17/523581 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/0037 (20130101) A61B 5/0095 (20130101) Original (OR) Class A61B 5/201 (20130101) A61B 2576/02 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175285 | Gabel |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Lafayette College (Easton, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Lisa Ann Gabel (Schnecksville, Pennsylvania) |
| ABSTRACT | A virtual Hebb-Williams maze task, comprising at least four of Hebb-Williams mazes selected from the group consisting of mazes 5, 6, 8, 11, and 12; a computer implemented software capable of detecting pointer position according to a coordinate system for tracking the position and time of the user; and wherein the position and time of the user can be annotated to define a score which can be compared to a control; and wherein a score of more than one standard deviation below the control identifies a child at risk for Reading Disorder. |
| FILED | Tuesday, February 22, 2022 |
| APPL NO | 17/652003 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/16 (20130101) Original (OR) Class Educational or Demonstration Appliances; Appliances for Teaching, or Communicating With, the Blind, Deaf or Mute; Models; Planetaria; Globes; Maps; Diagrams G09B 5/08 (20130101) Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 50/20 (20180101) G16H 50/30 (20180101) Technologies for Adaptation to Climate Change Y02A 90/10 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175341 | Waag et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Habico, Inc. (Honey Falls, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Robert C. Waag (Buffalo, New York); Jeffrey P. Astheimer (Honey Falls, New York) |
| ABSTRACT | A device, system, and method for volumetric ultrasound imaging is described. The device and system include an array of transducer elements grouped in triangular planar facets and substantially configured in the shape of a hemisphere to form a cup-shaped volumetric imaging region within the cavity of the hemisphere, A plurality of data-acquisition assemblies are connected to the transducers, which are configured to collect ultrasound signals received from the transducers and transmit image data to a network of processors that are configured to construct a volumetric image of an object within the imaging region based on the image data received from the data-acquisition assemblies. |
| FILED | Thursday, October 21, 2021 |
| APPL NO | 17/507319 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 8/08 (20130101) A61B 8/14 (20130101) A61B 8/15 (20130101) A61B 8/406 (20130101) A61B 8/483 (20130101) A61B 8/0825 (20130101) Original (OR) Class A61B 8/4281 (20130101) A61B 8/4494 (20130101) A61B 8/5207 (20130101) A61B 8/5269 (20130101) Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves G01S 15/8915 (20130101) G01S 15/8929 (20130101) G01S 15/8959 (20130101) G01S 15/8977 (20130101) G01S 15/8993 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175413 | AKSIT et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Aykut AKSIT (New York, New York); Jeffrey W. KYSAR (New York, New York); Anil K. LALWANI (New York, New York); Daniel N. ARTEAGA (NEW YORK, New York) |
| ABSTRACT | An apparatus for controlled perforation and aspiration of the inner ear having a distal portion including a plurality of apices and a plurality of valleys therebetween defining a plurality of serrated blades. An apparatus for controlled penetration of a membrane of the inner ear includes a member having a distal portion, and an outer surface defining a circumference around the member, the member defines a plurality of apices extending from a distal end of said member, a plurality of valleys, wherein each valley is disposed between neighboring apices, a plurality of cutting edges defined by the plurality of apices and the plurality of valleys disposed on the outer circumference of the member; a tip at a most distal end of each of the apices, and a trailing edge extending from the tip to the center of the member. |
| FILED | Tuesday, February 22, 2022 |
| APPL NO | 17/677940 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 17/3417 (20130101) A61B 17/32053 (20130101) Original (OR) Class A61B 2017/320064 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175510 | MacEwan et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Washington University (St. Louis, Missouri) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Matthew R. MacEwan (St. Louis, Missouri); Jingwei Xie (Chesapeake, Ohio); Zack Ray (St. Louis, Missouri); Younan Xia (Atlanta, Georgia) |
| ABSTRACT | A structure of aligned (e.g., radially and/or polygonally aligned) fibers, and systems and methods for producing and using the same. One or more structures provided may be created using an apparatus that includes one or more first electrodes that define an area and/or partially circumscribe an area. For example, a single first electrode may enclose the area, or a plurality of first electrode(s) may be positioned on at least a portion of the perimeter of the area. A second electrode is positioned within the area. Electrodes with rounded (e.g., convex) surfaces may be arranged in an array, and a fibrous structure created using such electrodes may include an array of wells at positions corresponding to the positions of the electrodes. |
| FILED | Friday, July 23, 2021 |
| APPL NO | 17/383958 |
| CURRENT CPC | Filters Implantable into Blood Vessels; Prostheses; Devices Providing Patency To, or Preventing Collapsing Of, Tubular Structures of the Body, e.g Stents; Orthopaedic, Nursing or Contraceptive Devices; Fomentation; Treatment or Protection of Eyes or Ears; Bandages, Dressings or Absorbent Pads; First-aid Kits A61F 2/02 (20130101) Original (OR) Class A61F 2/0063 (20130101) A61F 2/105 (20130101) Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 15/22 (20130101) A61L 15/42 (20130101) A61L 27/14 (20130101) A61L 27/50 (20130101) Shaping or Joining of Plastics; Shaping of Material in a Plastic State, Not Otherwise Provided For; After-treatment of the Shaped Products, e.g Repairing B29C 48/05 (20190201) B29C 48/142 (20190201) Apparatus for Enzymology or Microbiology; C12M 25/14 (20130101) Mechanical Methods or Apparatus in the Manufacture of Artificial Filaments, Threads, Fibres, Bristles or Ribbons D01D 5/0076 (20130101) D01D 5/0092 (20130101) Making Textile Fabrics, e.g From Fibres or Filamentary Material; Fabrics Made by Such Processes or Apparatus, e.g Felts, Non-woven Fabrics; Cotton-wool; Wadding D04H 1/728 (20130101) D04H 3/016 (20130101) D04H 3/073 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175681 | Traverso et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts); The Brigham and Women's Hospital, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts); The Brigham and Women's Hospital Inc. (Boston, Massachusetts) |
| INVENTOR(S) | Carlo Giovanni Traverso (Newton, Massachusetts); Alex G. Abramson (St. Louis, Missouri); Ester Caffarel Salvador (Cambridge, Massachusetts); Niclas Roxhed (Bromma, Sweden); Minsoo Khang (Boston, Massachusetts); Taylor Bensel (Walpole, Massachusetts); Robert S. Langer (Newton, Massachusetts) |
| ABSTRACT | Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject). In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. In some cases, the tissue interfacing component is associated with a self-actuating component. For example, the self-righting article may comprise a self-actuating component configured, upon exposure to a fluid, to release the tissue interfacing component from the self-righting article. In some cases, the tissue interfacing component may comprise and/or be associated with the pharmaceutical agent (e.g., for delivery to a location internal to a subject). |
| FILED | Friday, October 08, 2021 |
| APPL NO | 17/497849 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/14503 (20130101) A61B 5/14539 (20130101) A61B 10/02 (20130101) A61B 10/0233 (20130101) A61B 2010/0208 (20130101) Containers Specially Adapted for Medical or Pharmaceutical Purposes; Devices or Methods Specially Adapted for Bringing Pharmaceutical Products into Particular Physical or Administering Forms; Devices for Administering Food or Medicines Orally; Baby Comforters; Devices for Receiving Spittle A61J 3/07 (20130101) Preparations for Medical, Dental, or Toilet Purposes A61K 9/0002 (20130101) A61K 9/0012 (20130101) A61K 9/0021 (20130101) A61K 9/0065 (20130101) A61K 9/0092 (20130101) A61K 9/4808 (20130101) Original (OR) Class A61K 9/4866 (20130101) A61K 38/28 (20130101) Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor A61M 5/158 (20130101) A61M 5/329 (20130101) A61M 5/2033 (20130101) A61M 5/3295 (20130101) A61M 5/14276 (20130101) A61M 31/002 (20130101) A61M 37/0015 (20130101) A61M 2005/1585 (20130101) A61M 2005/14284 (20130101) A61M 2037/0023 (20130101) A61M 2037/0053 (20130101) A61M 2205/21 (20130101) A61M 2205/0238 (20130101) A61M 2210/106 (20130101) Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 1/325 (20130101) A61N 1/0509 (20130101) A61N 1/36007 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175687 | Suk et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Johns Hopkins University (Baltimore, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jung Soo Suk (Baltimore, Maryland); Karina Negron (Baltimore, Maryland); Justin Hanes (Baltimore, Maryland) |
| ABSTRACT | Non-adhesive brain-permeable nanoparticles as large as 200 nm can diffuse rapidly in the brain ECS preferably made entirely of generally recognized as safe (GRAS) materials having neutral surface charge are described. Synergistic improvement of therapeutic distribution enabled by these non-adhesive, brain-permeable nanoparticles and osmosis-driven brain extracellular matrix (ECM) modulation will significantly enhance drug and gene delivery within the CNS, offering higher drug payload, improved drug loading efficiency, and significantly longer drug release durations. |
| FILED | Monday, April 13, 2020 |
| APPL NO | 17/602664 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/5123 (20130101) A61K 9/5146 (20130101) Original (OR) Class A61K 9/5153 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175700 | Palczewski et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CASE WESTERN RESERVE UNIVERSITY (Cleveland, Ohio) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Krzysztof Palczewski (Bay Village, Ohio); Philip Kiser (Cleveland, Ohio); Jianye Zhang (Cleveland, Ohio); Mohsen Badiee (Shaker Heights, Ohio); Gregory Tochtrop (Shaker Heights, Ohio) |
| ABSTRACT | A method of treating an ocular disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a retinal sequestering compound of formula (I). |
| FILED | Tuesday, February 22, 2022 |
| APPL NO | 17/677524 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0048 (20130101) A61K 31/137 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 27/02 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175704 | Ye et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Trustees of the Leland Stanford Junior University (Stanford, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jiangbin Ye (Stanford, California); Haowen Jiang (Stanford, California); Yang Li (Sunnyvale, California) |
| ABSTRACT | Methods are provided for the treatment of cancer by administering a mitochondrial uncoupler in a dose effective to increase differentiation of the cancer cells, which may be provided in a combination with a retinoic acid to differentiate the cancer cells. The effect on the targeted cancer cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used. The cancer may be resistant to retinoic acid. |
| FILED | Friday, December 03, 2021 |
| APPL NO | 17/542145 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/06 (20130101) A61K 31/167 (20130101) Original (OR) Class A61K 31/203 (20130101) A61K 31/225 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175705 | Tomat et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (Tucson, Arizona) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Elisa Tomat (Tucson, Arizona); Eman A. Akam (Tucson, Arizona) |
| ABSTRACT | Pro-chelator compositions featuring disulfide masks that upon activation yield active chelators. The pro-chelator compositions may be activated intracellularly, for example within cells featuring metal ion dysregulation, cells that proliferate abnormally, etc. The pro-chelators of the present invention include thiosemicarbazones, semicarbazones, and aroyl hydrazones. The pro-chelator compositions of the present invention may be used for a variety of purposes including inhibiting cell proliferation, or treating conditions associated with metal ion dysregulation or abnormal cell proliferation. |
| FILED | Thursday, February 10, 2022 |
| APPL NO | 17/668810 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/175 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175722 | Gray et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | DANA-FARBER CANCER INSTITUTE, INC. (Boston, Massachusetts) |
| ASSIGNEE(S) | DANA-FARBER CANCER INSTITUTE, INC. (Boston, Massachusetts) |
| INVENTOR(S) | Nathanael Gray (Stanford, California); Tinghu Zhang (Brookline, Massachusetts); Guangyan Du (Roslindale, Massachusetts); Nathaniel Henning (Brookline, Massachusetts); Jie Jiang (Brookline, Massachusetts) |
| ABSTRACT | The present invention relates to bispecific compounds, compositions, and methods for treating diseases or conditions characterized or mediated by aberrant fibroblast growth factor receptor 2 (FGFR2) activity. |
| FILED | Thursday, April 09, 2020 |
| APPL NO | 17/601605 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/403 (20130101) Original (OR) Class A61K 31/426 (20130101) A61K 31/473 (20130101) A61K 31/519 (20130101) A61K 47/55 (20170801) A61K 47/555 (20170801) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175730 | Mammoto et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Medical College of Wisconsin, Inc. (Milwaukee, Wisconsin) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Akiko Mammoto (Pewaukee, Wisconsin); Tadamori Mammoto (Pewaukee, Wisconsin) |
| ABSTRACT | Described herein are angiogenic stimulating compositions comprising ML141 or a derivative thereof and methods of use of said angiogenic stimulating compositions for the treatment or prevention of a disease or injury in a subject, preferably a human subject of at least 50 years of age. |
| FILED | Thursday, March 12, 2020 |
| APPL NO | 17/439382 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/06 (20130101) A61K 31/415 (20130101) Original (OR) Class Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 1/30 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175736 | Reens et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of Colorado, a body Corporate (Denver, Colorado) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Abigail L. Reens (Boulder, Colorado); Amy L. Crooks (Erie, Colorado); Corrella S. Detweiler (Boulder, Colorado) |
| ABSTRACT | An empirical Screen for Anti-infectives using Fluorescence microscopy of IntracellulaR Enterobacteriaceae (SAFIRE) was developed. Using this methodology, a library of small molecules and identified antimicrobials that are cell permeable and non-host-toxic were screened. Inhibitors of bacterial efflux pumps were identified as being implicated in antibiotic resistance and are attractive therapeutic targets for antimicrobials. |
| FILED | Friday, July 30, 2021 |
| APPL NO | 17/389748 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/65 (20130101) A61K 31/426 (20130101) Original (OR) Class A61K 31/506 (20130101) A61K 31/517 (20130101) A61K 38/12 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/18 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175738 | Lough et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Medical College of Wisconsin, Inc. (Milwaukee, Wisconsin) |
| ASSIGNEE(S) | |
| INVENTOR(S) | John William Lough (Elm Grove, Wisconsin); John Allen Auchampach (Elm Grove, Wisconsin) |
| ABSTRACT | The present invention relates to compositions and methods of inducing cardiomyocyte proliferation by transiently contacting the cardiomyocytes with a Tip60 inhibitor. The present invention also provides methods of treating cardiac injury, myocardial infarction and methods of regenerating cardiac tissue. |
| FILED | Tuesday, March 31, 2020 |
| APPL NO | 17/442968 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/427 (20130101) Original (OR) Class A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 9/04 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175742 | Xu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Kentucky Research Foundation (Lexington, Kentucky) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ren Xu (Lexington, Kentucky); Shike Wang (Lexington, Kentucky) |
| ABSTRACT | The present invention relates to a methods for modulating Collagen Prolyl 4-hydroxylase (C-P4H1) in a cell. The present invention further relates to methods for inhibiting a cancer cell. The instant invention also relates to methods for identifying modulators of Collagen Prolyl 4-hydroxylase (C-P4H1). |
| FILED | Monday, February 28, 2022 |
| APPL NO | 17/682856 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/216 (20130101) A61K 31/337 (20130101) A61K 31/404 (20130101) A61K 31/4365 (20130101) Original (OR) Class Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/582 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175750 | HAUDENSCHILD et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); Tesio Pharmaceuticals, Inc. (Davis, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Dominik R. HAUDENSCHILD (Oakland, California); Jasper H. N. YIK (Oakland, California); Jamal S. LEWIS (Oakland, California); Tom YARBROUGH (Davis, California) |
| ABSTRACT | The present disclosure describes a novel sustained-release formulation for the local delivery of CDK9 inhibitors. |
| FILED | Tuesday, April 23, 2019 |
| APPL NO | 17/049798 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/5031 (20130101) A61K 31/453 (20130101) Original (OR) Class A61K 31/519 (20130101) A61K 31/4025 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 19/02 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175763 | Li et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | DUKE UNIVERISTY (Durham, North Carolina) |
| ASSIGNEE(S) | DUKE UNIVERSITY (Durham, North Carolina) |
| INVENTOR(S) | Chuan-Yuan Li (Durham, North Carolina); Mengjie Hu (Durham, North Carolina); Min Zhou (Durham, North Carolina); Fang Li (Durham, North Carolina) |
| ABSTRACT | The present disclosure provides, in part, compositions and methods for enhancing the efficacy of immune checkpoint blockade therapy in a subject. Methods for identifying subjects that are appropriate for immune checkpoint blockade therapy are also provided. |
| FILED | Friday, March 20, 2020 |
| APPL NO | 17/439903 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/4745 (20130101) Original (OR) Class A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 16/2818 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175767 | Shanmugam et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Emory University (Atlanta, Georgia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Malathy Shanmugam (Atlanta, Georgia); Richa Bajpai (Decatur, Georgia) |
| ABSTRACT | In certain embodiments, this disclosure relates to method of treating and diagnosing cancer by administering a Bcl-2 inhibitor optionally in combination with a mitochondrial complex II inhibitor. In certain embodiments, a subject is diagnosed with, exhibiting symptoms of, or at risk of cancer wherein the cancer is a hematological malignancy such as multiple myeloma, leukemia, or lymphoma. |
| FILED | Monday, February 21, 2022 |
| APPL NO | 17/676666 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/44 (20130101) A61K 31/381 (20130101) A61K 31/496 (20130101) Original (OR) Class A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/02 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175777 | Wise et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Southern Methodist University (Dallas, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | John G. Wise (Dallas, Texas); Pia D. Vogel (Dallas, Texas); Frances K. Brewer (Waxahachie, Texas); Courtney A. Follit (Dallas, Texas) |
| ABSTRACT | The present disclosure provides a method of treating a subject that is resistant to one or more drugs by identifying a subject having one or more drug resistant cells; administering to the subject a pharmaceutically effective amount of an inhibitor compound, and contacting one or more drug resistant cells with the inhibitor compound to reduce the export of the inhibitor compound from the one or more drug resistant tumor cells and to block the transport of drug(s) from the one or more drug resistant cells. |
| FILED | Wednesday, January 26, 2022 |
| APPL NO | 17/585286 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/352 (20130101) A61K 31/353 (20130101) A61K 31/4196 (20130101) A61K 31/4525 (20130101) A61K 31/5025 (20130101) Original (OR) Class A61K 45/06 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175778 | ROBICHAUX et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Board of Regents, The University of Texas System (Austin, Texas) |
| ASSIGNEE(S) | Board of Regents, The University of Texas System (Austin, Texas) |
| INVENTOR(S) | Jacqulyne ROBICHAUX (Houston, Texas); John V. HEYMACH (Houston, Texas) |
| ABSTRACT | The present disclosure provides methods of treating cancer in a patient determined to have an HER2 exon 21 mutation by administering a third-generation tyrosine kinase inhibitor, such as poziotinib. |
| FILED | Friday, March 27, 2020 |
| APPL NO | 17/600017 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/517 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 14/71 (20130101) C07K 14/82 (20130101) C07K 14/70596 (20130101) C07K 16/32 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/12 (20130101) Enzymes C12Y 207/10001 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175791 | Klausner |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jeffrey D. Klausner (Los Angeles, California) |
| ABSTRACT | Disclosed herein are methods for assaying whether a given Neisseria species, such as a given Neisseria gonorrhoeae strain, is susceptible to a cefixime compound and treatment methods based on the assay results. |
| FILED | Tuesday, April 14, 2020 |
| APPL NO | 17/599008 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/546 (20130101) Original (OR) Class A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/04 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175804 | FARESE et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF SOUTH FLORIDA (Tampa, Florida); UNITED STATES DEPARTMENT OF VETERANS AFFAIRS (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Robert Vito FARESE (St. Petersburg, Florida); Mini Paliyath SAJAN (Wesley Chapel, Florida); Margaret Genevieve HIGGS (St. Petersburg, Florida) |
| ABSTRACT | Provided herein are formulations effective for and methods of treating or preventing a neurodegenerative disorder in a subject in need thereof that can include administering an amount of an aPKC inhibitor to a subject in need thereof. |
| FILED | Friday, December 17, 2021 |
| APPL NO | 17/554924 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/122 (20130101) A61K 31/675 (20130101) Original (OR) Class A61K 33/242 (20190101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/28 (20180101) Enzymes C12Y 304/23046 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175810 | Pyle et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Yale University (New Haven, Connecticut) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Anna Marie Pyle (Guilford, Connecticut); Akiko Iwasaki (Guilford, Connecticut); Tianyang Mao (New Haven, Connecticut) |
| ABSTRACT | The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises a 5′-triphosphate or a 5′-diphosphate. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection, and/or ameliorating, minimizing, reversing, and/or preventing persistent SARS-CoV-2 viral infection, and/or minimizing or preventing SARS-CoV-2 viral infection-derived mortality and/or lethality, in a subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in a tumor-bearing subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in an immune-compromised and/or immunodeficient subject. |
| FILED | Tuesday, December 28, 2021 |
| APPL NO | 17/563686 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/7052 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/14 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/113 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175816 | Fukuda et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Massachusetts (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Keitaro Fukuda (Worcester, Massachusetts); John E. Harris (Sterling, Massachusetts); Anastasia Khvorova (Westborough, Massachusetts); Kate Fitzgerald (Wellesley, Massachusetts) |
| ABSTRACT | Described herein are AIM2 inhibitors (e.g., inhibitory nucleic acids), vectors, cells (e.g., dendritic cells), and compositions comprising same, and methods of using same in the treatment of cancer (e.g., melanoma). |
| FILED | Thursday, April 16, 2020 |
| APPL NO | 17/601522 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/713 (20130101) Original (OR) Class Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/113 (20130101) C12N 2310/14 (20130101) C12N 2310/315 (20130101) C12N 2310/343 (20130101) C12N 2310/346 (20130101) C12N 2310/3515 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175836 | Lum et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Virginia Patent Foundation (Charlottesville, Virginia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Lawrence G. Lum (Charlottesville, Virginia); Archana Thakur (Zion Crosseroads, Virginia) |
| ABSTRACT | Methods and compositions for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a targeted activated T cell, such as a bispecific antibody armed activated T cell (BAT), alone or in combination with an effective amount or a subtherapeutic amount of an additional therapeutic agent, wherein the targeted activated T cell selectively binds a cell of the cancer in the subject. |
| FILED | Friday, March 27, 2020 |
| APPL NO | 17/598567 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 35/17 (20130101) Original (OR) Class A61K 39/001104 (20180801) A61K 39/001106 (20180801) A61K 45/06 (20130101) A61K 2039/5158 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175844 | BERNSTEIN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Steven BERNSTEIN (Chevy Chase, Maryland); Candace L. KERR (Westminster, Maryland); Sally A. TEMPLE (Slingerlands, New York); University of Maryland, Baltimore (Baltimore, Maryland); REGENERATIVE RESEARCH FOUNDATION (Rensselaer, New York) |
| ASSIGNEE(S) | University of Maryland, Baltimore (Baltimore, Maryland); REGENERATIVE RESEARCH FOUNDATION (Rensselaer, New York) |
| INVENTOR(S) | Steven Lance BERNSTEIN (Chevy Chase, Maryland); Candace L. KERR (Westminster, Maryland); Sally TEMPLE STERN (Slingerlands, New York) |
| ABSTRACT | Optic nerve lamina region neural progenitor cells (ONLR-NPCs) are provided. Such cells secrete growth factors and survival factors that can be used in the treatment of optic nerve diseases, such as glaucoma. Also provided are methods of treating or preventing optic nerve diseases, such as glaucoma, using one or more factors secreted by ONLR-NPCs, combinations of factors secreted by ONLR-NPCs, or culture media conditioned by ONLR-NPCs. |
| FILED | Friday, February 01, 2019 |
| APPL NO | 16/966204 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 35/30 (20130101) Original (OR) Class A61K 38/18 (20130101) A61K 38/185 (20130101) A61K 38/1825 (20130101) A61K 38/1841 (20130101) A61K 38/1866 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 27/06 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175845 | Hodgkinson et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Duke University (Durham, North Carolina) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Conrad P. Hodgkinson (Durham, North Carolina); Victor J. Dzau (Durham, North Carolina) |
| ABSTRACT | The invention provides a method of promoting reprogramming of a cardiac fibroblast into a cardiomyocyte by contacting the cardiac fibroblast with an isolated polynucleotide molecule comprising at least two functional miRNA sequences using a multicistronic expression system for reprogramming of fibroblasts into functional mature cardiomyocytes. |
| FILED | Friday, December 03, 2021 |
| APPL NO | 17/541917 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 35/33 (20130101) Original (OR) Class Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0657 (20130101) C12N 15/113 (20130101) C12N 2310/141 (20130101) C12N 2320/31 (20130101) C12N 2501/65 (20130101) C12N 2501/999 (20130101) C12N 2506/1307 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175851 | Hsiao et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the UniversityCalifornia (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Elaine Y. Hsiao (Los Angeles, California); Geoffrey N. Pronovost (Los Angeles, California) |
| ABSTRACT | Disclosed herein are methods for promoting fetal growth, placental development, and angiogenesis, comprising administering to a female subject or to a maternal subject gestating an unborn baby (e.g., fetus) a composition of the present disclosure. Also disclosed are methods of inhibiting development of a disease or disorder, such as preeclampsia or fetal growth reduction (FGR), in a subject, comprising administering to a female subject or to a maternal subject gestating an unborn baby (e.g., fetus) a composition of the present disclosure. |
| FILED | Friday, March 13, 2020 |
| APPL NO | 17/437643 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/353 (20130101) A61K 31/575 (20130101) A61K 35/74 (20130101) Original (OR) Class A61K 38/18 (20130101) A61K 38/1875 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 3/02 (20180101) A61P 15/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175856 | Brady |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Rockefeller University (New York, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sean Brady (New York, New York) |
| ABSTRACT | The present invention relates to microorganisms and microbial metabolites derived therefrom that bind to a receptor and methods of use thereof |
| FILED | Monday, April 20, 2020 |
| APPL NO | 17/604106 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/20 (20130101) A61K 31/192 (20130101) A61K 31/7088 (20130101) A61K 35/745 (20130101) Original (OR) Class A61K 35/747 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175872 | Ziouzenkova et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Ohio State Innovation Foundation (Columbus, Ohio) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ouliana Ziouzenkova (Columbus, Ohio); Jonathan R. Parquette (Hilliard, Ohio) |
| ABSTRACT | Thermogenic molecules and methods of using these molecules for treating or preventing a condition in a subject selected from the group consisting of visceral fat accumulation (e.g., Crohn's disease associated with visceral fat accumulation), obesity, diabetes, pre-diabetes, hypothermia, and chronic inflammation are disclosed. Also disclosed is a method for promoting glucose uptake in peripheral tissues (e.g., adipocytes and muscles) of a subject, enhancing nerve innervation in a subject, activating PI3 kinase in cell, and inducing leptin secretion by an adipocyte. Also disclosed are inhibitors of thermogenic molecules and methods of using these inhibitors to decrease thermogenesis of adipocytes in a subject. Also disclosed are self-assembled, biocompatible nanostructure non-covalently associated with a therapeutic or diagnostic peptide or peptidomimetic. |
| FILED | Tuesday, July 20, 2021 |
| APPL NO | 17/380536 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/05 (20130101) A61K 38/07 (20130101) Original (OR) Class A61K 47/54 (20170801) A61K 47/545 (20170801) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 3/04 (20180101) A61P 3/10 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175877 | Khaled et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Central Florida Research Foundation, Inc. (Orlando, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Annette Khaled (Orlando, Florida); Rebecca Boohaker (Orlando, Florida); Michael Lee (Orlando, Florida); Jesus Perez Figueroa (Orlando, Florida) |
| ABSTRACT | In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells. |
| FILED | Monday, November 22, 2021 |
| APPL NO | 17/532597 |
| CURRENT CPC | Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators A01N 43/38 (20130101) Preparations for Medical, Dental, or Toilet Purposes A61K 9/513 (20130101) A61K 9/5153 (20130101) A61K 38/10 (20130101) Original (OR) Class A61K 38/16 (20130101) A61K 38/1761 (20130101) A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 7/08 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175886 | PONCZ et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (PHILADELPHIA, Pennsylvania) |
| ASSIGNEE(S) | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (PHILADELPHIA, Pennsylvania) |
| INVENTOR(S) | Mortimer PONCZ (Philadelphia, Pennsylvania); Kandace GOLLOMP (Philadelphia, Pennsylvania); Lubica RAUVO (Philadelphia, Pennsylvania); Anna M. KOWALSKA (Philadelphia, Pennsylvania) |
| ABSTRACT | The present disclosure is directed to the use of PF4 alone or anti-PF4 antibodies alone or the combination thereof to treat sepsis. Neutrophils release their histone-coated DNA termed neutrophil extracellular traps (NETs) during sepsis and related inflammatory disorders. NETs are broken down and release NET degradation products (NDPs) like histone that are toxic and contribute to the morbidity and mortality in sepsis and related inflammatory disorders. The inventors have shown that a native platelet protein, platelet factor 4 (PF4), which is highly positively-charged, compacts NETs that are in turn highly negatively-charged. These compact NETs are resistant to NDP release and breakdown by circulating DNases. PF4 protects against this lysis and NDP release and improves outcome. The inventors also found that an antibody to PF4 that cross-binds PF4 on NETs further protects against lysis and NDP release. Such antibodies, perhaps supplemented with additional PF4, are therapeutic candidates for treatment of sepsis. |
| FILED | Thursday, August 29, 2019 |
| APPL NO | 17/275412 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/195 (20130101) Original (OR) Class A61K 2039/505 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/04 (20180101) Peptides C07K 16/24 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175892 | Newman et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CALIFORNIA INSTITUTE OF TECHNOLOGY (Pasadena, California); YEDA RESEARCH and DEVELOPMENT CO LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE (Rehovot, Israel) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Dianne K Newman (Pasadena, California); Chelsey M VanDrisse (Pasadena, California); Rosalie Lipsh-Sokolik (Rehovot, Israel); Olga Khersonsky (Rehovot, Israel); Sarel J Fleishman (Rehovot, Israel) |
| ABSTRACT | Provided herein are engineered pyocyanine demethylases having replacements in in positions A53, I73, A87, T91, M99, A129 and K141 of pyocyanine demethylase PodA of SEQ ID NO: 1 or a derivative thereof and related phenazine degrading agents, compositions methods and systems, as well as a combined administration of one or more pyocyanine demethylases and antibiotics and/or antibiotics resulting in a synergic inhibition of viability of phenazine producing bacteria, and related phenazine degrading agents, compositions methods and systems. |
| FILED | Friday, November 05, 2021 |
| APPL NO | 17/520345 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/7036 (20130101) A61K 38/44 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/04 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/0004 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175904 | Pier et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Brigham and Women's Hospital, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | The Brigham and Women's Hospital, Inc. (Boston, Massachusetts) |
| INVENTOR(S) | Gerald B. Pier (Brookline, Massachusetts); Nikolay Nifantiev (Moscow, Russian Federation); Yury Tsvetkov (Moscow, Russian Federation); Marina Gening (Moscow, Russian Federation) |
| ABSTRACT | The invention relates to the compositions of synthetic oligo-γ-(1→6)-2-amino-2-deoxy-D-glu-copyranosides conjugated to carriers, and methods for making and use same. |
| FILED | Friday, August 20, 2021 |
| APPL NO | 17/408287 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/085 (20130101) Original (OR) Class A61K 47/646 (20170801) A61K 47/6415 (20170801) A61K 2039/6037 (20130101) Acyclic or Carbocyclic Compounds C07C 327/32 (20130101) Heterocyclic Compounds C07D 207/46 (20130101) Sugars; Derivatives Thereof; Nucleosides; Nucleotides; Nucleic Acids C07H 3/06 (20130101) Peptides C07K 16/1232 (20130101) C07K 16/1271 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175935 | Serafini et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF MIAMI (Miami, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Paolo Serafini (Miami Shores, Florida); Silvio Bicciato (Modena, Italy); Jimmy Caroli (Modena, Italy); Adriana De La Fuente (Miami, Florida); Dimitri Van Simaeys (Miami Beach, Florida); Serena Zilio (Miami, Florida); Vincenzo Bronte (Verona, Italy) |
| ABSTRACT | Described herein and RNA aptamers that specifically bind to tumor-infiltrating myeloid cells and uses thereof. |
| FILED | Tuesday, March 03, 2020 |
| APPL NO | 17/436773 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/704 (20130101) A61K 31/711 (20130101) A61K 31/7105 (20130101) A61K 47/549 (20170801) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175936 | Gendelman et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Board of Regents of the University of Nebraska (Lincoln, Nebraska) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Howard Gendelman (Omaha, Nebraska); Benson Edagwa (Omaha, Nebraska) |
| ABSTRACT | The present invention provides prodrugs and methods of use thereof. |
| FILED | Wednesday, November 27, 2019 |
| APPL NO | 17/309435 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/146 (20130101) A61K 47/55 (20170801) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/18 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175941 | Ruoslahti et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Sanford Burnham Prebys Medical Discovery Institute (La Jolla, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Erkki Ruoslahti (La Jolla, California); Tambet Teesalu (La Jolla, California); Kazuki Sugahara (La Jolla, California) |
| ABSTRACT | Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest. |
| FILED | Monday, July 12, 2021 |
| APPL NO | 17/373496 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 47/66 (20170801) Original (OR) Class Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 5/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175953 | Green et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Johns Hopkins University (Baltimore, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jordan J. Green (Nottingham, Maryland); Randall A. Meyer (Baltimore, Maryland); Elana Ben-Akiva (Baltimore, Maryland) |
| ABSTRACT | The presently disclosed subject matter provides a biomimetic particle platform that can be used to simulate natural cells found throughout the body. The particle comprises a polymeric core of defined shape, size, and mechanical properties and a surface comprising naturally derived cell membranes, such as red blood cells or platelets. Together these features enable a level of biomimicry that can be appropriated for various drug delivery applications and cell engineering applications. |
| FILED | Tuesday, December 14, 2021 |
| APPL NO | 17/550542 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/5068 (20130101) A61K 39/3955 (20130101) A61K 47/6901 (20170801) Original (OR) Class A61K 49/0002 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175956 | Mirkin et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | NORTHWESTERN UNIVERSITY (Evanston, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Chad A. Mirkin (Wilmette, Illinois); Gokay Yamankurt (Chicago, Illinois); Matthew K. Vasher (Pickney, Michigan) |
| ABSTRACT | The disclosure is generally related to oligonucleotides having a hairpin-like structure, nanoparticles comprising the same, and methods of using the same. |
| FILED | Thursday, March 05, 2020 |
| APPL NO | 17/435903 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 47/6923 (20170801) Original (OR) Class A61K 47/6937 (20170801) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/1138 (20130101) C12N 2310/14 (20130101) C12N 2310/122 (20130101) C12N 2310/351 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175957 | Kamata et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | The Regents of the University of California (Oakland, California) |
| INVENTOR(S) | Masakazu Kamata (Los Angeles, California); Irvin S.Y. Chen (Palos Verdes Estates, California); Yunfeng Lu (Culver City, California); Jing Wen (Culver City, California) |
| ABSTRACT | CNS metastases are a major cause of cancer deaths with few therapeutic options for treatment. Monoclonal anti-body-based therapy is one of the most successful therapeutic strategies for cancer; however, its efficacy is limited against CNS metastases due to insufficient CNS delivery. Here, we show significantly improved antibody delivery to the CNS using novel timed-release nanocapsules that encapsulate individual antibodies within a crosslinked phosphorylcholine polymer and gradually release cargo through hydrolysable crosslinkers. A single course of rituximab (RTX) nanocapsule treatment elevates RTX levels in the CNS by nearly 10-fold compared to native RTX. We improved control of CNS metastases in a murine xenograft model of non-Hodgkin lymphoma; moreover, using a xenograft humanized BLT mouse model, lymphomas were eliminated with a single course of RTX nanocapsule treatment. This approach is useful for treatment of cancers with CNS metastases and is generalizable for delivery of any antibody to the CNS. |
| FILED | Wednesday, February 19, 2020 |
| APPL NO | 17/425857 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/5138 (20130101) A61K 9/5153 (20130101) A61K 45/06 (20130101) A61K 47/58 (20170801) A61K 47/62 (20170801) A61K 47/6925 (20170801) Original (OR) Class Peptides C07K 14/521 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175964 | Duan et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE CURATORS OF THE UNIVERSITY OF MISSOURI (Columbia, Missouri) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Dongsheng Duan (Columbia, Macau); Yi Lai (Columbia, Missouri); Junling Zhao (Columbia, Missouri); Yongping Yue (Columbia, Missouri) |
| ABSTRACT | Synthetic nucleic acids encoding mini and microdystrophin genes comprising the membrane binding motifs or domains of the R10-R11-R12 region are provided. Also provided are vectors, host cells, and related methods of using the same to treat a subject suffering from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) or X-linked dilated cardiomyopathy (XLDC), or for ameliorating one or more adverse effects of DMD, BMD, or XLDC. Also provided are a fusion protein comprising a nNOS binding domain of dystrophin R16-R17 that is operably linked to a syntrophin PDZ domain and synthetic nucleic acids comprising the same that can be used to treat subjects with diseases characterized by loss of sarcolemmal neuronal nitric oxide synthase (nNOS) activity. |
| FILED | Friday, December 17, 2021 |
| APPL NO | 17/555233 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0019 (20130101) A61K 35/28 (20130101) A61K 38/00 (20130101) A61K 48/00 (20130101) A61K 48/005 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/14 (20180101) Peptides C07K 14/4716 (20130101) C07K 2319/00 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0663 (20130101) C12N 15/62 (20130101) C12N 15/85 (20130101) C12N 15/86 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175969 | Dyka et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Florida Research Foundation, Incorporated (Gainesville, Florida) |
| ASSIGNEE(S) | University of Florida Research Foundation, Incorporated (Gainesville, Florida) |
| INVENTOR(S) | Frank M. Dyka (Gainesville, Florida); William W. Hauswirth (Gainesville, Florida) |
| ABSTRACT | The present disclosure provides short enhanced human opsin promoters for rod-specific expression that satisfy a need in the art for promoters that are able to control transgene expression both efficiently and selectively in rod cells, with little to no off-target expression in other photoreceptor cells. The disclosure provides vector constructs comprising transgenes operably controlled by this enhanced human opsin promoter that may be delivered and targeted with high specificity to rod cells. The disclosure also provides compositions comprising these vector constructs and methods for administration of these compositions to subjects in need thereof. |
| FILED | Wednesday, March 04, 2020 |
| APPL NO | 17/436510 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 48/0058 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 27/00 (20180101) Peptides C07K 14/705 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/86 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175978 | Turker et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CORNELL UNIVERSITY (Ithaca, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Melik Z. Turker (Princeton, New Jersey); Thomas C. Gardinier (Raritan, New Jersey); Ulrich B. Wiesner (Ithaca, New York) |
| ABSTRACT | Silica nanorings, methods of making silica nanorings, and uses of silica nanorings. The silica nanorings may be surface selective functionalization, with one or more polyethylene glycol (PEG) group(s), one or more display group(s), one or more functional group(s), or a combination thereof. The silica nanorings may have a size of 5 to 20 nm. The silica nanorings may be made using micelles. The absence or presence of the micelles during PEGylation and/or functionalization allows for the surface selective functionalization. The silica nanorings may be used in various diagnostic and/or treatment methods. |
| FILED | Wednesday, April 15, 2020 |
| APPL NO | 17/603494 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/14 (20130101) A61K 49/04 (20130101) A61K 49/005 (20130101) A61K 49/0039 (20130101) A61K 49/0041 (20130101) A61K 51/1244 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175986 | MATSUMOTO et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Ushio Denki Kabushiki Kaisha (Tokyo, Japan); Director General of National Institute of Health Sciences (Kanagawa, Japan) |
| ASSIGNEE(S) | Ushio Denki Kabushiki Kaisha (Tokyo, Japan); Director General of National Institute of Health Sciences (Kanagawa, Japan) |
| INVENTOR(S) | Hiroko MATSUMOTO (Tokyo, Japan); Makoto YAMANAKA (Tokyo, Japan); Fumitoshi TAKEMOTO (Tokyo, Japan); Kenji HATAKEYAMA (Tokyo, Japan); Yuji HAISHIMA (Kawasaki-shi, Japan); Yukiko KUDO (Kawasaki-shi, Japan); Yutaka KIKUCHI (Kawasaki-shi, Japan); Chie FUKUI (Kawasaki-shi, Japan) |
| ABSTRACT | Disclosed herein is a method for decontaminating an object to be treated by reducing the activity of endotoxin in a simple manner. The decontamination method includes a step (a) of irradiating an object to be treated with ultraviolet light of a wavelength of less than 200 nm to reduce activity of endotoxin attached to the object to be treated. |
| FILED | Wednesday, March 11, 2020 |
| APPL NO | 17/440689 |
| CURRENT CPC | Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 2/10 (20130101) Original (OR) Class A61L 2202/11 (20130101) A61L 2202/24 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220176096 | AKSIT et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (NEW YORK, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Aykut AKSIT (New York, New York); Anil K. LALWANI (New York, New York); Jeffrey W. KYSAR (New York, New York); Alan WEST (New York, New York) |
| ABSTRACT | The disclosed subject matter relates to a system and method for delivery of therapeutic agents across membranes such as to the inner ear. The system includes a plurality of microneedles that can be delivered to the round window membrane by a delivery device, e.g. catheter, and is capable of controlled penetration of the round window membrane to create temporary and self-closing perforations. |
| FILED | Friday, February 18, 2022 |
| APPL NO | 17/675440 |
| CURRENT CPC | Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor A61M 37/0015 (20130101) Original (OR) Class A61M 2037/003 (20130101) A61M 2037/0007 (20130101) A61M 2037/0023 (20130101) A61M 2037/0046 (20130101) A61M 2037/0053 (20130101) A61M 2205/583 (20130101) A61M 2210/0662 (20130101) Processes for the Electrolytic or Electrophoretic Production of Coatings; Electroforming; Apparatus Therefor C25D 1/02 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177418 | Rettig et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); The United States Government represented by the Department of Veterans Affairs (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Matthew Rettig (Los Angeles, California); Michael E. Jung (Los Angeles, California); D. Elshan Nakath G. Ralalage (Los Angeles, California); Jiabin An (Los Angeles, California) |
| ABSTRACT | The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer. |
| FILED | Friday, March 27, 2020 |
| APPL NO | 17/599083 |
| CURRENT CPC | Acyclic or Carbocyclic Compounds C07C 49/537 (20130101) C07C 49/697 (20130101) C07C 69/618 (20130101) C07C 233/13 (20130101) Original (OR) Class C07C 233/40 (20130101) C07C 233/91 (20130101) C07C 235/76 (20130101) C07C 255/46 (20130101) C07C 307/04 (20130101) C07C 2601/02 (20170501) Heterocyclic Compounds C07D 207/38 (20130101) C07D 207/273 (20130101) C07D 211/70 (20130101) C07D 213/46 (20130101) C07D 263/32 (20130101) C07D 303/32 (20130101) C07D 307/46 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177422 | SOLWAY et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The University of Chicago (Chicago, Illinois); The United States of America,as Represented by the Secretary, Department of Health and Human Servic (Bethesda, Maryland); President and Fellows of Harvard College (Cambridge, Massachusetts); IIT Research Institute (Chicago, Illinois); Beth Israel Deaconess Medical Center, Inc. (Boston, Massachusetts); REGENTS OF THE UNIVERSITY OF MINNESOTA (Minneapolis, Minnesota); THE TRUSTEES OF PURDUE UNIVERSITY (West Lafayette, Indiana) |
| ASSIGNEE(S) | The University of Chicago (Chicago, Illinois); The United States of America,as Represented by the Secretary, Department of Health and Human Servic (Bethesda, Maryland); President and Fellows of Harvard College (Cambridge, Massachusetts); IIT Research Institute (Chicago, Illinois); Beth Israel Deaconess Medical Center, Inc. (Boston, Massachusetts) |
| INVENTOR(S) | Julian SOLWAY (, None); Nickolai DULIN (, None); Diane Luci (, None); David MALONEY (, None); Chan Young PARK (, None); Jeffrey FREDBERG (, None); David MCCORMICK (, None); Ramaswamy KRISHNAN (, None) |
| ABSTRACT | Disclosed herein is a class of molecules termed remodilins that are effective in treating asthma, pulmonary fibrosis, and associated disorders. The molecules ameliorate asthma and pulmonary fibrosis symptoms by various mechanisms, including inhibiting airway smooth muscle contractile protein accumulation, reducing airway constrictor hyperresponsiveness, inhibiting bronchial fibroblast transformation into myofibroblasts, and/or treating or preventing airway or pulmonary fibrosis. |
| FILED | Thursday, April 02, 2020 |
| APPL NO | 17/594086 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 11/00 (20180101) Acyclic or Carbocyclic Compounds C07C 311/46 (20130101) Original (OR) Class C07C 2601/16 (20170501) Heterocyclic Compounds C07D 207/48 (20130101) C07D 211/96 (20130101) C07D 277/52 (20130101) C07D 295/26 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177425 | Bannister et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE SCRIPPS RESEARCH INSTITUTE (La Jolla, California); THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (Albany, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Thomas D. Bannister (Palm Beach Gardens, Florida); Chao Wang (Palm Beach Gardens, Florida); Agnieszka Bialkowska (East Setauket, New York); Vincent Yang (East Setauket, New York) |
| ABSTRACT | The present disclosure provides compounds of formula (I), as described herein, their pharmaceutically acceptable salts, and their pharmaceutical compositions, which are effective in reducing the expression level of KLF5 or EGR1 in a living cell, and for the treatment of tumors and colorectal cancer in a human patient. |
| FILED | Friday, April 10, 2020 |
| APPL NO | 17/602924 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Heterocyclic Compounds C07D 207/09 (20130101) Original (OR) Class C07D 207/48 (20130101) C07D 211/28 (20130101) C07D 211/96 (20130101) C07D 243/08 (20130101) C07D 295/26 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177443 | Verano et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | DANA-FARBER CANCER INSTITUTE, INC. (Boston, Massachusetts) |
| ASSIGNEE(S) | DANA-FARBER CANCER INSTITUTE, INC. (Boston, Massachusetts) |
| INVENTOR(S) | Alyssa Verano (Allston, Massachusetts); Eric Wang (Brookline, Massachusetts); Radoslaw Nowak (Boston, Massachusetts); Jing Ting Christine Yuan (Brookline, Massachusetts); Nathanael Gray (Boston, Massachusetts); Eric Fischer (Chestnut Hill, Massachusetts); Tinghu Zhang (Brookline, Massachusetts); Hu Liu (Newton, Massachusetts) |
| ABSTRACT | Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that may cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders characterized or mediated by aberrant protein activity. |
| FILED | Tuesday, December 03, 2019 |
| APPL NO | 17/298823 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Heterocyclic Compounds C07D 401/04 (20130101) Original (OR) Class C07D 401/14 (20130101) C07D 417/14 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177452 | Pathak et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Southern Research Institute (Birmingham, Alabama); Oregon Health and Science University (Portland, Oregon) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ashish Kumar Pathak (Birmingham, Alabama); Corinne E. Augelli-Szafran (Homewood, Alabama); Atefeh Garzan (Hoover, Alabama); Daniel Steblow (Banks, Oregon); Nicole Haese (Beaverton, Oregon) |
| ABSTRACT | The present disclosure is concerned with 2-pyrimidone compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. |
| FILED | Friday, April 02, 2021 |
| APPL NO | 17/221666 |
| CURRENT CPC | Heterocyclic Compounds C07D 213/69 (20130101) C07D 213/70 (20130101) C07D 213/74 (20130101) C07D 403/04 (20130101) Original (OR) Class C07D 491/052 (20130101) C07D 498/08 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177457 | KRIWACKI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | St. Jude Children's Hospital, Inc. (Memphis, Japan) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Richard KRIWACKI (Memphis, Tennessee); Jian ZUO (Memphis, Tennessee); Luigi ICONARU (Memphis, Tennessee); Sourav DAS (Memphis, Tennessee); Anang SHELAT (Memphis, Tennessee); Brandon YOUNG (Memphis, Tennessee) |
| ABSTRACT | Various compounds and pharmaceutically acceptable salts thereof are provided capable of binding cyclin-dependent kinase inhibitor 1B. The compounds can have a structure according to Formula I or Formula II as detailed herein. The compounds can include SJ747, SJ749, SJ755, SJ757. Pharmaceutical formulations containing the compounds or pharmaceutically acceptable salts are also provided along with methods of use thereof. The formulations and methods can be useful for treating cancer. In some aspects, the cancer is associated with a mislocalization of the intrinsically disordered protein p27. In some aspects, the cancer is resistant to an anticancer therapy. The pharmaceutical formulation can therefore include a second active agent and/or can be given in combination with a second active agent such as a cancer therapeutic. In various aspects, methods of promoting reentry into the cell division cycle in a subject in need thereof using compounds and formulations described herein are also provided. |
| FILED | Thursday, March 12, 2020 |
| APPL NO | 17/438857 |
| CURRENT CPC | Heterocyclic Compounds C07D 405/12 (20130101) Original (OR) Class C07D 405/14 (20130101) C07D 407/14 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177464 | MURPHY et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Icahn School of Medicine At Mount Sinai (New York, New York) |
| ASSIGNEE(S) | Icahn School of Medicine At Mount Sinai (New York, New York) |
| INVENTOR(S) | Barbara MURPHY (New York, New York); Bhaskar DAS (New York, New York); Chengguo WEI (New York, New York); Li LI (New York, New York) |
| ABSTRACT | Compounds which are thiazole and triazole derivatives are disclosed, including compounds of the following genus: The compounds are inhibitors of hematopoietic cell kinase (HCK) and exhibit anti-fibrotic and anti-proliferative effects. They are useful in the treatment of a variety of disorders, including a fibrosis or a fibrotic disease, such as renal fibrosis. |
| FILED | Wednesday, April 01, 2020 |
| APPL NO | 17/593960 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 13/12 (20180101) Heterocyclic Compounds C07D 249/12 (20130101) C07D 277/56 (20130101) C07D 417/12 (20130101) Original (OR) Class C07D 513/04 (20130101) Acyclic, Carbocyclic or Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium or Tellurium C07F 5/025 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177466 | Gray et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | DANA-FARBER CANCER INSTITUTE, INC. (Boston, Massachusetts) |
| ASSIGNEE(S) | DANA-FARBER CANCER INSTITUTE, INC. (Boston, Massachusetts) |
| INVENTOR(S) | Nathanael Gray (Stanford, California); Tinghu Zhang (Brookline, Massachusetts); Guangyan Du (Roslindale, Massachusetts); Nathaniel Henning (Brookline, Massachusetts); Jie Jiang (Brookline, Massachusetts); Eric Fischer (Chestnut Hill, Massachusetts); Katherine Donovan (Boston, Massachusetts) |
| ABSTRACT | The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by Kelch-like ECH-associated protein 1 (KEAP1). In some aspects, the present invention is directed to methods of treating diseases or disorders involving dysfunctional (e.g., dysregulated) KEAP1 activity, that entails administration of a therapeutically effective amount of a bifunctional compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof, to a subject in need thereof. |
| FILED | Tuesday, April 07, 2020 |
| APPL NO | 17/601536 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 47/545 (20170801) Heterocyclic Compounds C07D 401/04 (20130101) C07D 401/14 (20130101) C07D 419/04 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177472 | Forrest et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF KANSAS (Lawrence, Kansas); HYLAPHARM, LLC (Laawrence, Kansas) |
| ASSIGNEE(S) | UNIVERSITY OF KANSAS (Lawrence, Kansas); HYLAPHARM, LLC. (Lawrence, Kansas) |
| INVENTOR(S) | Laird Forrest (Lawrence, Kansas); Daniel Aires (Mission Hills, Kansas); Ryan Moulder (Lawrence, Kansas); Ruolin Lu (Lawrence, Kansas); Jordan Hunt (Lawrence, Kansas); Peter Kleindl (Lawrence, Kansas); Ti Zhang (Lawrence, Kansas); Chad Groer (Lawrence, Kansas); Shuang Cai (Lawrence, Kansas) |
| ABSTRACT | The present technology is directed to TLR7 and TLR8 agonist compounds, compositions, and methods of using the same for the treatment of cancers and as vaccine adjuvants. |
| FILED | Thursday, April 16, 2020 |
| APPL NO | 17/598160 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 47/61 (20170801) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 29/00 (20180101) A61P 35/00 (20180101) Heterocyclic Compounds C07D 471/04 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177488 | Ouyang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | SUVALENT THERAPEUTICS, INC. (Thousand Oaks, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Xiaohu Ouyang (Rosemead, California); Miles Kubota (Monrovia, California); Ted Charles Judd (Granada Hills, California); Andrew S. Tasker (Simi Valley, California) |
| ABSTRACT | The present invention relates to compounds and compositions capable of acting as inhibitors of small ubiquitin-like modifier (SUMO) family of proteins. The compounds and compositions may be used in the treatment of cancer. There are disclosed, inter alia, methods of inhibiting an E1 enzyme, and compounds useful for inhibiting an E1 enzyme. |
| FILED | Thursday, March 19, 2020 |
| APPL NO | 17/435855 |
| CURRENT CPC | Heterocyclic Compounds C07D 209/08 (20130101) C07D 217/06 (20130101) C07D 217/14 (20130101) C07D 217/16 (20130101) C07D 333/54 (20130101) C07D 401/04 (20130101) C07D 401/12 (20130101) C07D 405/06 (20130101) C07D 471/04 (20130101) C07D 491/048 (20130101) C07D 495/04 (20130101) Original (OR) Class Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/573 (20130101) G01N 2440/36 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177489 | Ansari et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | WISCONSIN ALUMNI RESEARCH FOUNDATION (Madison, Wisconsin) |
| ASSIGNEE(S) | WISCONSIN ALUMNI RESEARCH FOUNDATION (Madison, Wisconsin) |
| INVENTOR(S) | Aseem Z. Ansari (Madison, Wisconsin); Ashraf Mohammed (Madison, Wisconsin) |
| ABSTRACT | Synthetic transcriptions factors for modulation of frataxin expression and methods of use are described herein. |
| FILED | Tuesday, October 22, 2019 |
| APPL NO | 17/287901 |
| CURRENT CPC | Heterocyclic Compounds C07D 403/14 (20130101) C07D 471/04 (20130101) C07D 495/14 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177523 | PEI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Entrada Therapeutics, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Dehua PEI (Columbus, Ohio); Ziqing QIAN (Boston, Massachusetts) |
| ABSTRACT | Disclosed herein are compounds having activity as cell penetrating peptides. In some examples, the compounds can comprise a cell penetrating peptide moiety and a cargo moiety. The cargo moiety can comprise one or more detectable moieties, one or more therapeutic moieties, one or more targeting moieties, or any combination thereof. In some examples, the cell penetrating peptide moiety is cyclic. In some examples, the cell penetrating peptide moiety and cargo moiety together are cyclic. In some examples, the cell penetrating peptide moiety is cyclic and the cargo moiety is appended to the cyclic cell penetrating peptide moiety structure. In some examples, the cargo moiety is cyclic and the cell penetrating peptide moiety is cyclic, and together they form a fused bicyclic system. |
| FILED | Friday, November 19, 2021 |
| APPL NO | 17/530664 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/05 (20130101) A61K 38/12 (20130101) A61K 38/465 (20130101) A61K 47/64 (20170801) A61K 49/0039 (20130101) A61K 49/0041 (20130101) A61K 49/0043 (20130101) A61K 49/0047 (20130101) A61K 49/0056 (20130101) Peptides C07K 7/06 (20130101) C07K 7/64 (20130101) Original (OR) Class Enzymes C12Y 301/03048 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177527 | Zuchner et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF MIAMI (Miami, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Stephan L. Zuchner (Pinecrest, Florida); Mohammad A. Faghihi (Miami, Florida) |
| ABSTRACT | The present disclosure relates to methods of detecting and, optionally, treating Hereditary Spastic Paraplegia and other neurological diseases. |
| FILED | Friday, March 13, 2020 |
| APPL NO | 17/439338 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/00 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/00 (20180101) Peptides C07K 14/435 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177531 | Koide et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | New York University (New York, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Shohei Koide (New York, New York); Kai Wen Teng (Flushing, New York); Akiko Koide (New York, New York); Takamitsu Hattori (West New York, New Jersey) |
| ABSTRACT | Provided are proteins or peptides, which may be referred to as monobodies. Fusion proteins and proteolysis targeting chimeras (PROTACs) comprising the proteins or peptides are also provided. Also provided are compositions of the proteins or peptides of the present disclosure, as well as compositions of fusion proteins and compositions of PROTACs. Methods of treating an individual in need of treatment are also provided. The methods may be to treat an individual suffering from or suspected of having KRAS(G12V), KRAS(G12S), KRAS(G12A) and/or KRAS(G12C)-associated cancers. A method may be for inhibiting ERK activation and/or proliferation of KRAS(G12V), KRAS(G12S), KRAS(G12A) and/or KRAS(G12C)-associated cancers. |
| FILED | Monday, December 06, 2021 |
| APPL NO | 17/543464 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/00 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) General Methods of Organic Chemistry; Apparatus Therefor C07B 2200/13 (20130101) Peptides C07K 14/4702 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177534 | DUBINETT et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); The United States Government Represented by the Department of Veterans Affairs (Washington, District of Columbia) |
| ASSIGNEE(S) | The Regents of the University of California (Oakland, California); The United States Government Represented by the Department of Veterans Affairs (Washington, District of Columbia) |
| INVENTOR(S) | Steven M. DUBINETT (Los Angeles, California); Jay Moon LEE (Manhattan Beach, California); Bin LIU (Woodland Hills, California); Ramin SALEHI-RAD (Encino, California); Sharvendra SHARMA (Culver City, California) |
| ABSTRACT | The present disclosure relates, in general, to methods for treating cancer comprising administering to a subject in need thereof an effective amount of dendritic cells comprising the human CCL21 gene in combination with an anti-PD-1 antibody. In one aspect, the treatment is amenable to patients with tumors having a high mutational burden. |
| FILED | Friday, May 10, 2019 |
| APPL NO | 17/053872 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/00 (20130101) Peptides C07K 14/521 (20130101) Original (OR) Class C07K 14/70596 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177548 | Somasundaram et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Wistar Institute of Anatomy and Biology (Philadelphia, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Rajasekharan Somasundaram (West Chester, Pennsylvania); Meenhard Herlyn (Wynnewood, Pennsylvania); Dorothee Herlyn (Wynnewood, Pennsylvania) |
| ABSTRACT | Compositions and methods for treating melanoma are provided. Compositions include BRAFV600E-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAFV600E-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAFV600E-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies. |
| FILED | Monday, November 22, 2021 |
| APPL NO | 17/533095 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/127 (20130101) A61K 35/15 (20130101) A61K 38/1709 (20130101) A61K 39/39541 (20130101) A61K 2039/505 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 14/82 (20130101) Original (OR) Class C07K 16/2818 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/12 (20130101) Enzymes C12Y 207/11001 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177556 | Song et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, Pennsylvania); KIRA PHARMACEUTICALS (US) LLC (Arlington, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Wenchao Song (Bryn Mawr, Pennsylvania); Takashi Miwa (Bala Cynwyd, Pennsylvania); Damodar Gullipalli (Philadelphia, Pennsylvania); Ping Tsui (North Potomac, Maryland); Sayaka Sato (Philadelphia, Pennsylvania) |
| ABSTRACT | This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody. |
| FILED | Friday, September 06, 2019 |
| APPL NO | 17/273753 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 2039/505 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 37/02 (20180101) Peptides C07K 16/18 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177559 | MILLER et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); The George Washington University (Washington, District of Columbia); Baker Heart and Diabetes Research Institute (Melbourne, Australia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Yury MILLER (San Diego, California); Michael BUKRINSKY (Washington D.C., District of Columbia); Dmitri SVIRIDOV (Melbourne, Australia) |
| ABSTRACT | In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for preventing or slowing the spread of a viral infection, wherein optionally the viral infection is a coronavirus infection, optionally a COVID-19 infection or variant thereof, or a human immunodeficiency virus (HIV) infection, preventing or decreasing coronavirus or HIV-co-morbidities in an individual, or inhibiting, or slowing the rate of, coronavirus (optionally COVID-19) or HIV replication in vitro and in vitro. |
| FILED | Tuesday, December 07, 2021 |
| APPL NO | 17/544416 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/18 (20180101) Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 5/00 (20130101) Peptides C07K 16/18 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177561 | MOSCAT et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Sanford Burnham Prebys Medical Discovery Institute (La Jolla, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jorge MOSCAT (New York, New York); Maria T. DIAZ-MECO (New York, New York); Angeles DURAN (New York, New York); Yuki NAKANISHI (Kyoto, Japan) |
| ABSTRACT | Disclosed herein are methods for identifying a subject as having serrated colorectal cancer (CRC), and models of human serrated CRC. Also provided herein are methods for treating serrated CRC in the subject. |
| FILED | Tuesday, December 10, 2019 |
| APPL NO | 17/312855 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 45/06 (20130101) Peptides C07K 16/22 (20130101) Original (OR) Class C07K 16/2827 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177598 | Trinh et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Kham M. Trinh (Alhambra, California); John Matthew Timmerman (Los Angeles, California); Sherie Leaver Morrison (Los Angeles, California) |
| ABSTRACT | In various embodiments targeted interferon constructs are provided. In certain embodiments the constructs comprise a full-length immunoglobulin or a camelid antibody attached to an interferon gamma (IFNγ) where said immunoglobulin or camelid antibody is an antibody that binds to a tumor associated antigen; a first interferon gamma (IFNγ) is attached to a first constant heavy region 3 (CH3) of the immunoglobulin or camelid antibody by a first proteolysis resistant peptide linker; a second interferon gamma is attached to a second constant heavy region 3 (CH3) of the immunoglobulin or camelid antibody by a second proteolysis resistant peptide linker; and the first proteolysis resistant linker and the second proteolysis linker have a length and flexibility that permits said first interferon gamma and said second interferon gamma to dimerize. |
| FILED | Wednesday, January 29, 2020 |
| APPL NO | 17/310279 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 14/57 (20130101) C07K 16/30 (20130101) Original (OR) Class C07K 16/2887 (20130101) C07K 16/2896 (20130101) C07K 2317/22 (20130101) C07K 2317/53 (20130101) C07K 2317/732 (20130101) C07K 2317/734 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177605 | GU et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF WASHINGTON (Seattle, Washington) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Liangcai GU (Seattle, Washington); Shoukai KANG (Seattle, Washington); Luis GOMEZ-CASTILLO (Seattle, Washington); Huayi JIANG (Seattle, Washington) |
| ABSTRACT | The disclosure provides polypeptides, fusion proteins, kits, dimers, nucleic acids, expression vectors, or host cells for use hi chemically induced dimerization systems, exemplified by a chemically induced dimerization system in which two recombinant antibodies dimerize only in the presence of cannabidiol. |
| FILED | Tuesday, April 21, 2020 |
| APPL NO | 17/604928 |
| CURRENT CPC | Peptides C07K 16/44 (20130101) Original (OR) Class C07K 2317/565 (20130101) C07K 2317/622 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/6845 (20130101) G01N 33/6854 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177664 | Laurencin et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Connecticut (Farmington, Connecticut) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Cato Laurencin (Farmington, Connecticut); Leila Daneshmandi (Farmington, Connecticut) |
| ABSTRACT | The disclosure provides porous scaffold that include a plurality of microspheres, where the microspheres include a biodegradable polymer blended with a graphene family material (GFM), micro spheres, and methods for making and using such scaffolds and microspheres. |
| FILED | Tuesday, March 31, 2020 |
| APPL NO | 17/598428 |
| CURRENT CPC | Working-up; General Processes of Compounding; After-treatment Not Covered by Subclasses C08B, C08C, C08F, C08G or C08H C08J 9/24 (20130101) C08J 9/0066 (20130101) Original (OR) Class C08J 2205/044 (20130101) C08J 2207/10 (20130101) C08J 2367/04 (20130101) Use of Inorganic or Non-macromolecular Organic Substances as Compounding Ingredients C08K 3/042 (20170501) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177703 | Bouché et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Trustees of the University of Pennsylvania (Philadelphia, Pennsylvania) |
| ASSIGNEE(S) | The Trustees Of The University Of Pennsylvania (Philadelphia, Pennsylvania) |
| INVENTOR(S) | Mathilde Bouché (Philadelphia, Pennsylvania); David Cormode (Philadelphia, Pennsylvania); Saad Sheikh (Pittsford, New York); Jay Dorsey (Media, Pennsylvania) |
| ABSTRACT | The present invention provides a hydrogel for comprising a biodegradable polyphosphazene polymer, a radiation-sensitive diselenide cross-linker; and one or more payloads releasably loaded within the hydrogel. The present invention further provides methods for radiosensitizing target tissues such as tumors and providing sustained delivery of therapeutics triggered by irradiation. In another aspect, the present invention provides a method that includes: introducing the hydrogel, as describes herein, adjacent to malignant or marginal tissue; and administering radiation to the hydrogel, thereby disrupting the selenocystamine cross-linkers and releasing the one or more payloads. |
| FILED | Monday, March 30, 2020 |
| APPL NO | 17/593982 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/06 (20130101) A61K 41/0033 (20130101) A61K 41/0057 (20130101) A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds C08G 79/025 (20130101) Compositions of Macromolecular Compounds C08L 85/02 (20130101) Original (OR) Class C08L 2201/06 (20130101) C08L 2312/06 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177838 | Humes et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | SeaStar Medical, Inc. (Denver, Colorado) |
| ASSIGNEE(S) | |
| INVENTOR(S) | H. David Humes (Ann Arbor, Michigan); Deborah A. Buffington (Ann Arbor, Michigan); Christopher J. Pino (Saline, Michigan) |
| ABSTRACT | The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions within a subject and to related methods. More particularly, the invention relates to a cytopheretic cartridge that includes a housing and, disposed within the housing, a solid support capable of sequestering activated leukocytes and/or platelets. |
| FILED | Monday, September 13, 2021 |
| APPL NO | 17/473176 |
| CURRENT CPC | Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor A61M 1/1698 (20130101) A61M 1/3672 (20130101) A61M 1/3675 (20130101) A61M 1/3679 (20130101) A61M 2202/0439 (20130101) Separation B01D 63/02 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0634 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177843 | Thom et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (Philadelphia, Pennsylvania); THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Christopher Thom (Media, Pennsylvania); Benjamin Voight (Philadelphia, Pennsylvania); Deborah French (Newark, Delaware) |
| ABSTRACT | Improved platelet producing megakaryocytes and methods of use thereof are disclosed. |
| FILED | Wednesday, April 29, 2020 |
| APPL NO | 17/604954 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 35/19 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0644 (20130101) Original (OR) Class C12N 2501/998 (20130101) C12N 2506/45 (20130101) C12N 2510/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177845 | Murphy et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | BOSTON MEDICAL CENTER CORPORATION (Boston, Massachusetts); TRUSTEES OF BOSTON UNIVERSITY (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | George J. Murphy (Boston, Massachusetts); David H. Sherr (West Roxbury, Massachusetts); Sarah S. Rozelle (Jamaica Plain, Massachusetts); Brenden W. Smith (Warwick, Rhode Island) |
| ABSTRACT | This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a MEP precursor cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) modulator. In some embodiments the AhR modulator is an AhR antagonist. In some embodiments the AhR modulator is an AhR agonist. In some embodiments the methods comprise culturing MEP precursor cells in the presence of an AHR antagonist and then culturing MEP precursor cells in the presence of an AHR agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR modulator are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs, among other things. |
| FILED | Friday, August 20, 2021 |
| APPL NO | 17/407349 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/404 (20130101) A61K 31/655 (20130101) A61K 35/18 (20130101) A61K 35/19 (20130101) A61K 45/06 (20130101) A61K 2035/124 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0641 (20130101) C12N 5/0644 (20130101) C12N 5/0647 (20130101) Original (OR) Class C12N 2501/60 (20130101) C12N 2506/03 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/80 (20130101) G01N 33/86 (20130101) G01N 33/5044 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177847 | KLEMKE et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (La Jolla, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Richard KLEMKE (La Jolla, California); Huawei WANG (San Diego, California) |
| ABSTRACT | Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods. |
| FILED | Friday, December 17, 2021 |
| APPL NO | 17/554531 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0019 (20130101) A61K 35/12 (20130101) A61K 35/28 (20130101) A61K 38/2066 (20130101) A61K 39/215 (20130101) A61K 39/001102 (20180801) A61K 2039/515 (20130101) A61K 2039/545 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0662 (20130101) Original (OR) Class C12N 15/85 (20130101) C12N 2501/999 (20130101) C12N 2510/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177853 | Ashton et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Wisconsin Alumni Research Foundation (Madison, Wisconsin) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Randolph Scott Ashton (Madison, Wisconsin); Gavin Thomas Knight (Madison, Wisconsin); Benjamin John Knudsen (Menomonee Falls, Wisconsin); Nisha Ramdas Iyer (Madison, Wisconsin); Carlos Marti-Figueroa (Madison, Wisconsin) |
| ABSTRACT | Described herein are methods, compositions, and kits for directed differentiation of human pluripotent stem cells, neuromesodermal progenitors, and neural stem cells into bioengineered elliptical neuroepithelial tissues and bioengineered neuroepithelial tubes that contain a single rosette of polarized neuroepithelial cells and have microscale cellular organization similar to that of an in vivo developing human neural tube. |
| FILED | Wednesday, December 08, 2021 |
| APPL NO | 17/545416 |
| CURRENT CPC | Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 27/3604 (20130101) A61L 27/3675 (20130101) A61L 27/3687 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0618 (20130101) C12N 5/0697 (20130101) Original (OR) Class C12N 2501/41 (20130101) C12N 2501/999 (20130101) C12N 2506/02 (20130101) C12N 2531/00 (20130101) C12N 2533/30 (20130101) C12N 2535/10 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177856 | Stafford et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The University of North Carolina at Chapel Hill (Chapel Hill, North Carolina) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Darrel W. Stafford (Carrboro, North Carolina); Tao Li (San Diego, California) |
| ABSTRACT | The present invention provides a stable cell line overexpressing a recombinant vitamin K-dependent (VKD) protein and both a recombinant vitamin K epoxide reductase (VKOR) and a recombinant vitamin K dependent gamma carboxylase (VKGC), wherein the amount of fully carboxylated VKD protein produced in the cell is increased 10% as compared to the amount of fully carboxylated VKD protein produced in the cell in the absence of the recombinant VKOR and the recombinant VKGC. |
| FILED | Friday, July 16, 2021 |
| APPL NO | 17/377978 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/0006 (20130101) Original (OR) Class C12N 9/50 (20130101) C12N 9/64 (20130101) C12N 9/88 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6883 (20130101) C12Q 2600/106 (20130101) C12Q 2600/156 (20130101) C12Q 2600/158 (20130101) C12Q 2600/172 (20130101) Enzymes C12Y 101/04001 (20130101) C12Y 304/21006 (20130101) C12Y 401/0109 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177862 | LEVY et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF WASHINGTON (Seattle, Washington) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Shiri LEVY (Seattle, Washington); Hannele RUOHOLA-BAKER (Seattle, Washington); David BAKER (Seattle, Washington) |
| ABSTRACT | Disclosed herein are compositions including an embryonic ectoderm development (BED) polypeptide binder (EB) domain and a CRISPR associated protein 9 (CAS9) domain linked to the EB domain, and uses thereof for gene activation in a biological cell. |
| FILED | Wednesday, March 11, 2020 |
| APPL NO | 17/434832 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/00 (20130101) Peptides C07K 2319/01 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/22 (20130101) Original (OR) Class C12N 15/11 (20130101) C12N 15/907 (20130101) C12N 2310/20 (20170501) C12N 2800/80 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177863 | Zhang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE BROAD INSTITUTE, INC. (Cambridge, Massachusetts); MASSACHUSETTS INSTITUTE OF TECHNOLOGY (Cambridge, Massachusetts) |
| ASSIGNEE(S) | THE BROAD INSTITUTE, INC. (Cambridge, Massachusetts); MASSACHUSETTS INSTITUTE OF TECHNOLOGY (Cambridge, Massachusetts) |
| INVENTOR(S) | Feng Zhang (Cambridge, Massachusetts); Han Altae-Tran (Cambridge, Massachusetts) |
| ABSTRACT | The present application provides systems, methods and compositions used for targeted gene modification, targeted insertion, perturbation of gene transcripts, and nucleic acid editing. Novel nucleic acid targeting systems comprise components of Type VII Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems and transposable elements. |
| FILED | Wednesday, March 18, 2020 |
| APPL NO | 17/440493 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/22 (20130101) Original (OR) Class C12N 9/78 (20130101) C12N 15/11 (20130101) C12N 15/907 (20130101) C12N 15/8213 (20130101) C12N 2310/20 (20170501) C12N 2800/80 (20130101) Enzymes C12Y 305/04004 (20130101) C12Y 305/04005 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177866 | Sonnenburg et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Trustees of the Leland Stanford Junior University (Stanford, California); Novome Biotechnologies, Inc. (Daly City, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Justin L. Sonnenburg (Redwood City, California); Weston R. Whitaker (Daly City, California); Elizabeth Stanley (Portola Valley, California); William C. DeLoache (Oakland, California) |
| ABSTRACT | Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome. |
| FILED | Friday, February 18, 2022 |
| APPL NO | 17/675721 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 35/741 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 1/00 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 1/20 (20130101) C12N 9/2402 (20130101) Original (OR) Class C12N 15/52 (20130101) C12N 15/74 (20130101) Enzymes C12Y 302/01178 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177867 | Dong et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Paul Stenmark (Stockholm, Sweden); Children's Medical Center Corporation (Boston, Massachusetts) |
| ASSIGNEE(S) | Children's Medical Center Corporation (Boston, Massachusetts) |
| INVENTOR(S) | Min Dong (Weatogue, Connecticut); Sicai Zhang (Boston, Massachusetts); Paul Stenmark (Stockholm, Sweden) |
| ABSTRACT | Provided herein are Clostridial Botulinum neurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications. |
| FILED | Monday, December 20, 2021 |
| APPL NO | 17/555570 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0019 (20130101) A61K 38/00 (20130101) Peptides C07K 14/33 (20130101) C07K 2319/55 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/52 (20130101) Original (OR) Class Enzymes C12Y 304/24069 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177869 | Bohm et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Trustees of Tufts College (Medford, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Alex A. Bohm (Newton, Massachusetts); Gretchen Meinke (Sharon, Massachusetts); Nahide Dalda (Dietenbach, Germany) |
| ABSTRACT | The present invention provides methods and kits for efficiently generating edited DNA, ranging from DNA molecules with simple point mutations to complex DNA libraries. The methods and kits use a single-stranded deoxyuridine (dU)-containing template to align a series of DNA oligomers that contain mutations relative to the template strand, giving rise to the sequence variation in the product. The methods and kits may be used to produce DNA libraries or to generate multiple, widely spaced mutations in a target sequence. |
| FILED | Wednesday, December 08, 2021 |
| APPL NO | 17/545612 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/1252 (20130101) C12N 15/1031 (20130101) Original (OR) Class C12N 15/1093 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6806 (20130101) Enzymes C12Y 207/07007 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177878 | SIMPSON et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (Philadelphia, Pennsylvania) |
| ASSIGNEE(S) | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (Philadelphia, Pennsylvania) |
| INVENTOR(S) | Bryan SIMPSON (Philadelphia, Pennsylvania); Beverly DAVIDSON (Philadelphia, Pennsylvania); Alejandro MAS MONTEYS (Philadelphia, Pennsylvania) |
| ABSTRACT | CRISPR/Cas9-mediated genome editing holds clinical potential for treating genetic diseases, such as spinocerebellar ataxia type 2, which is caused by mutations in the ATXN2 gene. Here, compositions and methods for the treatment of spinocerebellar taxia type 2 are provided. In some embodiments, a composition providing a vector encoding a guide RNA of the disclosure and a vector encoding a Cas9 protein or nuclease domain thereof of the disclosure are provided for use in the treatment of spinocerebellar ataxia type 2. |
| FILED | Friday, April 24, 2020 |
| APPL NO | 17/594651 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/22 (20130101) C12N 15/86 (20130101) C12N 15/90 (20130101) C12N 15/111 (20130101) Original (OR) Class C12N 15/113 (20130101) C12N 2310/20 (20170501) C12N 2320/34 (20130101) C12N 2750/14143 (20130101) C12N 2830/008 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177879 | Gersbach et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Duke University (Durham, North Carolina) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Charles A. Gersbach (Chapel Hill, North Carolina); Veronica Gough (Durham, North Carolina) |
| ABSTRACT | Disclosed herein are CRISPR/Cas-based base editing compositions and methods for treating Duchenne Muscular Dystrophy by restoring dystrophin function. In an aspect, the disclosure relates to a CRISPR/Cas-based base editing system for altering a RNA splice site encoded in the genomic DMA of a subject. In some embodiments, altering the RNA splice site encoded in the genomic DNA results in exclusion or inclusion of at least one exon sequence in an RNA transcript. |
| FILED | Sunday, April 12, 2020 |
| APPL NO | 17/603243 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/713 (20130101) A61K 38/00 (20130101) Peptides C07K 14/4708 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/22 (20130101) C12N 15/111 (20130101) Original (OR) Class C12N 2310/20 (20170501) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177889 | Yao et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Baylor College of Medicine (Houston, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Qizhi Yao (Houston, Texas); Christian Marin-Muller (League City, Texas); Changyi Chen (Houston, Texas) |
| ABSTRACT | A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors, with important clinical implications. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, according to the present disclosure, MiR-198 replacement reverses tumorigenicity in vitro and in vivo. As such, an embodiment of the disclosure is a method of treating cancer in an individual, comprising the step of increasing the level of active microRNA-198 molecules in the pancreatic cancer tumor cells of the individual by an amount sufficient to cause an improvement in the pancreatic cancer in the individual |
| FILED | Wednesday, April 21, 2021 |
| APPL NO | 17/236851 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/713 (20130101) A61K 31/7088 (20130101) A61K 31/7105 (20130101) A61K 45/06 (20130101) A61K 51/00 (20130101) A61K 2300/00 (20130101) Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 5/10 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/113 (20130101) C12N 15/1135 (20130101) Original (OR) Class C12N 2310/141 (20130101) C12N 2320/30 (20130101) C12N 2320/31 (20130101) Technical Subjects Covered by Former USPC Cross-reference Art Collections [XRACs] and Digests Y10S 977/704 (20130101) Technical Subjects Covered by Former US Classification Y10T 428/13 (20150115) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177890 | Shapiro et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The United States of America,as represented by the Secretary,Department of Health and Human Services (Bethesda, Maryland) |
| ASSIGNEE(S) | The United States of America,as represented by the Secretary,Department of Health and Human Services (Bethesda, Maryland) |
| INVENTOR(S) | Bruce A. Shapiro (Gaithersburg, Maryland); Paul J. Zakrevsky (Baltimore, Maryland) |
| ABSTRACT | Disclosed are DNA/RNA hybrid nucleic acid nanoparticles comprising at least one trigger toehold or at least one exchange toehold, wherein each at least one trigger toehold and the at least one exchange toehold independently comprise DNA and/or RNA, and at least one single stranded RNA output strand, wherein no portion of the at least one trigger toehold hybridizes to any portion of the at least one output strand, the at least one trigger toehold is complementary and hybridizes to a first target sequence when the nanoparticle is in the presence of the first target sequence, and the nanoparticle does not contain the target sequence. Related pharmaceutical compositions, methods of treating a patient with a disease or condition, and methods of diagnosing a patient with a disease or condition are also disclosed. |
| FILED | Friday, April 10, 2020 |
| APPL NO | 17/602204 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/51 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/1135 (20130101) Original (OR) Class C12N 15/1136 (20130101) C12N 2310/113 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177905 | Bier et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ethan Bier (San Diego, California); Annabel Guichard (La Jolla, California); Valentino Gantz (San Diego, California) |
| ABSTRACT | An active genetic approach to preferentially transmit allelic variants (allelic-drive) resulting from only a single or a few nucleotide alterations. Embodiments are provided for allelic-drive: one, copy-cutting, in which a non-preferred allele is selectively targeted for Cas9/guide RNA (gRNA) cleavage, and a more general approach, copy-grafting, that permits selective inheritance of a desired allele located at some distance from the gRNA cut site. A lethal mosaicism is provided that dominantly eliminates NHEJ-induced mutations and favors inheritance of functional cleavage-resistant alleles. These two efficient allelic-drive methods, enhanced by lethal mosaicism and a trans-generational drive process provide a shadow-drive, that are applicable to improvements in health and agriculture. |
| FILED | Friday, April 03, 2020 |
| APPL NO | 17/600820 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/90 (20130101) C12N 15/102 (20130101) C12N 15/8279 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177913 | Church et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | President and Fellows of Harvard College (Cambridge, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | George M. Church (Brookline, Massachusetts); Prashant G. Mali (La Jolla, California); Luhan Yang (Somerville, Massachusetts) |
| ABSTRACT | A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner. |
| FILED | Wednesday, February 16, 2022 |
| APPL NO | 17/672744 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/22 (20130101) C12N 15/01 (20130101) C12N 15/10 (20130101) C12N 15/63 (20130101) C12N 15/81 (20130101) C12N 15/85 (20130101) Original (OR) Class C12N 15/87 (20130101) C12N 15/90 (20130101) C12N 15/102 (20130101) C12N 15/907 (20130101) C12N 15/1024 (20130101) C12N 15/8201 (20130101) C12N 2310/20 (20170501) C12N 2800/80 (20130101) C12N 2810/55 (20130101) Enzymes C12Y 301/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177947 | DeBoer et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | The Regents of the University of California (Oakland, California) |
| INVENTOR(S) | Tara Renee DeBoer (Berkeley, California); Nicole Jeanne Tarlton (Berkeley, California); Niren Murthy (Berkeley, California); Lee W. Riley (Berkeley, California); Angel Resendez (Berkeley, California); Nicole Jackson (Berkeley, California) |
| ABSTRACT | Provided herein are β-lactamase probes that can be used to identify specific types and classes of β-lactamases in a sample, and methods of use thereof. |
| FILED | Sunday, February 20, 2022 |
| APPL NO | 17/676211 |
| CURRENT CPC | Heterocyclic Compounds C07D 477/14 (20130101) C07D 501/36 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/34 (20130101) Original (OR) Class Enzymes C12Y 305/02006 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177963 | Chen et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE BROAD INSTITUTE, INC. (Cambridge, Massachusetts); PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, Massachusetts) |
| ASSIGNEE(S) | THE BROAD INSTITUTE, INC. (Cambridge, Massachusetts); PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, Massachusetts) |
| INVENTOR(S) | Fei Chen (Cambridge, Massachusetts); Sophia Liu (Cambridge, Massachusetts) |
| ABSTRACT | The present disclosure relates to compositions and methods for assessing extended length T-cell receptor (TCR) transcript sequences (i.e., TCR transcript sequences that span TCR transcript variable regions) in a spatially-defined manner across a tissue sample, specifically providing for obtaining useful TCR sequences at high spatial resolution while also assessing relative macromolecule abundance (e.g., RNA expression levels) with deep transcriptomic coverage at similarly high-resolution across the tissue sample. |
| FILED | Monday, December 06, 2021 |
| APPL NO | 17/542650 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/686 (20130101) C12Q 1/6804 (20130101) C12Q 1/6837 (20130101) C12Q 1/6874 (20130101) Original (OR) Class C12Q 1/6876 (20130101) C12Q 2600/158 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 1/30 (20130101) G01N 33/54353 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178834 | Tao et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Arizona Board of Regents on behalf of Arizona State University (Scottsdale, Arizona) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Nongjian Tao (Fountain Hills, Arizona); Di Wang (Tempe, Arizona); Chenwen Lin (Tempe, Arizona) |
| ABSTRACT | A micro-colorimetric sensor for sensing target chemicals using edge tracking includes a substrate. A plurality of parallel linear channels of porous media is entrenched into the substrate and each linear channel includes a sensing material adapted to sense one of several specific target chemicals in air. The plurality of parallel linear channels is separated by barrier material from the adjacent parallel linear channel where the barrier material blocks diffusion of chemicals from one linear channel to another. A plate is affixed over the substrate top to cover the plurality of parallel linear channels. An air sample is diffused along the micro-colorimetric sensor and color images are captured. An intensity profile is derived from the plurality of color images to determine a maximum and a minimum intensity value along the sensor. A plurality of positions along the sensor is tracked to determine an edge position. |
| FILED | Friday, February 25, 2022 |
| APPL NO | 17/681128 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/783 (20130101) Original (OR) Class G01N 33/0037 (20130101) G01N 33/0039 (20130101) G01N 33/0047 (20130101) G01N 2021/7763 (20130101) G01N 2201/0621 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178910 | Russell et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Mayo Foundation for Medical Education and Research (Rochester, Minnesota); Vyriad, Inc. (Rochester, Minnesota) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Luke Russell (Rochester, Minnesota); Kah-Whye Peng (Rochester, Minnesota); Stephen James Russell (Rochester, Minnesota) |
| ABSTRACT | The present invention generally relates to pharmacokinetic and pharmacodynamics markers for cancer therapeutic regimens and methods of treating cancer. Oncolytic virus probes that comprise a nucleic acid encoding soluble interferon beta (IFNβ) and methods for use thereof are provided. |
| FILED | Friday, March 27, 2020 |
| APPL NO | 17/598510 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/5017 (20130101) Original (OR) Class G01N 33/6866 (20130101) G01N 33/57407 (20130101) G01N 2333/565 (20130101) G01N 2800/52 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178911 | Hockemeyer et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | The Regents of the University of California (Oakland, California) |
| INVENTOR(S) | Dirk Friedrich Hockemeyer (Berkeley, California); Timothy K. Turkalo (Berkeley, California) |
| ABSTRACT | An in vitro culture system of human embryonic stem (hES) derived cells is used as a synthetic lethality screening platform for cells undergoing alternative lengthening of telomeres (ALT). |
| FILED | Saturday, February 26, 2022 |
| APPL NO | 17/681714 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0606 (20130101) C12N 9/22 (20130101) C12N 15/11 (20130101) C12N 15/907 (20130101) C12N 15/1093 (20130101) C12N 2310/20 (20170501) C12N 2510/04 (20130101) C12N 2800/80 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/5023 (20130101) Original (OR) Class G01N 33/5073 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178912 | Schwartz et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of Colorado, A Body Corporate (Aurora, Colorado) |
| ASSIGNEE(S) | |
| INVENTOR(S) | David Schwartz (Denver, Colorado); Ian Stancil (Denver, Colorado) |
| ABSTRACT | A method of screening a test compound, e.g., a fibrosis or IPF inhibitor, for induction of an unjammed-to-jammed transition (UJT) in fibrotic primary human bronchial epithelial cells (HBECs) isolated from a subject with a fibrotic lung disease includes culturing the fibrotic primary HBECs at an air-liquid interface for a time sufficient to provide a differentiated pseudostratified epithelium contacting the cultured cells with the test compound; and monitoring the motility of the cultured cells to identify the cultured cells as moving or stationary; wherein stationary cultured cells indicate that the test compound induces the UJT. Also included are methods of identifying lung fibrosis biomarkers. |
| FILED | Thursday, December 09, 2021 |
| APPL NO | 17/546554 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/5029 (20130101) Original (OR) Class G01N 33/5044 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178924 | Tao et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Weiguo Andy Tao (West Lafayette, Indiana); I-Hsuan Chen (White Plains, New York); Hillary Andaluz Aguilar (West Lafayette, Indiana); Juan Sebastian Paez Paez (West Lafayette, Indiana) |
| ABSTRACT | Noninvasive methods of determining breast cancer subtype in a subject are provided that employ newly identified biomarkers. Said methods comprise isolating a population of extracellular vehicles in a biofluid sample of a subject and detecting differential expression in one or more proteins or peptides therein. Such differential expression is compared to one or more expression profiles within a panel of biomarkers, with each expression profile in the panel associated with a subtype of breast cancer. Also provided are kits for detecting a subtype of breast cancer and/or identifying the recurrence thereof, each comprising an antibody, aptamer, or other detection means against the aforesaid biomarkers. Methods for monitoring treatment efficacy in a subject experiencing breast cancer using the same platforms are also provided. |
| FILED | Tuesday, March 03, 2020 |
| APPL NO | 17/436530 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/5023 (20130101) G01N 33/57415 (20130101) Original (OR) Class G01N 2333/4712 (20130101) G01N 2333/91205 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178925 | Varley et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF UTAH RESEARCH FOUNDATION (Salt Lake City, Utah) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Katherine (K-T) E. Varley (Salt Lake City, Utah); Rachel L. Stewart (Lexington, Kentucky); Philip S. Bernard (Salt Lake City, Utah); Katherine Updike (Salt Lake City, Utah) |
| ABSTRACT | Disclosed herein are biomarkers and methods of using the same for determining the risk of recurrence of cancer in a subject. The methods may include determining the level of expression of at least one MHCII gene, determining the level of expression of at least one TIL gene, and determining an Immune Activation Score for the subject. Further provided are methods of diagnosing a subject with triple-negative breast cancer (TNBC) as having TNBC Basal-like subtype, and methods of treating cancer in a subject. |
| FILED | Friday, April 03, 2020 |
| APPL NO | 17/598185 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/57415 (20130101) Original (OR) Class G01N 33/57484 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178950 | Levitsky et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northwestern University (Evanston, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Josh Levitsky (Evanston, Illinois); Michael M. Abecassis (Highland Park, Illinois) |
| ABSTRACT | Disclosed are methods for predicting, inhibiting, and treating chronic kidney disease (CKD) in a subject that that is preparing to undergo a liver transplant. The methods may include detecting a protein biomarker in a serum sample from the subject prior to the subject being administered a liver transplant procedure and/or after the subject has been administered the liver transplant procedure. Suitable protein markers for the disclosed methods may include but are not limited to osteopontin (OPN) and/or tissue inhibitor of metalloproteases 1 (TIMP1). |
| FILED | Friday, February 25, 2022 |
| APPL NO | 17/681315 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/70 (20130101) Original (OR) Class G01N 33/6803 (20130101) G01N 2800/52 (20130101) G01N 2800/56 (20130101) G01N 2800/60 (20130101) G01N 2800/245 (20130101) G01N 2800/347 (20130101) Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 50/30 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178953 | Remaley et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The United States of America,as represented by the Secretary,Department of Health and Human Services (Bethesda, Maryland) |
| ASSIGNEE(S) | The United States of America,as represented by the Secretary,Department of Health and Human Services (Bethesda, Maryland) |
| INVENTOR(S) | Alan T. Remaley (Bethesda, Maryland); Edward B. Neufeld (Washington, District of Columbia); Masaki Sato (Rockville, Maryland) |
| ABSTRACT | A method of assessing the risk for development of cardiovascular disease (CVD) or an inflammatory disease in a patient comprises (i) incubating a sample of body fluid with donor particles, wherein the donor particles are coated with a lipid and a first quantity of detectably labeled, non-exchangeable lipid probe (NELP); (ii) separating the detectably labeled NELP-associated HDL into a first portion and the donor particles into a second portion; (iii) measuring the second quantity of detectably labeled NELP in the first portion; (iv) determining a detectably labeled NELP efflux value for the patient; and (v) comparing the detectably labeled NELP efflux value for the patient to a reference standard. Related methods of lowering the risk for development of CVD or an inflammatory disease in a patient and methods of measuring the quantity of functional HDL in a sample of body fluid are also provided. |
| FILED | Friday, March 06, 2020 |
| APPL NO | 17/437094 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 30/74 (20130101) G01N 33/92 (20130101) Original (OR) Class G01N 33/54313 (20130101) G01N 2030/027 (20130101) G01N 2333/775 (20130101) G01N 2800/32 (20130101) G01N 2800/50 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178954 | Kastenmüller et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | DUKE UNIVERSITY (Durham, North Carolina) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Gabi Kastenmüller (Oberschleißheim, Germany); Rima F. Kaddurah-Daouk (Belmont, Massachusetts); Matthias Arnold (Oberschleißheim, Germany) |
| ABSTRACT | Described herein are methods for stratifying Alzheimer's disease among male and female subjects by analyzing biomarker metabolites. In one aspect, the biomarker metabolite comprises one or more of PC ae C44:4, PC ac C44:5, or PA ae C44:6; or PC ac C44:4, PC ac C44:5, PC aa C32:1, PC aa C32:0, or PC ae C42:4. |
| FILED | Friday, March 06, 2020 |
| APPL NO | 17/437122 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/92 (20130101) Original (OR) Class G01N 33/6896 (20130101) G01N 2405/06 (20130101) G01N 2405/08 (20130101) G01N 2800/2821 (20130101) Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 10/60 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178983 | Franklin et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Duke University (Durham, North Carolina) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Aaron D. Franklin (Durham, North Carolina); Steven G. Noyce (Durham, North Carolina); James L. Doherty (Durham, North Carolina) |
| ABSTRACT | Electronic device characterization platforms, systems, devices, and methods for use in testing instruments, devices, and sensors that is portable, modular, multiplexed, and automated are disclosed. The system includes a substrate, a chip adapter, such as a chip socket, and an optional housing. Chip samples to be tested can be disposed in the chip adapter and various environmental modules designed to supply different environmental conditions to the chip sample can be disposed over the chip adapter, enabling testing of the chip samples to be performed in the different environment conditions. The system can further include various connectors that allow for add-on modules to be included as part of the system. Methods of characterizing electronic devices and sensors are also disclosed. |
| FILED | Tuesday, December 07, 2021 |
| APPL NO | 17/544916 |
| CURRENT CPC | Measuring Electric Variables; Measuring Magnetic Variables G01R 1/0458 (20130101) G01R 31/003 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220179022 | Davids et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE GENERAL HOSPITAL CORPORATION (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Mathias Davids (Manheim, Germany); Bastien Guerin (Cambridge, Massachusetts); Lawrence L. Wald (Cambridge, Massachusetts) |
| ABSTRACT | Systems and methods for designing and manufacturing electromagnetic coils for use with a magnetic resonance imaging (“MRI”) system are described. More particularly, described here are methods for designing and manufacturing gradient coils for producing magnetic field gradients with greater peripheral nerve stimulation (“PNS”) thresholds relative to conventional gradient coils. The gradient coil design is constrained using an oracle penalty that is computed to account for a PNS requirement for the coil. In other applications, the oracle penalty can be used to optimize driving patterns for an electromagnetic stimulation system, such that a target PNS requirement is achieved. |
| FILED | Thursday, March 26, 2020 |
| APPL NO | 17/442808 |
| CURRENT CPC | Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 2/02 (20130101) A61N 2/006 (20130101) Measuring Electric Variables; Measuring Magnetic Variables G01R 33/3858 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220179024 | Berman et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE GENERAL HOSPITAL CORPORATION (Boston, Massachusetts); Vanderbilt University (Nashville, Tennessee) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Avery J.L. Berman (Jamaica Plain, Massachusetts); Jonathan R. Polimeni (Cambridge, Massachusetts); William A. Grissom (Nashville, Tennessee); Kawin Setsompop (Charlestown, Massachusetts); Thomas Witzel (Boston, Massachusetts) |
| ABSTRACT | Described here are systems and methods for producing images with a magnetic resonance imaging (“MRI”) system using a high-resolution, motion-robust, artifact-free segmented echo planar imaging (“EPI”) technique. In particular, a fast low angle excitation echo planar imaging technique (“FLEET”) using variable flip angle (“VFA”) radio frequency (“RF”) excitation pulses that are recursively designed to have a flat magnitude and phase profile across a slice for a range of different flip angles by accounting for longitudinal magnetization remaining after each preceding RF pulse is applied. |
| FILED | Friday, March 27, 2020 |
| APPL NO | 17/598035 |
| CURRENT CPC | Measuring Electric Variables; Measuring Magnetic Variables G01R 33/4818 (20130101) G01R 33/4835 (20130101) Original (OR) Class G01R 33/5608 (20130101) G01R 33/5616 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220179030 | Tian et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE GENERAL HOSPITAL CORPORATION (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Qiyuan Tian (Charlestown, Massachusetts); Susie Yi Huang (Boston, Massachusetts); Berkin Bilgic (Boston, Massachusetts) |
| ABSTRACT | Higher quality diffusion metrics and/or diffusion-weighted images are generated from lower quality input diffusion-weighted images using a suitably trained neural network (or other machine learning algorithm). High-fidelity scalar and orientational diffusion metrics can be extracted using a theoretical minimum of a single non-diffusion-weighted image and six diffusion-weighted images, achieved with data-driven supervised deep learning. As an example, a deep convolutional neural network (“CNN”) is used to map the input non-diffusion-weighted image and diffusion-weighted images sampled along six optimized diffusion-encoding directions to the residuals between the input and output high-quality non-diffusion-weighted image and diffusion-weighted images, which enables residual learning to boost the performance of CNN and full tensor fitting to generate any scalar and orientational diffusion metrics. |
| FILED | Friday, March 27, 2020 |
| APPL NO | 17/442817 |
| CURRENT CPC | Measuring Electric Variables; Measuring Magnetic Variables G01R 33/5608 (20130101) G01R 33/56341 (20130101) Original (OR) Class Computer Systems Based on Specific Computational Models G06N 3/08 (20130101) G06N 3/0454 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220180482 | Wang |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | HURA IMAGING, INC (Calabasas, California) |
| ASSIGNEE(S) | HURA IMAGING, INC (Calabasas, California) |
| INVENTOR(S) | Danny JJ Wang (Calabasas, California) |
| ABSTRACT | Reducing noise and dose (radiation or contrast) for perfusion imaging in Computed Tomography Perfusion (CTP), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI) medical scanning devices by using a k-space based method. The time sequence of images from the scanner data set is converted as necessary, such as using a 2D Fast Fourier Transform (FFT), into a k-space having multiple timeframes. View-shared averaging is performed to reduce noise and preserve spatial and temporal resolutions of CTP, PET, SPECT and MRI data by progressively increasing the number of time frames for view-shared averaging for more distant regions of “k-space”, before converting the data, such as through a 2D FFT into a time sequence of noise reduced images. |
| FILED | Thursday, January 13, 2022 |
| APPL NO | 17/574988 |
| CURRENT CPC | Image Data Processing or Generation, in General G06T 5/002 (20130101) Original (OR) Class G06T 11/006 (20130101) G06T 2207/10081 (20130101) G06T 2207/10088 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Defense (DOD)
| US 20220175254 | HUI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Cornell University (Ithaca, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Xiaonan HUI (Ithaca, New York); Edwin C. KAN (Ithaca, New York) |
| ABSTRACT | Near-field coherent sensing (NCS) methods and systems are described herein. The techniques may be used to monitor vital signs is introduced herein. Multiple-input, multiple output near-field techniques may be used to characterize motion. In some embodiments, the methods and systems are used to measure cardiac motion. In some embodiments, the disclosed system is integrated into a seat, such as, for example, a car seat. The system be configured to monitor the vital signs of a seat occupant with multiple sensing points. The sensor can be integrated into the cushion and hence “invisible” to the user. |
| FILED | Thursday, March 26, 2020 |
| APPL NO | 17/598180 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/0205 (20130101) Original (OR) Class A61B 5/0265 (20130101) A61B 5/02405 (20130101) Transmission H04B 5/0043 (20130101) Wireless Communication Networks H04W 4/38 (20180201) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175306 | Cotero et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | General Electric Company (Schenectady, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Victoria Eugenia Cotero (Troy, New York); Christopher Michael Puleo (Niskayuna, New York); John Frederick Graf (Ballston Lake, New York) |
| ABSTRACT | The subject matter of the present disclosure generally relates to techniques for neuromodulation that include applying energy (e.g., ultrasound energy) into the tissue to cause a change in a glucose transporter pathway molecule and/or an incretin pathway molecule. In one embodiment, the neuromodulation is performed as a treatment of a metabolic disorder. |
| FILED | Thursday, March 12, 2020 |
| APPL NO | 17/437731 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/4244 (20130101) Original (OR) Class A61B 5/4848 (20130101) A61B 5/14532 (20130101) Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 7/00 (20130101) A61N 2007/0026 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/66 (20130101) G01N 33/6872 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175750 | HAUDENSCHILD et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); Tesio Pharmaceuticals, Inc. (Davis, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Dominik R. HAUDENSCHILD (Oakland, California); Jasper H. N. YIK (Oakland, California); Jamal S. LEWIS (Oakland, California); Tom YARBROUGH (Davis, California) |
| ABSTRACT | The present disclosure describes a novel sustained-release formulation for the local delivery of CDK9 inhibitors. |
| FILED | Tuesday, April 23, 2019 |
| APPL NO | 17/049798 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/5031 (20130101) A61K 31/453 (20130101) Original (OR) Class A61K 31/519 (20130101) A61K 31/4025 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 19/02 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175935 | Serafini et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF MIAMI (Miami, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Paolo Serafini (Miami Shores, Florida); Silvio Bicciato (Modena, Italy); Jimmy Caroli (Modena, Italy); Adriana De La Fuente (Miami, Florida); Dimitri Van Simaeys (Miami Beach, Florida); Serena Zilio (Miami, Florida); Vincenzo Bronte (Verona, Italy) |
| ABSTRACT | Described herein and RNA aptamers that specifically bind to tumor-infiltrating myeloid cells and uses thereof. |
| FILED | Tuesday, March 03, 2020 |
| APPL NO | 17/436773 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/704 (20130101) A61K 31/711 (20130101) A61K 31/7105 (20130101) A61K 47/549 (20170801) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175941 | Ruoslahti et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Sanford Burnham Prebys Medical Discovery Institute (La Jolla, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Erkki Ruoslahti (La Jolla, California); Tambet Teesalu (La Jolla, California); Kazuki Sugahara (La Jolla, California) |
| ABSTRACT | Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest. |
| FILED | Monday, July 12, 2021 |
| APPL NO | 17/373496 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 47/66 (20170801) Original (OR) Class Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 5/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175964 | Duan et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE CURATORS OF THE UNIVERSITY OF MISSOURI (Columbia, Missouri) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Dongsheng Duan (Columbia, Macau); Yi Lai (Columbia, Missouri); Junling Zhao (Columbia, Missouri); Yongping Yue (Columbia, Missouri) |
| ABSTRACT | Synthetic nucleic acids encoding mini and microdystrophin genes comprising the membrane binding motifs or domains of the R10-R11-R12 region are provided. Also provided are vectors, host cells, and related methods of using the same to treat a subject suffering from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) or X-linked dilated cardiomyopathy (XLDC), or for ameliorating one or more adverse effects of DMD, BMD, or XLDC. Also provided are a fusion protein comprising a nNOS binding domain of dystrophin R16-R17 that is operably linked to a syntrophin PDZ domain and synthetic nucleic acids comprising the same that can be used to treat subjects with diseases characterized by loss of sarcolemmal neuronal nitric oxide synthase (nNOS) activity. |
| FILED | Friday, December 17, 2021 |
| APPL NO | 17/555233 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0019 (20130101) A61K 35/28 (20130101) A61K 38/00 (20130101) A61K 48/00 (20130101) A61K 48/005 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/14 (20180101) Peptides C07K 14/4716 (20130101) C07K 2319/00 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0663 (20130101) C12N 15/62 (20130101) C12N 15/85 (20130101) C12N 15/86 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175975 | Mahmood et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The General Hospital Corporation (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Umar Mahmood (Winchester, Massachusetts); Benjamin Larimer (Woburn, Massachusetts) |
| ABSTRACT | Provided herein are compositions useful for imaging HER3. An exemplary composition provided herein is useful as a radiotracer for position emission tomography (PET) imaging. Methods of imaging HER3 and combination therapies comprising the HER3 imaging agents are also provided. |
| FILED | Monday, December 27, 2021 |
| APPL NO | 17/562861 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 51/088 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220176017 | FRANCIS et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | EMBODY INC. (Norfolk, Virginia) |
| ASSIGNEE(S) | EMBODY INC. (Norfolk, Virginia) |
| INVENTOR(S) | Michael P. FRANCIS (Norfolk, Virginia); Yas MAGHDOURI-WHITE (Norfolk, Virginia); Hilary WRIGGERS (Norfolk, Virginia); Nardos SORI (Norfolk, Virginia); Stella PETROVA (Norfolk, Virginia); Seth POLK (Norfolk, Virginia); Nicholas THAYER (Norfolk, Virginia) |
| ABSTRACT | Compositions and blends of biopolymers and bio-acceptable polymers are described, along with the use of benign solvent systems to prepare biocompatible scaffolds and surgically implantable devices for use in supporting and facilitating the repair of soft tissue injuries. |
| FILED | Thursday, December 16, 2021 |
| APPL NO | 17/552880 |
| CURRENT CPC | Filters Implantable into Blood Vessels; Prostheses; Devices Providing Patency To, or Preventing Collapsing Of, Tubular Structures of the Body, e.g Stents; Orthopaedic, Nursing or Contraceptive Devices; Fomentation; Treatment or Protection of Eyes or Ears; Bandages, Dressings or Absorbent Pads; First-aid Kits A61F 2/08 (20130101) Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 27/24 (20130101) A61L 27/26 (20130101) A61L 27/3662 (20130101) Original (OR) Class A61L 27/3804 (20130101) A61L 27/3834 (20130101) A61L 2430/10 (20130101) Mechanical Methods or Apparatus in the Manufacture of Artificial Filaments, Threads, Fibres, Bristles or Ribbons D01D 5/003 (20130101) D01D 5/0038 (20130101) D01D 5/0076 (20130101) Wall, Floor, or Like Covering Materials, e.g Linoleum, Oilcloth, Artificial Leather, Roofing Felt, Consisting of a Fibrous Web Coated With a Layer of Macromolecular Material; Flexible Sheet Material Not Otherwise Provided for D06N 3/0043 (20130101) Technical Subjects Covered by Former US Classification Y10T 428/249921 (20150401) Y10T 428/249978 (20150401) Y10T 442/419 (20150401) Y10T 442/2484 (20150401) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220176313 | Pearce et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Honeywell International Inc. (Charlotte, North Carolina) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Daniel Pearce (Chard, United Kingdom); Ian Kerr (Broadway, United Kingdom) |
| ABSTRACT | In some examples, an air treatment system includes a filter, an ozone sensor, and a separator configured to separate air into a nitrogen-enriched gas and an oxygen-enriched gas. The filter is configured to remove ozone from an air stream and supply filtered air to the separator. The ozone sensor is configured to sense an ozone level of the filtered air issuing from the filter prior to encountering the separator. The air treatment system may include processing circuitry configured to monitor the ozone level sensed. The air treatment system may be part of an inerting system configured to supply the nitrogen-enriched gas to an ullage space of a fuel tank. |
| FILED | Tuesday, February 09, 2021 |
| APPL NO | 17/171620 |
| CURRENT CPC | Separation B01D 46/44 (20130101) B01D 46/0086 (20130101) B01D 53/229 (20130101) Original (OR) Class B01D 53/8675 (20130101) B01D 2257/106 (20130101) B01D 2279/40 (20130101) Equipment for Fitting in or to Aircraft; Flying Suits; Parachutes; Arrangements or Mounting of Power Plants or Propulsion Transmissions in Aircraft B64D 13/00 (20130101) B64D 37/005 (20130101) Non-metallic Elements; Compounds Thereof; C01B 21/0494 (20130101) C01B 2210/001 (20130101) C01B 2210/0006 (20130101) C01B 2210/0045 (20130101) C01B 2210/0092 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220176346 | Gurtowski et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | United States of America, as Represented by The Secretary of The Army (Alexandria, Virginia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Luke A. Gurtowski (Vicksburg, Mississippi); David P. Martin (Clinton, Mississippi); Christopher S. Griggs (Vicksburg, Mississippi); Manoj K. Shukla (Vicksburg, Mississippi); Christian T. Hubley (Vicksburg, Mississippi) |
| ABSTRACT | In one embodiment, a method of removing a substance from a solution by adsorption includes: interfacing a delivery component containing a quantity of amine functionalized chitin (AFC) compound as an adsorbent AFC compound with the solution containing the substance as an adsorbate substance; mixing the adsorbent AFC compound and the adsorbate substance in the solution for a period of time; and removing a mixture of the adsorbent AFC compound and at least a portion of the adsorbate substance from the solution. |
| FILED | Wednesday, September 29, 2021 |
| APPL NO | 17/488311 |
| CURRENT CPC | Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus B01J 20/265 (20130101) Original (OR) Class Polysaccharides; Derivatives Thereof C08B 37/003 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177127 | Cooper et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY (Washington, District of Columbia) |
| ASSIGNEE(S) | GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY (Washington, District of Columbia) |
| INVENTOR(S) | Neil E. Cooper (Sterling Heights, Michigan); Eric S. Paternoster (Saint Clair Shores, Michigan); Jason A. Schrader (Washington, Michigan); Gary L. Bronstetter (Macomb, Michigan) |
| ABSTRACT | An enclosure for a UAS includes a housing having a base and a plurality of sidewalls coupled to the base, a motive apparatus coupled to the housing, a platform coupled to the motive apparatus, and a plurality of lids pivotably coupled to the sidewalls and the platform. The platform and the plurality of lids move collectively under control of the motive apparatus (e.g., a linear actuator). Driving the motive apparatus in a first direction causes the platform to raise from a stowed position toward a deployed position and causes each of the plurality of lids to pivot from a closed position toward an open position. Conversely, driving the motive apparatus in a second direction opposite the first direction causes the platform to lower from the deployed position toward the stowed position and causes each of the plurality of lids to pivot from the open position toward the closed position. |
| FILED | Monday, September 27, 2021 |
| APPL NO | 17/485633 |
| CURRENT CPC | Aeroplanes; Helicopters B64C 39/024 (20130101) Original (OR) Class B64C 2201/042 (20130101) B64C 2201/141 (20130101) B64C 2201/201 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177331 | Yang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY (Hoboken, New Jersey) |
| ASSIGNEE(S) | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY (Hoboken, New Jersey) |
| INVENTOR(S) | Eui-Hyeok Yang (Fort Lee, New Jersey); Ronald Besser (New Providence, New Jersey); Jian Xu (West Lafayette, Indiana); Wei Xu (Farmingdale, New York); Brendan Englot (New York, New York); Chang-Hwan Choi (Tenafly, New Jersey) |
| ABSTRACT | Smart membranes are integrated into a small, unmanned surface vessel to enable the efficient, automated cleanup of oil spills. Such a vessel has the potential to provide a low-cost, modular solution for day-to-day oil-spill cleanup operations, especially in confined aquatic areas (e.g., under piers or in the small spaces between marine vessels and piers). The membranes are provided on the surface of a conveyor belt that circulates the membranes through the surrounding body of water for oil collection, as well as through an internal reduction chamber of the vessel for oil release. The smart membranes are adapted to attract and repel oil in response to low-voltage commands applied across the conveyor belt, using a process that is repeatable for a number of cycles, offering high efficiency and long durability. Segments of the conveyor belt can be electrically isolated from one another to allow disparate electrical potentials to be imposed thereon. |
| FILED | Friday, February 25, 2022 |
| APPL NO | 17/681581 |
| CURRENT CPC | Treatment of Water, Waste Water, Sewage, or Sludge C02F 1/40 (20130101) Original (OR) Class C02F 1/285 (20130101) C02F 1/288 (20130101) C02F 2101/32 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177379 | Amini et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Raytheon Technologies Corporation (Farmington, Connecticut) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Shahram Amini (Glastonbury, Connecticut); Wayde R. Schmidt (Pomfret Center, Connecticut); Tania Bhatia Kashyap (West Hartford, Connecticut); Mark A. Hermann (Glastonbury, Connecticut); Paul Sheedy (Bolton, Connecticut); Andi M. Limarga (Vernon, Connecticut); Michael G. McCaffrey (Windsor, Connecticut) |
| ABSTRACT | A disclosed method of forming a ceramic article includes forming a pre-ceramic polymer article within a mold tool, and performing a first pyrolizing step on the initial pre-ceramic polymer article to form a ceramic article. The method further includes performing at least one pre-heat treatment polymer infiltration and pyrolizing (PIP) cycle on the ceramic article and an initial heat treatment cycle of the ceramic article after the at least one pre-heat treatment PIP cycle. Subsequent PIP cycles and heat treatment cycles are performed in combination to form a ceramic article including a desired density. |
| FILED | Monday, November 29, 2021 |
| APPL NO | 17/536216 |
| CURRENT CPC | Shaping Clay or Other Ceramic Compositions; Shaping Slag; Shaping Mixtures Containing Cementitious Material, e.g Plaster B28B 1/24 (20130101) B28B 1/52 (20130101) Lime, Magnesia; Slag; Cements; Compositions Thereof, e.g Mortars, Concrete or Like Building Materials; Artificial Stone; Ceramics; Refractories; Treatment of Natural Stone C04B 35/80 (20130101) Original (OR) Class C04B 35/524 (20130101) C04B 35/532 (20130101) C04B 38/0022 (20130101) C04B 2235/48 (20130101) C04B 2235/602 (20130101) C04B 2235/616 (20130101) C04B 2235/5252 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177457 | KRIWACKI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | St. Jude Children's Hospital, Inc. (Memphis, Japan) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Richard KRIWACKI (Memphis, Tennessee); Jian ZUO (Memphis, Tennessee); Luigi ICONARU (Memphis, Tennessee); Sourav DAS (Memphis, Tennessee); Anang SHELAT (Memphis, Tennessee); Brandon YOUNG (Memphis, Tennessee) |
| ABSTRACT | Various compounds and pharmaceutically acceptable salts thereof are provided capable of binding cyclin-dependent kinase inhibitor 1B. The compounds can have a structure according to Formula I or Formula II as detailed herein. The compounds can include SJ747, SJ749, SJ755, SJ757. Pharmaceutical formulations containing the compounds or pharmaceutically acceptable salts are also provided along with methods of use thereof. The formulations and methods can be useful for treating cancer. In some aspects, the cancer is associated with a mislocalization of the intrinsically disordered protein p27. In some aspects, the cancer is resistant to an anticancer therapy. The pharmaceutical formulation can therefore include a second active agent and/or can be given in combination with a second active agent such as a cancer therapeutic. In various aspects, methods of promoting reentry into the cell division cycle in a subject in need thereof using compounds and formulations described herein are also provided. |
| FILED | Thursday, March 12, 2020 |
| APPL NO | 17/438857 |
| CURRENT CPC | Heterocyclic Compounds C07D 405/12 (20130101) Original (OR) Class C07D 405/14 (20130101) C07D 407/14 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177754 | Pollum, Jr. et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | PPG Industries Ohio, Inc. (Cleveland, Ohio) |
| ASSIGNEE(S) | PPG Industries Ohio, Inc. (Cleveland, Ohio) |
| INVENTOR(S) | Marvin M. Pollum, Jr. (Pittsburgh, Pennsylvania); Masayuki Nakajima (Wexford, Pennsylvania); Hongying Zhou (Allison Park, Pennsylvania); Joseph P. Kriley (Valencia, Pennsylvania); Brian K. Rearick (Allison Park, Pennsylvania) |
| ABSTRACT | Disclosed herein are curable compositions comprising an epoxide-functional polymer and a curing agent that reacts with the epoxide-functional polymer that is activatable by an external energy source. The epoxide-functional polymer may be a solid a solid epoxide-functional polyurethane comprising a di-isocyanate. Also disclosed are articles comprising one of the compositions in an at least partially cured state positioned between first and second substrates. Also disclosed are methods of forming an adhesive on a substrate. |
| FILED | Thursday, February 27, 2020 |
| APPL NO | 17/605325 |
| CURRENT CPC | Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds C08G 18/10 (20130101) C08G 18/73 (20130101) C08G 18/831 (20130101) C08G 18/2845 (20130101) C08G 18/4833 (20130101) C08G 59/28 (20130101) C08G 59/4021 (20130101) C08G 2170/20 (20130101) Compositions of Macromolecular Compounds C08L 75/08 (20130101) C08L 2207/53 (20130101) Adhesives; Non-mechanical Aspects of Adhesive Processes in General; Adhesive Processes Not Provided for Elsewhere; Use of Materials as Adhesives C09J 7/35 (20180101) C09J 163/00 (20130101) C09J 175/08 (20130101) Original (OR) Class C09J 2400/163 (20130101) C09J 2463/00 (20130101) C09J 2475/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177765 | Trifu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Aspen Aerogels, Inc. (Northborough, Massachusetts) |
| ASSIGNEE(S) | Aspen Aerogels, Inc. (Northborough, Massachusetts) |
| INVENTOR(S) | Roxana Trifu (Worcester, None); Redouane Begag (Hudson, None); George Gould (Mendon, None); Shannon White (Bolton, None) |
| ABSTRACT | The present disclosure can provide aerogel compositions which have a thermal storage capacity, and which are durable and easy to handle. The present disclosure can provide aerogel compositions which include PCM coatings, particle mixtures, or PCM materials confined within the porous network of an aerogel composition. The present disclosure can provide methods for producing aerogel compositions by coating an aerogel composition with PCM materials, by forming particle mixtures with PCM materials, or by confining PCM materials within the porous network of an aerogel composition. |
| FILED | Monday, September 27, 2021 |
| APPL NO | 17/486152 |
| CURRENT CPC | Layered Products, i.e Products Built-up of Strata of Flat or Non-flat, e.g Cellular or Honeycomb, Form B32B 5/18 (20130101) Non-metallic Elements; Compounds Thereof; C01B 33/1585 (20130101) Working-up; General Processes of Compounding; After-treatment Not Covered by Subclasses C08B, C08C, C08F, C08G or C08H C08J 9/0009 (20130101) C08J 9/0014 (20130101) C08J 9/0023 (20130101) C08J 9/42 (20130101) C08J 9/0061 (20130101) C08J 9/0066 (20130101) C08J 9/0085 (20130101) C08J 9/286 (20130101) C08J 9/365 (20130101) Use of Inorganic or Non-macromolecular Organic Substances as Compounding Ingredients C08K 3/16 (20130101) C08K 5/01 (20130101) C08K 5/053 (20130101) Materials for Miscellaneous Applications, Not Provided for Elsewhere C09K 5/063 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177838 | Humes et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | SeaStar Medical, Inc. (Denver, Colorado) |
| ASSIGNEE(S) | |
| INVENTOR(S) | H. David Humes (Ann Arbor, Michigan); Deborah A. Buffington (Ann Arbor, Michigan); Christopher J. Pino (Saline, Michigan) |
| ABSTRACT | The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions within a subject and to related methods. More particularly, the invention relates to a cytopheretic cartridge that includes a housing and, disposed within the housing, a solid support capable of sequestering activated leukocytes and/or platelets. |
| FILED | Monday, September 13, 2021 |
| APPL NO | 17/473176 |
| CURRENT CPC | Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor A61M 1/1698 (20130101) A61M 1/3672 (20130101) A61M 1/3675 (20130101) A61M 1/3679 (20130101) A61M 2202/0439 (20130101) Separation B01D 63/02 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0634 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177911 | Zhu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | California Institute of Technology (Pasadena, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ronghui Zhu (Pasadena, California); Michael B. Elowitz (Pasadena, California) |
| ABSTRACT | Disclosed herein include circuits, compositions, nucleic acids, populations, systems, and methods enabling single circuits to generate multiple molecularly and functionally distinct states that are each stable across multiple cell division cycles. Synthetic circuits provided herein can stably exist in multiple distinct states characterized by differences in the concentrations and expression levels of its components. In the absence of changes to the external environment, each of these states can be stable. In some embodiments, transcription factors provided herein activate when dimerized, and show much weaker activity as monomers. In some embodiments, each transcription factor homodimer activates expression of its own gene. In some embodiments, transcription factors can form mixed heterodimers with one another that do not strongly activate any genes in the circuit. Different embodiments of the synthetic circuits provided herein can use different numbers of transcription factors to produce a growing number of stable states. |
| FILED | Tuesday, December 07, 2021 |
| APPL NO | 17/544865 |
| CURRENT CPC | Peptides C07K 14/4705 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/85 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177941 | Jewett et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northwestern University (Evanston, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Michael Christopher Jewett (Evanston, Illinois); Anne E. d'Aquino (Evanston, Illinois) |
| ABSTRACT | Disclosed are engineered or modified E. coli ribosomes and methods, components, compositions, and kits for preparing and identifying engineered or modified E. coli ribosomes. The engineered or modified E. coli ribosomes may be prepared and identified under a set of defined conditions, such as in the presences of a engineered or modified tRNA comprising a non-natural, non-α-amino acid monomer (NNA), in order to obtain an engineered or modified ribosome that utilizes the engineered or modified tRNA as a substrate for synthesizing a polymer comprising the NNA. |
| FILED | Monday, July 08, 2019 |
| APPL NO | 17/258377 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 1/20 (20130101) C12N 9/104 (20130101) C12N 15/113 (20130101) C12N 15/1058 (20130101) C12N 2310/128 (20130101) Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 21/02 (20130101) Original (OR) Class Enzymes C12Y 203/02012 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178042 | Choi et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY (Hoboken, New Jersey) |
| ASSIGNEE(S) | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY (Hoboken, New Jersey) |
| INVENTOR(S) | Chang-Hwan Choi (Tenafly, New Jersey); Junghoon Lee (Palisades Park, New Jersey) |
| ABSTRACT | A process includes means for depositing an anti-corrosion coating filled with liquid oil on an aluminum substrate. Aluminum is anodized and then treated with a thin hydrophobic sub-coating. The pores created through anodization are then impregnated with liquid oil. Oil penetration is maximized and residual air is minimized by first filling the pores with a filling solution, replacing the filling solution with an exchange fluid, and then replacing the exchange fluid with perfluorinated oil. The oil gives the surface coating anti-wetting properties and self-healing properties, thereby protecting the aluminum substrate underneath from corrosion. |
| FILED | Tuesday, January 25, 2022 |
| APPL NO | 17/584160 |
| CURRENT CPC | Processes for the Electrolytic or Electrophoretic Production of Coatings; Electroforming; Apparatus Therefor C25D 11/246 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178813 | Jalali et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Bahram Jalali (Los Angeles, California); Eric D. Diebold (Los Angeles, California); Brandon Buckley (Los Angeles, California) |
| ABSTRACT | An imaging flow cytometry apparatus and method which allows registering multiple locations across a cell, and/or across multiple flow channels, in parallel using radio-frequency-tagged emission (FIRE) coupled with a parallel optical detection scheme toward increasing analysis throughput. An optical source is modulated by multiple RF frequencies to produce an optical interrogation beam having a spatially distributed beat frequency. This beam is directed to one or more focused streams of cells whose responsive fluorescence, in different frequencies, is registered in parallel by an optical detector. |
| FILED | Tuesday, February 08, 2022 |
| APPL NO | 17/666841 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 15/1434 (20130101) Original (OR) Class G01N 15/1459 (20130101) G01N 15/1484 (20130101) G01N 21/64 (20130101) G01N 33/537 (20130101) G01N 2015/1006 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178831 | Robinson et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Penn State Research Foundation (University Park, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Joshua A. Robinson (State College, Pennsylvania); Natalie Briggs (Benton City, Washington); Kenneth Knappenberger (State College, Pennsylvania); Tian Zhao (State College, Pennsylvania) |
| ABSTRACT | Embodiments relate to a layered material (having a substrate, at least a buffer layer, with zero or more growth layers) that has been intercalated via a process that decouples (physically and electronically) the buffer layer from the substrate, thereby resulting in the creation of few-atom thick metal layers that exhibit a range of optical properties, including plasmonic or electronic resonance, that enables superior optical (e.g. Raman) detection of molecules. |
| FILED | Tuesday, April 21, 2020 |
| APPL NO | 17/594595 |
| CURRENT CPC | Single-crystal-growth; Unidirectional Solidification of Eutectic Material or Unidirectional Demixing of Eutectoid Material; Refining by Zone-melting of Material; Production of a Homogeneous Polycrystalline Material With Defined Structure; Single Crystals or Homogeneous Polycrystalline Material With Defined Structure; After-treatment of Single Crystals or a Homogeneous Polycrystalline Material With Defined Structure; Apparatus Therefor C30B 23/025 (20130101) C30B 25/183 (20130101) C30B 29/06 (20130101) C30B 29/46 (20130101) C30B 29/68 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/658 (20130101) Original (OR) Class G01N 2201/06113 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 21/02378 (20130101) H01L 21/02499 (20130101) H01L 21/02527 (20130101) H01L 21/02532 (20130101) H01L 21/02631 (20130101) H01L 21/02694 (20130101) H01L 29/1606 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178912 | Schwartz et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of Colorado, A Body Corporate (Aurora, Colorado) |
| ASSIGNEE(S) | |
| INVENTOR(S) | David Schwartz (Denver, Colorado); Ian Stancil (Denver, Colorado) |
| ABSTRACT | A method of screening a test compound, e.g., a fibrosis or IPF inhibitor, for induction of an unjammed-to-jammed transition (UJT) in fibrotic primary human bronchial epithelial cells (HBECs) isolated from a subject with a fibrotic lung disease includes culturing the fibrotic primary HBECs at an air-liquid interface for a time sufficient to provide a differentiated pseudostratified epithelium contacting the cultured cells with the test compound; and monitoring the motility of the cultured cells to identify the cultured cells as moving or stationary; wherein stationary cultured cells indicate that the test compound induces the UJT. Also included are methods of identifying lung fibrosis biomarkers. |
| FILED | Thursday, December 09, 2021 |
| APPL NO | 17/546554 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/5029 (20130101) Original (OR) Class G01N 33/5044 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220179244 | Shaltout et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| ASSIGNEE(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| INVENTOR(S) | Amr Mohammad E. Shaltout (West Lafayette, Indiana); Alexander V. Kildishev (West Lafayette, Indiana); Vladimir M. Shalaev (West Lafayette, Indiana) |
| ABSTRACT | A time-varying optical metasurface, comprising a plurality of modulated nano-antennas configured to vary dynamically over time. The metasurface may be implemented as part of an optical isolator, wherein the time-varying metasurface provides uni-directional light flow. The metasurface allows the breakage of Lorentz reciprocity in time-reversal. The metasurface may operate in a transmission mode or a reflection mode. |
| FILED | Wednesday, July 28, 2021 |
| APPL NO | 17/387817 |
| CURRENT CPC | Optical Elements, Systems, or Apparatus G02B 1/002 (20130101) G02B 3/0081 (20130101) Devices or Arrangements, the Optical Operation of Which Is Modified by Changing the Optical Properties of the Medium of the Devices or Arrangements for the Control of the Intensity, Colour, Phase, Polarisation or Direction of Light, e.g Switching, Gating, Modulating or Demodulating; Techniques or Procedures for the Operation Thereof; Frequency-changing; Non-linear Optics; Optical Logic Elements; Optical Analogue/digital Converters G02F 1/29 (20130101) G02F 1/0063 (20130101) Original (OR) Class G02F 1/093 (20130101) G02F 1/0136 (20130101) G02F 1/355 (20130101) G02F 2202/30 (20130101) G02F 2203/10 (20130101) Holographic Processes or Apparatus G03H 2001/0224 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220179284 | Bourassa et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The University of Chicago (Chicago, Illinois) |
| ASSIGNEE(S) | The University of Chicago (Chicago, Illinois) |
| INVENTOR(S) | Alexandre Bourassa (Chicago, Illinois); Christopher P. Anderson (Chicago, Illinois); David D. Awschalom (Chicago, Illinois) |
| ABSTRACT | This disclosure relates to optical devices for quantum information processing applications. In one example implementation, a semiconductor structure is provided. The semiconductor structure may be embedded with single defects that can be individually addressed. An electric bias and/or one or more optical excitations may be configured to control the single defects in the semiconductor structure to produce single photons for use in quantum information processing. The electric bias and optical excitations are selected and adjusted to control various carrier processes and to reduce environmental charge instability of the single defects to achieve optical emission with wide wavelength tunability and narrow spectral linewidth. Electrically controlled single photon source and other electro-optical devices may be achieved. |
| FILED | Friday, March 13, 2020 |
| APPL NO | 17/438600 |
| CURRENT CPC | Devices or Arrangements, the Optical Operation of Which Is Modified by Changing the Optical Properties of the Medium of the Devices or Arrangements for the Control of the Intensity, Colour, Phase, Polarisation or Direction of Light, e.g Switching, Gating, Modulating or Demodulating; Techniques or Procedures for the Operation Thereof; Frequency-changing; Non-linear Optics; Optical Logic Elements; Optical Analogue/digital Converters G02F 3/022 (20130101) Original (OR) Class Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 39/10 (20130101) H01L 39/221 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220179417 | Blankespoor et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Boston Dynamics, Inc. (Waltham, Massachusetts) |
| ASSIGNEE(S) | Boston Dynamics, Inc. (Waltham, Massachusetts) |
| INVENTOR(S) | Kevin Blankespoor (Arlington, Massachusetts); Gabriel Nelson (Waltham, Massachusetts); Neil Neville (Waltham, Massachusetts) |
| ABSTRACT | A method for estimating a ground plane includes receiving a pose of a robotic device with respect to a gravity aligned reference frame, receiving one or more locations of one or more corresponding contact points between the robotic device and a ground surface, and determining a ground plane estimation of the ground surface based on the orientation of the robotic device with respect to the gravity aligned reference frame and the one or more locations of one or more corresponding contact points between the robotic device and the ground surface. The ground plane estimation includes a ground surface contour approximation. The method further includes determining a distance between a body of the robotic device and the determined ground plane estimation and causing adjustment of the pose of the robotic device with respect to the ground surface based on the determined distance and the determined ground plane estimation. |
| FILED | Wednesday, February 23, 2022 |
| APPL NO | 17/652103 |
| CURRENT CPC | Manipulators; Chambers Provided With Manipulation Devices B25J 9/0006 (20130101) B25J 9/1615 (20130101) B25J 9/1694 (20130101) B25J 9/1697 (20130101) Motor Vehicles; Trailers B62D 57/032 (20130101) Systems for Controlling or Regulating Non-electric Variables G05D 1/0088 (20130101) Original (OR) Class G05D 1/0891 (20130101) Technical Subjects Covered by Former USPC Cross-reference Art Collections [XRACs] and Digests Y10S 901/01 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220179465 | Bose et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | International Business Machines Corporation (Armonk, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Pradip Bose (Yorktown Heights, New York); Alper Buyuktosunoglu (White Plains, New York); Timothy Joseph Chainer (Putnam Valley, New York); Pritish Ranjan Parida (Fishkill, New York); Augusto Javier Vega (Astoria, New York) |
| ABSTRACT | Techniques for inducing non-uniform cooling are described. According to an embodiment, a system is provided. The system can comprise at least one processor device that executes components stored in a memory, wherein the components comprise: a flow control device that distributes coolant to a location of the at least one processor device; and a sensor controller component that detects a location of a thermal anomaly of the at least one processor device. The components can also comprise a cooling controller component that adjusts the flow control device to direct the coolant to the location of the thermal anomaly. |
| FILED | Friday, January 03, 2020 |
| APPL NO | 16/733362 |
| CURRENT CPC | Control or Regulating Systems in General; Functional Elements of Such Systems; Monitoring or Testing Arrangements for Such Systems or Elements G05B 2219/50324 (20130101) Systems for Controlling or Regulating Non-electric Variables G05D 23/1932 (20130101) Electric Digital Data Processing G06F 1/20 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220179891 | Ceze et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Washington (Seattle, Washington); Microsoft Technology Licensing, LLC (Redmond, Washington) |
| ASSIGNEE(S) | University of Washington (Seattle, Washington); Microsoft Technology Licensing, LLC (Redmond, Washington) |
| INVENTOR(S) | Luis Ceze (Seattle, Washington); Karin Strauss (Seattle, Washington); Georg Seelig (Seattle, Washington); Callie Bee (Seattle, Washington); Yuan-Jyue Chen (Seattle, Washington) |
| ABSTRACT | In some embodiments, techniques are provided for conducting similarity-based searches using DNA. In some embodiments, sets of features that represent stored data sets are encoded in DNA sequences such that a hybridization yield between a molecule having a given stored DNA sequence and a molecule having a reverse complement of a DNA sequence that encodes a set of features that represent a query data set reflects an amount of similarity between the set of features that represent the query data set and the set of features encoded in the given stored DNA sequence. In some embodiments, machine learning techniques are used to determine the DNA sequence encoding. In some embodiments, machine learning techniques are used to predict hybridization yields between DNA molecules. |
| FILED | Thursday, April 09, 2020 |
| APPL NO | 17/602075 |
| CURRENT CPC | Electric Digital Data Processing G06F 16/3346 (20190101) Original (OR) Class Bioinformatics, i.e Information and Communication Technology [ICT] Specially Adapted for Genetic or Protein-related Data Processing in Computational Molecular Biology G16B 30/10 (20190201) G16B 40/20 (20190201) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220180083 | Whitesides et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | President and Fellows of Harvard College (Cambridge, Massachusetts); Northwestern University (Evanston, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | George M. Whitesides (Newton, Massachusetts); Albert Siangyoong Wong (Enschede, Netherlands); Michael Johannes Fink (Cambridge, Massachusetts); Khaled Abdelazim Mohamed (Cambridge, Massachusetts); Alexei S. Ten (Evanston, Illinois); Milan M. Mrksich (Hinsdale, Illinois) |
| ABSTRACT | Storage media are provided. A substrate has an array of addressable locations thereon, each addressable location adapted to be physically associated with a collection of molecules, each collection comprising at least a first subcollection of molecules and a second subcollection of molecules. The molecules in the collection are selected from a set of unambiguously identifiable molecules, the set comprising at least a first subset of molecules and a second subset of molecules. Each molecule in the first subset is identifiable by a first physical property, and each molecule in the second subset is identifiable by a second physical property, different from the first physical property. Each molecule in the set is uniquely associated with a predetermined position in a numerical value, wherein the presence of the molecule in the collection indicates a predetermined digit at the associated position and the absence of said molecule in the collection indicates a zero at said associated position. |
| FILED | Friday, February 25, 2022 |
| APPL NO | 17/681155 |
| CURRENT CPC | Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus B01J 19/0046 (20130101) B01J 2219/00605 (20130101) B01J 2219/00659 (20130101) B01J 2219/00695 (20130101) B01J 2219/00725 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 30/90 (20130101) Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers G06K 7/1434 (20130101) Original (OR) Class G06K 19/06037 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220181877 | LEEB et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Steven B. LEEB (Belmont, Massachusetts); John K. NOWOCIN (Cambridge, Massachusetts); Peter LINDAHL (Wellesley, Massachusetts); Spencer C. SHABSHAB (McLean, Virginia) |
| ABSTRACT | Described are systems and techniques for extracting frequency and voltage harmonic transients corresponding to individual load events. Such systems and techniques can be used to make electrical loads aware of the operation of other loads in an electric grid. Thus, awareness is achieved using information derived only from a utility voltage waveform at a load. Also described are systems and techniques for incorporating such awareness into load controllers which allows loads to autonomously meet system level objectives in addition to their individual requirements. |
| FILED | Friday, February 14, 2020 |
| APPL NO | 17/430752 |
| CURRENT CPC | Measuring Electric Variables; Measuring Magnetic Variables G01R 23/16 (20130101) Control or Regulating Systems in General; Functional Elements of Such Systems; Monitoring or Testing Arrangements for Such Systems or Elements G05B 19/042 (20130101) G05B 2219/2639 (20130101) Circuit Arrangements or Systems for Supplying or Distributing Electric Power; Systems for Storing Electric Energy H02J 3/00125 (20200101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220182070 | Fan et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Trustees of the Leland Stanford Junior Univeristy (Stanford, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Shanhui Fan (Stanford, California); Bo Zhao (Menlo Park, California); Sid Assawaworrarit (Redwood City, California); Parthiban Santhanam (Redwood City, California); Meir Orenstein (Haifa, Israel) |
| ABSTRACT | In certain examples, methods and semiconductor structures are directed to an apparatus including a photon emitter such as an LED which operates over an emission wavelength range and a photo-voltaic device arranged relative to the photon emitter to provide index-matched optical coupling between the photo-voltaic device and the photon emitter for an emission wavelength range of the photon emitter. |
| FILED | Friday, December 03, 2021 |
| APPL NO | 17/541521 |
| CURRENT CPC | Coding; Decoding; Code Conversion in General H03M 1/66 (20130101) H03M 7/008 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220182402 | Leslie |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Raytheon Company (Waltham, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Nandi O. Leslie (Silver Spring, Maryland) |
| ABSTRACT | Discussed herein are devices, systems, and methods for detecting anomalous or malicious processes based on in-vehicle network traffic data. A method includes receiving, at a monitor device, a controller access network (CAN) bus packet from an electronic control unit (ECU), implementing an ensemble hierarchical agglomerative clustering (E-HAC) algorithm to identify respective clusters to which the CAN bus data maps, and determining, based on the identified respective clusters, whether the CAN bus packet is associated with in-vehicle network intrusion. |
| FILED | Monday, November 01, 2021 |
| APPL NO | 17/516101 |
| CURRENT CPC | Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers G06K 9/6219 (20130101) Transmission of Digital Information, e.g Telegraphic Communication H04L 12/40071 (20130101) H04L 63/1425 (20130101) Original (OR) Class H04L 2012/40215 (20130101) H04L 2012/40273 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
National Science Foundation (NSF)
| US 20220174962 | Webb et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CORNELL UNIVERSITY (Ithaca, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | James Webb (Ithaca, New York); Jing Chen (Ithaca, New York); Minglin Ma (Ithaca, New York) |
| ABSTRACT | A composition for detoxifying insect pollinators from one or more organophosphate pesticides, the composition containing microparticles comprising: (i) a phosphotriesterase; (ii) nanoparticles; and (iii) a surface active agent. Also disclosed herein is an aqueous suspension comprising the above-described detoxifying microparticles in an external aqueous medium, which may also contain an insect pollinator attractant. Also described herein is a method for detoxifying insect pollinators of one or more organophosphate pesticides, the method comprising placing the detoxifying aqueous suspension in a location accessible to the insect pollinators to permit the insect pollinators to ingest the detoxifying aqueous suspension, wherein the detoxifying aqueous suspension comprises microparticles, as described above, suspended in an external aqueous medium, typically also including an insect pollinator attractant in the external aqueous medium. |
| FILED | Tuesday, December 07, 2021 |
| APPL NO | 17/544375 |
| CURRENT CPC | Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators A01N 25/04 (20130101) A01N 25/08 (20130101) A01N 63/50 (20200101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175510 | MacEwan et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Washington University (St. Louis, Missouri) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Matthew R. MacEwan (St. Louis, Missouri); Jingwei Xie (Chesapeake, Ohio); Zack Ray (St. Louis, Missouri); Younan Xia (Atlanta, Georgia) |
| ABSTRACT | A structure of aligned (e.g., radially and/or polygonally aligned) fibers, and systems and methods for producing and using the same. One or more structures provided may be created using an apparatus that includes one or more first electrodes that define an area and/or partially circumscribe an area. For example, a single first electrode may enclose the area, or a plurality of first electrode(s) may be positioned on at least a portion of the perimeter of the area. A second electrode is positioned within the area. Electrodes with rounded (e.g., convex) surfaces may be arranged in an array, and a fibrous structure created using such electrodes may include an array of wells at positions corresponding to the positions of the electrodes. |
| FILED | Friday, July 23, 2021 |
| APPL NO | 17/383958 |
| CURRENT CPC | Filters Implantable into Blood Vessels; Prostheses; Devices Providing Patency To, or Preventing Collapsing Of, Tubular Structures of the Body, e.g Stents; Orthopaedic, Nursing or Contraceptive Devices; Fomentation; Treatment or Protection of Eyes or Ears; Bandages, Dressings or Absorbent Pads; First-aid Kits A61F 2/02 (20130101) Original (OR) Class A61F 2/0063 (20130101) A61F 2/105 (20130101) Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 15/22 (20130101) A61L 15/42 (20130101) A61L 27/14 (20130101) A61L 27/50 (20130101) Shaping or Joining of Plastics; Shaping of Material in a Plastic State, Not Otherwise Provided For; After-treatment of the Shaped Products, e.g Repairing B29C 48/05 (20190201) B29C 48/142 (20190201) Apparatus for Enzymology or Microbiology; C12M 25/14 (20130101) Mechanical Methods or Apparatus in the Manufacture of Artificial Filaments, Threads, Fibres, Bristles or Ribbons D01D 5/0076 (20130101) D01D 5/0092 (20130101) Making Textile Fabrics, e.g From Fibres or Filamentary Material; Fabrics Made by Such Processes or Apparatus, e.g Felts, Non-woven Fabrics; Cotton-wool; Wadding D04H 1/728 (20130101) D04H 3/016 (20130101) D04H 3/073 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175661 | Chikan et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Kansas State University Research Foundation (Manhattan, Kansas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Viktor Chikan (Manhattan, Kansas); Ryan Rafferty (Manhattan, Kansas) |
| ABSTRACT | Methods for enhancing intracellular uptake of active agents by inducing temporary pore formation in a cell membrane are described. The methods generally comprise introducing nanoparticles to a cell in vivo, ex vivo, or in cell culture to magnetic nanoparticles that are taken up into the cell interior. The methods further comprise introducing active agents to the cell. A magnetic field is applied to the cell for targeted excitation of the internalized magnetic nanoparticles to induce temporary pore formation in the cell membrane, such that the active agent is taken up in an increased amount and/or at an increased rate by the cell. |
| FILED | Wednesday, March 25, 2020 |
| APPL NO | 17/442349 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0009 (20130101) Original (OR) Class A61K 9/0019 (20130101) A61K 41/0023 (20130101) A61K 41/0047 (20130101) Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 2/002 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 13/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175833 | Xie et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Children's Medical Center Corporation (Boston, Massachusetts); Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| ASSIGNEE(S) | Children's Medical Center Corporation (Boston, Massachusetts); Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| INVENTOR(S) | Yushu J. Xie (Brookline, Massachusetts); Hidde L. Ploegh (Boston, Massachusetts) |
| ABSTRACT | Provided herein are engineered cells that comprising a chimeric antigen receptor comprising an extracellular target-binding moiety and an intracellular signaling domain; and secrets a heavy-chain antibody (VHH) or a VHH fusion protein. Methods of using the engineered cell to treat a disease (e.g., cancer or autoimmune disease) are also provided. |
| FILED | Friday, March 06, 2020 |
| APPL NO | 17/436131 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 35/17 (20130101) Original (OR) Class Peptides C07K 16/2827 (20130101) C07K 2317/22 (20130101) C07K 2317/569 (20130101) C07K 2319/33 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175978 | Turker et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CORNELL UNIVERSITY (Ithaca, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Melik Z. Turker (Princeton, New Jersey); Thomas C. Gardinier (Raritan, New Jersey); Ulrich B. Wiesner (Ithaca, New York) |
| ABSTRACT | Silica nanorings, methods of making silica nanorings, and uses of silica nanorings. The silica nanorings may be surface selective functionalization, with one or more polyethylene glycol (PEG) group(s), one or more display group(s), one or more functional group(s), or a combination thereof. The silica nanorings may have a size of 5 to 20 nm. The silica nanorings may be made using micelles. The absence or presence of the micelles during PEGylation and/or functionalization allows for the surface selective functionalization. The silica nanorings may be used in various diagnostic and/or treatment methods. |
| FILED | Wednesday, April 15, 2020 |
| APPL NO | 17/603494 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/14 (20130101) A61K 49/04 (20130101) A61K 49/005 (20130101) A61K 49/0039 (20130101) A61K 49/0041 (20130101) A61K 51/1244 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220176177 | SETHI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | HEN Nozzles Inc. (Castro Valley, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sunny SETHI (Castro Valley, California); Nicholas J. MCKIBBEN (Oakland, California) |
| ABSTRACT | An adjustable nozzle having a nozzle body having an inlet section with an inlet opening, an outlet section with an outlet opening, and a fluid flow path extending from the inlet opening to the outlet opening; a spray restrictor segment located in the outlet section; and an actuator that displaces the spray restrictor segment toward and away from a center of the fluid flow path, thereby varying a pattern of fluid flowing from the fluid flow path through the outlet opening. |
| FILED | Thursday, January 06, 2022 |
| APPL NO | 17/569821 |
| CURRENT CPC | Fire-fighting A62C 31/03 (20130101) Original (OR) Class Spraying Apparatus; Atomising Apparatus; Nozzles B05B 1/06 (20130101) B05B 1/12 (20130101) B05B 1/26 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220176321 | Mitra et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | New Jersey Institute of Technology (Newark, New Jersey) |
| ASSIGNEE(S) | New Jersey Institute of Technology (Newark, New Jersey) |
| INVENTOR(S) | Somenath Mitra (Bridgewater, New Jersey); Sagar Roy (Newark, New Jersey); Oindrila Gupta (Harrison, New Jersey) |
| ABSTRACT | A membrane distillation (MD) system consisting of a membrane module and carbon nanotube immobilized membrane for organic solvent separation is disclosed. The MD module includes a feed inlet and outlet, a sweep gas inlet, and a sweep gas outlet. Thermostats are positioned at the feed inlet and outlet to measure the change in temperature. Preferential sorption of the organic on carbon nanotube immobilized membrane contributes to enhanced solvent removal of the MD system. A pervaporation (PV) system consisting of a membrane module and polyvinyl alcohol (PVA) mixed matrix membranes with graphene oxide (GO)—carbon nanotubes (CNTs) for enhanced purification of the alcohol solution after membrane distillation to remove trace amount of water is disclosed. |
| FILED | Monday, December 06, 2021 |
| APPL NO | 17/543488 |
| CURRENT CPC | Separation B01D 17/02 (20130101) B01D 61/58 (20130101) Original (OR) Class B01D 61/362 (20130101) B01D 61/364 (20130101) B01D 61/366 (20130101) B01D 69/02 (20130101) B01D 69/148 (20130101) B01D 71/021 (20130101) B01D 71/36 (20130101) B01D 71/38 (20130101) B01D 2311/2615 (20130101) B01D 2325/023 (20130101) Treatment of Water, Waste Water, Sewage, or Sludge C02F 1/447 (20130101) C02F 1/448 (20130101) C02F 2101/34 (20130101) C02F 2209/40 (20130101) Acyclic or Carbocyclic Compounds C07C 7/04 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220176377 | Seitter et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Cerillo, LLC (Charlottesville, Virginia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Kevin Seitter (Charlottesville, Virginia); Kristin Schmidt (Charlottesville, Virginia); Thomas Moutinho, Jr. (Charlottesville, Virginia) |
| ABSTRACT | The present invention generally relates to a solid-state, multi-well plate reader including an emitter assembly having a plurality of emitters and a receptor assembly having a plurality of receptors, where the positions of these assemblies are not fixed relative to each other but are temporarily aligned for measurement by way of two alignment trays. |
| FILED | Monday, October 18, 2021 |
| APPL NO | 17/451162 |
| CURRENT CPC | Chemical or Physical Laboratory Apparatus for General Use B01L 3/502715 (20130101) B01L 3/502784 (20130101) Original (OR) Class B01L 2200/10 (20130101) B01L 2200/12 (20130101) B01L 2300/041 (20130101) B01L 2300/0654 (20130101) B01L 2300/0819 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/3563 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220176422 | Quigley et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Loci Controls, Inc. (Wareham, Massachusetts) |
| ASSIGNEE(S) | Loci Controls, Inc. (Wareham, Massachusetts) |
| INVENTOR(S) | Peter Quigley (Duxbury, Massachusetts); Ian Martin (Sharon, Massachusetts); Nicole Neff (Colorado Springs, Colorado); Jack Rowbottom (Swansea, Massachusetts) |
| ABSTRACT | Systems and methods for controlling extraction of landfill gas from a landfill via a gas extraction system comprising a plurality of wells are provided herein. In some embodiments, the method comprises obtaining a concentration of a greenhouse gas measured a distance above a surface of a region comprising the plurality of wells; determining whether the measure of the concentration of the greenhouse gas is greater than a first threshold; and in response to determining that the measure of the concentration of the greenhouse gas is greater than the first threshold, increasing a flow rate of landfill gas being extracted from at least one well of the plurality of wells. |
| FILED | Thursday, December 02, 2021 |
| APPL NO | 17/540833 |
| CURRENT CPC | Disposal of Solid Waste B09B 3/80 (20220101) Original (OR) Class B09B 2101/25 (20220101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220176563 | Rus et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| ASSIGNEE(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| INVENTOR(S) | Daniela Rus (Weston, Massachusetts); Jeffrey Lipton (Medford, Massachusetts); Aidan Fay (La Jolla, California); Changhyun Choi (Minneapolis, Minnesota) |
| ABSTRACT | In some aspects, a system comprises a computer hardware processor and a non-transitory computer-readable storage medium storing processor-executable instructions for receiving, from one or more sensors, sensor data relating to a robot; generating, using a statistical model, based on the sensor data, first control information for the robot to accomplish a task; transmitting, to the robot, the first control information for execution of the task; and receiving, from the robot, a result of execution of the task. |
| FILED | Friday, February 25, 2022 |
| APPL NO | 17/680748 |
| CURRENT CPC | Manipulators; Chambers Provided With Manipulation Devices B25J 9/163 (20130101) B25J 9/1689 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177327 | JU et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | PRINCETON UNIVERSITY (Princeton, New Jersey); HiT NANO, INC. (Princeton, New Jersey) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Yiguang JU (PRINCETON, New Jersey); Xiaofang YANG (AMBLER, Pennsylvania); Jingning SHAN (LAWRENCEVILLE, New Jersey) |
| ABSTRACT | A material synthesis method may comprise: obtaining at least one liquid precursor solution comprising one or more solutes determined based on atomic stoichiometry of target particles; adding the at least one liquid precursor solution to an atomizer device; generating at the atomizer device an aerosol; transporting the aerosol to a reactive zone of a predetermined temperature for a predetermined time; and obtaining synthesized particles by evaporating one or more solvents from the aerosol in the reactive zone. |
| FILED | Wednesday, March 11, 2020 |
| APPL NO | 17/438008 |
| CURRENT CPC | Compounds Containing Metals Not Covered by Subclasses C01D or C01F C01G 53/50 (20130101) Original (OR) Class Indexing Scheme Relating to Structural and Physical Aspects of Solid Inorganic Compounds C01P 2002/85 (20130101) C01P 2004/03 (20130101) C01P 2004/52 (20130101) C01P 2004/62 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177331 | Yang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY (Hoboken, New Jersey) |
| ASSIGNEE(S) | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY (Hoboken, New Jersey) |
| INVENTOR(S) | Eui-Hyeok Yang (Fort Lee, New Jersey); Ronald Besser (New Providence, New Jersey); Jian Xu (West Lafayette, Indiana); Wei Xu (Farmingdale, New York); Brendan Englot (New York, New York); Chang-Hwan Choi (Tenafly, New Jersey) |
| ABSTRACT | Smart membranes are integrated into a small, unmanned surface vessel to enable the efficient, automated cleanup of oil spills. Such a vessel has the potential to provide a low-cost, modular solution for day-to-day oil-spill cleanup operations, especially in confined aquatic areas (e.g., under piers or in the small spaces between marine vessels and piers). The membranes are provided on the surface of a conveyor belt that circulates the membranes through the surrounding body of water for oil collection, as well as through an internal reduction chamber of the vessel for oil release. The smart membranes are adapted to attract and repel oil in response to low-voltage commands applied across the conveyor belt, using a process that is repeatable for a number of cycles, offering high efficiency and long durability. Segments of the conveyor belt can be electrically isolated from one another to allow disparate electrical potentials to be imposed thereon. |
| FILED | Friday, February 25, 2022 |
| APPL NO | 17/681581 |
| CURRENT CPC | Treatment of Water, Waste Water, Sewage, or Sludge C02F 1/40 (20130101) Original (OR) Class C02F 1/285 (20130101) C02F 1/288 (20130101) C02F 2101/32 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177704 | Deming et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE REGENTS OF THEUNIVERSITY OF CALIFORNIA (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Timothy J. Deming (Los Angele, California); Yintao Sun (Los Angeles, California) |
| ABSTRACT | The present disclosure is directed to physical mixtures of diblock copolypeptide hydrogel (DCH) systems. These systems exhibit mechanical strength and stiffness that are synergistically increased over the individual component DCHs, to greater than would be expected for a linear combination of the components. Such systems may have utility in biomedical applications such as drug delivery. |
| FILED | Friday, March 27, 2020 |
| APPL NO | 17/598761 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 47/42 (20130101) Working-up; General Processes of Compounding; After-treatment Not Covered by Subclasses C08B, C08C, C08F, C08G or C08H C08J 3/075 (20130101) C08J 2389/00 (20130101) C08J 2489/00 (20130101) Compositions of Macromolecular Compounds C08L 89/00 (20130101) Original (OR) Class C08L 2205/03 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177853 | Ashton et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Wisconsin Alumni Research Foundation (Madison, Wisconsin) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Randolph Scott Ashton (Madison, Wisconsin); Gavin Thomas Knight (Madison, Wisconsin); Benjamin John Knudsen (Menomonee Falls, Wisconsin); Nisha Ramdas Iyer (Madison, Wisconsin); Carlos Marti-Figueroa (Madison, Wisconsin) |
| ABSTRACT | Described herein are methods, compositions, and kits for directed differentiation of human pluripotent stem cells, neuromesodermal progenitors, and neural stem cells into bioengineered elliptical neuroepithelial tissues and bioengineered neuroepithelial tubes that contain a single rosette of polarized neuroepithelial cells and have microscale cellular organization similar to that of an in vivo developing human neural tube. |
| FILED | Wednesday, December 08, 2021 |
| APPL NO | 17/545416 |
| CURRENT CPC | Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 27/3604 (20130101) A61L 27/3675 (20130101) A61L 27/3687 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0618 (20130101) C12N 5/0697 (20130101) Original (OR) Class C12N 2501/41 (20130101) C12N 2501/999 (20130101) C12N 2506/02 (20130101) C12N 2531/00 (20130101) C12N 2533/30 (20130101) C12N 2535/10 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177941 | Jewett et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northwestern University (Evanston, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Michael Christopher Jewett (Evanston, Illinois); Anne E. d'Aquino (Evanston, Illinois) |
| ABSTRACT | Disclosed are engineered or modified E. coli ribosomes and methods, components, compositions, and kits for preparing and identifying engineered or modified E. coli ribosomes. The engineered or modified E. coli ribosomes may be prepared and identified under a set of defined conditions, such as in the presences of a engineered or modified tRNA comprising a non-natural, non-α-amino acid monomer (NNA), in order to obtain an engineered or modified ribosome that utilizes the engineered or modified tRNA as a substrate for synthesizing a polymer comprising the NNA. |
| FILED | Monday, July 08, 2019 |
| APPL NO | 17/258377 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 1/20 (20130101) C12N 9/104 (20130101) C12N 15/113 (20130101) C12N 15/1058 (20130101) C12N 2310/128 (20130101) Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 21/02 (20130101) Original (OR) Class Enzymes C12Y 203/02012 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178831 | Robinson et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Penn State Research Foundation (University Park, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Joshua A. Robinson (State College, Pennsylvania); Natalie Briggs (Benton City, Washington); Kenneth Knappenberger (State College, Pennsylvania); Tian Zhao (State College, Pennsylvania) |
| ABSTRACT | Embodiments relate to a layered material (having a substrate, at least a buffer layer, with zero or more growth layers) that has been intercalated via a process that decouples (physically and electronically) the buffer layer from the substrate, thereby resulting in the creation of few-atom thick metal layers that exhibit a range of optical properties, including plasmonic or electronic resonance, that enables superior optical (e.g. Raman) detection of molecules. |
| FILED | Tuesday, April 21, 2020 |
| APPL NO | 17/594595 |
| CURRENT CPC | Single-crystal-growth; Unidirectional Solidification of Eutectic Material or Unidirectional Demixing of Eutectoid Material; Refining by Zone-melting of Material; Production of a Homogeneous Polycrystalline Material With Defined Structure; Single Crystals or Homogeneous Polycrystalline Material With Defined Structure; After-treatment of Single Crystals or a Homogeneous Polycrystalline Material With Defined Structure; Apparatus Therefor C30B 23/025 (20130101) C30B 25/183 (20130101) C30B 29/06 (20130101) C30B 29/46 (20130101) C30B 29/68 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/658 (20130101) Original (OR) Class G01N 2201/06113 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 21/02378 (20130101) H01L 21/02499 (20130101) H01L 21/02527 (20130101) H01L 21/02532 (20130101) H01L 21/02631 (20130101) H01L 21/02694 (20130101) H01L 29/1606 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220179244 | Shaltout et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| ASSIGNEE(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| INVENTOR(S) | Amr Mohammad E. Shaltout (West Lafayette, Indiana); Alexander V. Kildishev (West Lafayette, Indiana); Vladimir M. Shalaev (West Lafayette, Indiana) |
| ABSTRACT | A time-varying optical metasurface, comprising a plurality of modulated nano-antennas configured to vary dynamically over time. The metasurface may be implemented as part of an optical isolator, wherein the time-varying metasurface provides uni-directional light flow. The metasurface allows the breakage of Lorentz reciprocity in time-reversal. The metasurface may operate in a transmission mode or a reflection mode. |
| FILED | Wednesday, July 28, 2021 |
| APPL NO | 17/387817 |
| CURRENT CPC | Optical Elements, Systems, or Apparatus G02B 1/002 (20130101) G02B 3/0081 (20130101) Devices or Arrangements, the Optical Operation of Which Is Modified by Changing the Optical Properties of the Medium of the Devices or Arrangements for the Control of the Intensity, Colour, Phase, Polarisation or Direction of Light, e.g Switching, Gating, Modulating or Demodulating; Techniques or Procedures for the Operation Thereof; Frequency-changing; Non-linear Optics; Optical Logic Elements; Optical Analogue/digital Converters G02F 1/29 (20130101) G02F 1/0063 (20130101) Original (OR) Class G02F 1/093 (20130101) G02F 1/0136 (20130101) G02F 1/355 (20130101) G02F 2202/30 (20130101) G02F 2203/10 (20130101) Holographic Processes or Apparatus G03H 2001/0224 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220179281 | YANG et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, Pennsylvania); TRUSTEES OF TUFTS COLLEGE (Medford, Massachusetts); SHEFFIELD HALLAM UNIVERSITY (Sheffield, United Kingdom) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Shu YANG (Swarthmore, Pennsylvania); Yu XIA (Swarthmore, Pennsylvania); Timothy J. ATHERTON (Boston, Massachusetts); Douglas J. CLEAVER (Chesterfield, United Kingdom); Andrew A. DEBENEDICTIS (Somerville, Massachusetts); Dae Seok KIM (Philadelphia, Pennsylvania) |
| ABSTRACT | Multi-state switchability is highly desirable in optoelectronic devices. For liquid crystal (LC) based devices, the stability of any configuration is achieved through a balance between imposed interactions and the LC's orientational elasticity. In most cases, the latter acts to resist deformation. By combining surface topography and chemical patterning, provided here are the effects of saddle-splay orientational elasticity, a property that, despite being intrinsic to all LCs, is routinely suppressed. Utilizing theory and continuum elastic calculations, provided here are example conditions for which, even using generic, achiral LC materials, spontaneously broken surface symmetries develop. Also provided are multi-stable devices in which a weak, but directional, applied field switches between spontaneously-polar surface state domains. The disclosed approach is useful in low-field and fast-switching optoelectronic devices, beyond those attainable by current technologies. |
| FILED | Wednesday, March 04, 2020 |
| APPL NO | 17/435407 |
| CURRENT CPC | Devices or Arrangements, the Optical Operation of Which Is Modified by Changing the Optical Properties of the Medium of the Devices or Arrangements for the Control of the Intensity, Colour, Phase, Polarisation or Direction of Light, e.g Switching, Gating, Modulating or Demodulating; Techniques or Procedures for the Operation Thereof; Frequency-changing; Non-linear Optics; Optical Logic Elements; Optical Analogue/digital Converters G02F 1/31 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220179284 | Bourassa et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The University of Chicago (Chicago, Illinois) |
| ASSIGNEE(S) | The University of Chicago (Chicago, Illinois) |
| INVENTOR(S) | Alexandre Bourassa (Chicago, Illinois); Christopher P. Anderson (Chicago, Illinois); David D. Awschalom (Chicago, Illinois) |
| ABSTRACT | This disclosure relates to optical devices for quantum information processing applications. In one example implementation, a semiconductor structure is provided. The semiconductor structure may be embedded with single defects that can be individually addressed. An electric bias and/or one or more optical excitations may be configured to control the single defects in the semiconductor structure to produce single photons for use in quantum information processing. The electric bias and optical excitations are selected and adjusted to control various carrier processes and to reduce environmental charge instability of the single defects to achieve optical emission with wide wavelength tunability and narrow spectral linewidth. Electrically controlled single photon source and other electro-optical devices may be achieved. |
| FILED | Friday, March 13, 2020 |
| APPL NO | 17/438600 |
| CURRENT CPC | Devices or Arrangements, the Optical Operation of Which Is Modified by Changing the Optical Properties of the Medium of the Devices or Arrangements for the Control of the Intensity, Colour, Phase, Polarisation or Direction of Light, e.g Switching, Gating, Modulating or Demodulating; Techniques or Procedures for the Operation Thereof; Frequency-changing; Non-linear Optics; Optical Logic Elements; Optical Analogue/digital Converters G02F 3/022 (20130101) Original (OR) Class Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 39/10 (20130101) H01L 39/221 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220180465 | Cheng et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Lu Cheng (Tempe, Arizona); Jundong Li (Tempe, Arizona); Kasim Candan (Mesa, Arizona); Huan Liu (Tempe, Arizona) |
| ASSIGNEE(S) | Arizona Board of Regents on Behalf of Arizona State University (Tempe, Arizona) |
| INVENTOR(S) | Lu Cheng (Tempe, Arizona); Jundong Li (Tempe, Arizona); Kasim Candan (Mesa, Arizona); Huan Liu (Tempe, Arizona) |
| ABSTRACT | Various embodiments for systems and methods of tracking disaster footprints using social streaming media using nonnegative matrix factorization are disclosed herein. The system extracts a summarization output from historical data and compares the summarization output with incoming data to identify differing or similar topics within the data. The summarization output is projected to adjust a time-dependency of the summarization output to enable a more direct comparison. The system additionally uses the summarization output to encode topic data within historical data to reduce computational overhead. |
| FILED | Tuesday, December 07, 2021 |
| APPL NO | 17/544008 |
| CURRENT CPC | Electric Digital Data Processing G06F 17/16 (20130101) Data Processing Systems or Methods, Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes; Systems or Methods Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes, Not Otherwise Provided for G06Q 50/01 (20130101) G06Q 50/265 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220181507 | Ghidiu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Drexel University (Philadelphia, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Michael J Ghidiu (Bridgeton, New Jersey); Michel W Barsoum (Moorestown, New Jersey); Yury Gogotsi (Warminster, Pennsylvania); Aaron Thomas Fafarman (Philadelphia, Pennsylvania); Andrew DeVries Dillon (Philadelphia, Pennsylvania) |
| ABSTRACT | The present invention(s) is directed to novel conductive Mn+1Xn(Ts) compositions exhibiting high volumetric capacitances, and methods of making the same. The present invention(s) is also directed to novel conductive Mn+1Xn(Ts) compositions, methods of preparing transparent conductors using these materials, and products derived from these methods. |
| FILED | Wednesday, February 23, 2022 |
| APPL NO | 17/678120 |
| CURRENT CPC | Non-metallic Elements; Compounds Thereof; C01B 32/914 (20170801) C01B 32/921 (20170801) C01B 32/949 (20170801) Lime, Magnesia; Slag; Cements; Compositions Thereof, e.g Mortars, Concrete or Like Building Materials; Artificial Stone; Ceramics; Refractories; Treatment of Natural Stone C04B 35/56 (20130101) C04B 35/58 (20130101) C04B 35/5607 (20130101) C04B 35/5618 (20130101) C04B 35/58007 (20130101) C04B 2235/445 (20130101) C04B 2235/3201 (20130101) C04B 2235/3203 (20130101) C04B 2235/3205 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 31/022466 (20130101) Original (OR) Class H01L 33/42 (20130101) H01L 51/5203 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220181607 | BELMONT et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF WYOMING (Laramie, Wyoming) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Erica BELMONT (Laramie, Wyoming); Kurt STAHLFELD (Laramie, Wyoming) |
| ABSTRACT | Embodiments of the present disclosure generally relate to carbon foams, processes for forming carbon foams, doped carbon composites, processes for forming doped carbon composites, and uses thereof, e.g., as electrodes. Processes described herein relate to fabrication of carbon foam and materials derived from the pyrolyzation of biomass at supercritical and subcritical conditions for CO2, N2, H2O, or combinations thereof. The process includes exposing biomass to CO2, N2, H2O, or combinations thereof under various parameters for temperature, pressure, heating rate and fluid flow rate. Silicon-carbon composites and sulfur-carbon composites for use as, e.g., electrodes, are also described. |
| FILED | Thursday, December 02, 2021 |
| APPL NO | 17/541105 |
| CURRENT CPC | Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus B01J 3/008 (20130101) Non-metallic Elements; Compounds Thereof; C01B 32/05 (20170801) Indexing Scheme Relating to Structural and Physical Aspects of Solid Inorganic Compounds C01P 2002/85 (20130101) C01P 2002/88 (20130101) C01P 2004/03 (20130101) C01P 2006/10 (20130101) C01P 2006/16 (20130101) C01P 2006/40 (20130101) Producing, e.g by Pressing Raw Materials or by Extraction From Waste Materials, Refining or Preserving Fats, Fatty Substances, e.g Lanolin, Fatty Oils or Waxes; Essential Oils; Perfumes C11B 1/00 (20130101) Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy H01M 4/364 (20130101) Original (OR) Class H01M 4/386 (20130101) H01M 4/587 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220182092 | Bendlin et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | AT and T Intellectual Property I, L.P. (Atlanta, Georgia); University of Notre Dame du Lac (South Bend, Indiana) |
| ASSIGNEE(S) | AT and T Intellectual Property I, L.P. (Atlanta, Georgia); University of Notre Dame du Lac (South Bend, Indiana) |
| INVENTOR(S) | Ralf Bendlin (Cedar Park, Texas); Jonathan David Chisum (South Bend, Indiana); Nicholas Joseph Estes (South Bend, Indiana); Bertrand Martyn Hochwald (South Bend, Indiana); Aditya Chopra (Austin, Texas) |
| ABSTRACT | Aspects of the subject disclosure may include, for example, receiving, by a first radio module at a first location, a wireless signal, to obtain a first received RF signal. The wireless signal includes information originating at a remote transmitter and conveyed via a wireless channel. An envelope of the first received RF signal is detected by the first radio module without requiring a local oscillator, to obtain a first baseband signal. The first baseband signal may be filtered and/or amplified, after which it is provided to a processor. The processor also obtains a second digital signal from a second radio module receiving the wireless signal at a second location and determines an estimate of the information originating at the remote transmitter according to the first and second signals. Other embodiments are disclosed. |
| FILED | Friday, February 25, 2022 |
| APPL NO | 17/681323 |
| CURRENT CPC | Transmission H04B 1/22 (20130101) Original (OR) Class H04B 7/08 (20130101) H04B 7/0413 (20130101) Transmission of Digital Information, e.g Telegraphic Communication H04L 27/06 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220182351 | Cheng et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Arizona Board of Regents on Behalf of Arizona State University (Tempe, Arizona) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Lu Cheng (Tempe, Arizona); Kai Shu (Mesa, Arizona); Siqi Wu (Canberra, Australia); Yasin Silva (Glendale, Arizona); Deborah Hall (Phoenix, Arizona); Huan Liu (Tempe, Arizona) |
| ABSTRACT | A computer-implemented framework and/or system for cyberbullying detection is disclosed. The system includes two main components: (1) A representation learning network that encodes the social media session by exploiting multi-modal features, e.g., text, network, and time; and (2) a multi-task learning network that simultaneously fits the comment inter-arrival times and estimates the bullying likelihood based on a Gaussian Mixture Model. The system jointly optimizes the parameters of both components to overcome the shortcomings of decoupled training. The system includes an unsupervised cyberbullying detection model that not only experimentally outperforms the state-of-the-art unsupervised models, but also achieves competitive performance compared to supervised models. |
| FILED | Thursday, December 09, 2021 |
| APPL NO | 17/546648 |
| CURRENT CPC | Electric Digital Data Processing G06F 40/30 (20200101) Computer Systems Based on Specific Computational Models G06N 3/088 (20130101) Transmission of Digital Information, e.g Telegraphic Communication H04L 51/12 (20130101) H04L 51/32 (20130101) Original (OR) Class H04L 67/22 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220182400 | Sikder et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Amit Kumar Sikder (Miami, Florida); Hidayet Aksu (Miami, Florida); A. Selcuk Uluagac (Miami, Florida) |
| ASSIGNEE(S) | The Florida International University Board of Trustees (Miami, Florida) |
| INVENTOR(S) | Amit Kumar Sikder (Miami, Florida); Hidayet Aksu (Miami, Florida); A. Selcuk Uluagac (Miami, Florida) |
| ABSTRACT | Context-aware security frameworks to detect malicious behavior in a smart environment (e.g., a home, office, or other building) are provided. The framework can address the emerging threats to smart environments by observing the changing patterns of the conditions (e.g., active/inactive) of smart entities (e.g., sensors and other devices) of the smart environment for different user activities, and building a contextual model to detect malicious activities in the smart environment. |
| FILED | Friday, December 04, 2020 |
| APPL NO | 17/112204 |
| CURRENT CPC | Computer Systems Based on Specific Computational Models G06N 20/00 (20190101) Transmission of Digital Information, e.g Telegraphic Communication H04L 63/1425 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Energy (DOE)
| US 20220175254 | HUI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Cornell University (Ithaca, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Xiaonan HUI (Ithaca, New York); Edwin C. KAN (Ithaca, New York) |
| ABSTRACT | Near-field coherent sensing (NCS) methods and systems are described herein. The techniques may be used to monitor vital signs is introduced herein. Multiple-input, multiple output near-field techniques may be used to characterize motion. In some embodiments, the methods and systems are used to measure cardiac motion. In some embodiments, the disclosed system is integrated into a seat, such as, for example, a car seat. The system be configured to monitor the vital signs of a seat occupant with multiple sensing points. The sensor can be integrated into the cushion and hence “invisible” to the user. |
| FILED | Thursday, March 26, 2020 |
| APPL NO | 17/598180 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/0205 (20130101) Original (OR) Class A61B 5/0265 (20130101) A61B 5/02405 (20130101) Transmission H04B 5/0043 (20130101) Wireless Communication Networks H04W 4/38 (20180201) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175981 | Kroc |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | FERMI RESEARCH ALLIANCE, LLC (Batavia, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Thomas Kroc (Batavia, Illinois) |
| ABSTRACT | A magnetic apparatus and a method of operating the magnetic apparatus can include a scanning electromagnet that redirects a beam of charged particles, a vacuum chamber that prevents the atmosphere from interfering with the charged particles, and, a parallelizing permanent magnet array for parallelizing the beam of charged particles. The parallelizing permanent magnet array can be located proximate to a target comprising a Bremsstrahlung target or an object that is being irradiated. The magnetic field of the scanning electromagnet can be variable to produce all angles necessary to sweep the beam of charged particles across the target and the parallelizing permanent magnet array can be configured from a magnetic material that does not require an electric current. |
| FILED | Friday, February 25, 2022 |
| APPL NO | 17/681668 |
| CURRENT CPC | Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 2/082 (20130101) A61L 2/087 (20130101) Original (OR) Class Electric Discharge Tubes or Discharge Lamps H01J 37/1475 (20130101) H01J 2237/152 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220176495 | BROWAR et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Lawrence Livermore National Security, LLC (Livermore, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Allison Eileen Marie BROWAR (Livermore, California); Gabriel Mark GUSS (Manteca, California); Manyalibo Joseph MATTHEWS (Livermore, California); Nathan James RAY (Tracy, California); Nan SHEN (Milpitas, California) |
| ABSTRACT | The present disclosure relates to an apparatus for modifying a curvature of a thin plate optic using controlled heat and densification of portions of the optic. In one embodiment the system has a support structure for supporting the optic about a perimeter thereof, a laser configured to generate a beam having a predetermined energy, and the beam being directed at one surface of the optic. The beam heats and densifies portions of the optic to create a force on the optic. The force induces a stress produces a controlled deformation of the optic. The controlled deformation at least one of modifies a curvature of, or corrects a defect in, the optic. |
| FILED | Friday, December 04, 2020 |
| APPL NO | 17/112519 |
| CURRENT CPC | Soldering or Unsoldering; Welding; Cladding or Plating by Soldering or Welding; Cutting by Applying Heat Locally, e.g Flame Cutting; Working by Laser Beam B23K 26/032 (20130101) B23K 26/53 (20151001) Original (OR) Class B23K 26/082 (20151001) B23K 26/127 (20130101) B23K 26/0626 (20130101) B23K 26/704 (20151001) B23K 26/705 (20151001) Optical Elements, Systems, or Apparatus G02B 26/0816 (20130101) Devices or Arrangements, the Optical Operation of Which Is Modified by Changing the Optical Properties of the Medium of the Devices or Arrangements for the Control of the Intensity, Colour, Phase, Polarisation or Direction of Light, e.g Switching, Gating, Modulating or Demodulating; Techniques or Procedures for the Operation Thereof; Frequency-changing; Non-linear Optics; Optical Logic Elements; Optical Analogue/digital Converters G02F 1/11 (20130101) Devices Using the Process of Light Amplification by Stimulated Emission of Radiation [LASER] to Amplify or Generate Light; Devices Using Stimulated Emission of Electromagnetic Radiation in Wave Ranges Other Than Optical H01S 3/2232 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177327 | JU et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | PRINCETON UNIVERSITY (Princeton, New Jersey); HiT NANO, INC. (Princeton, New Jersey) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Yiguang JU (PRINCETON, New Jersey); Xiaofang YANG (AMBLER, Pennsylvania); Jingning SHAN (LAWRENCEVILLE, New Jersey) |
| ABSTRACT | A material synthesis method may comprise: obtaining at least one liquid precursor solution comprising one or more solutes determined based on atomic stoichiometry of target particles; adding the at least one liquid precursor solution to an atomizer device; generating at the atomizer device an aerosol; transporting the aerosol to a reactive zone of a predetermined temperature for a predetermined time; and obtaining synthesized particles by evaporating one or more solvents from the aerosol in the reactive zone. |
| FILED | Wednesday, March 11, 2020 |
| APPL NO | 17/438008 |
| CURRENT CPC | Compounds Containing Metals Not Covered by Subclasses C01D or C01F C01G 53/50 (20130101) Original (OR) Class Indexing Scheme Relating to Structural and Physical Aspects of Solid Inorganic Compounds C01P 2002/85 (20130101) C01P 2004/03 (20130101) C01P 2004/52 (20130101) C01P 2004/62 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178036 | Campbell et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Lawrence Livermore National Security, LLC (Livermore, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Patrick Campbell (Oakland, California); Maira Ceron Hernandez (Livermore, California); Jeremy Taylor Feaster (Fremont, California); Sneha Anil Akhade (Oakland, California) |
| ABSTRACT | A thermo-electrochemical reactive capture apparatus includes an anode and a cathode, wherein the anode includes a first catalyst, wherein the cathode includes a second catalyst, a porous ceramic support positioned between the anode and the cathode, an electrolyte mixture in pores of the ceramic support, and a steam flow system on an outer side of the cathode. The outer side of the cathode is opposite an inner side of the cathode and the inner side of the cathode is adjacent to the ceramic support. In addition, the electrolyte mixture is configured to be molten at a temperature below about 600° C. |
| FILED | Tuesday, December 08, 2020 |
| APPL NO | 17/115534 |
| CURRENT CPC | Separation B01D 53/62 (20130101) B01D 53/228 (20130101) B01D 53/229 (20130101) B01D 67/0093 (20130101) B01D 69/02 (20130101) B01D 2257/102 (20130101) B01D 2257/504 (20130101) B01D 2258/0283 (20130101) B01D 2323/36 (20130101) B01D 2325/02 (20130101) Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering B33Y 70/10 (20200101) B33Y 80/00 (20141201) Electrolytic or Electrophoretic Processes for the Production of Compounds or Non-metals; Apparatus Therefor C25B 1/23 (20210101) C25B 5/00 (20130101) C25B 11/031 (20210101) C25B 13/02 (20130101) C25B 13/07 (20210101) Original (OR) Class C25B 15/027 (20210101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220178859 | Iftime et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Palo Alto Research Center Incorporated (Palo Alto, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Gabriel Iftime (Dublin, California); Clinton Smith (San Francisco, California); David Eric Schwartz (San Carlos, California); Yong Zhang (Millbrae, California); Vedasri Vedharathinam (Sunnyvale, California) |
| ABSTRACT | Disclosed herein are methods of producing metal nanoparticle-decorated carbon nanotubes. The methods include forming a reaction mixture by combining a first solution with a second solution, wherein the first solution comprises polymer-coated metal nanoparticles comprising metallic nanoparticles coated with a polymer, and wherein the second solution comprises carbon nanotubes. The methods also include heating the reaction mixture to a temperature greater than a glass transition temperature of the polymer for a time sufficient to cause the polymer-coated metal nanoparticles to bind to the carbon nanotubes forming the metal nanoparticle-decorated carbon nanotubes. |
| FILED | Tuesday, February 22, 2022 |
| APPL NO | 17/677716 |
| CURRENT CPC | Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus B01J 20/205 (20130101) B01J 20/0225 (20130101) B01J 20/327 (20130101) B01J 20/3204 (20130101) Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 30/00 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 27/04 (20130101) Original (OR) Class G01N 27/126 (20130101) G01N 27/127 (20130101) G01N 33/0009 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220179378 | Gourisetti et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Battelle Memorial Institute (Richland, Washington) |
| ASSIGNEE(S) | Battelle Memorial Institute (Richland, Washington) |
| INVENTOR(S) | Sri Nikhil Gupta Gourisetti (Richland, Washington); Steven E. Widergren (Kennewick, Washington); Michael E. Mylrea (Alexandria, Virginia); David J. Sebastian Cardenas (Pullman, Washington); Mark I. Borkum (Richland, Washington); Bishnu P. Bhattarai (Kennewick, Washington); Peng Wang (Billerica, Massachusetts); Alysha M. Randall (West Richland, Washington); Hayden M. Reeve (Indianola, Washington) |
| ABSTRACT | This document describes techniques, apparatuses, and systems for a blockchain-based transactive energy system. A blockchain-based transactive energy system receives a bid associated with a supply/demand curve of a utility from a transactive node through a smart contract. A universal identifier associated with the bid may be verified by consensus nodes of the blockchain-based transactive energy system to determine a verified set of bids. The universal identifier or other data associated with the bid may be stored in an immutable database provided by a blockchain. Based on the verified set of bids, a market-clearing price of the utility may be determined and used to satisfy the bid of the transactive node according to an actual production or consumption of the utility by the transactive node. The actual production or consumption of the utility may be stored in the immutable database for future audits or verification. |
| FILED | Monday, November 29, 2021 |
| APPL NO | 17/537231 |
| CURRENT CPC | Control or Regulating Systems in General; Functional Elements of Such Systems; Monitoring or Testing Arrangements for Such Systems or Elements G05B 19/042 (20130101) Original (OR) Class G05B 2219/2639 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220180028 | Mudunuru et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Chevron U.S.A. Inc. (San Ramon, California); Triad National Security, LLC (Los Alamos, New Mexico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Maruti Kumar Mudunuru (Los Alamos, New Mexico); Vamshi Krishna Chillara (Los Alamos, New Mexico); Bulbul Ahmmed (Los Alamos, New Mexico); Satish Karra (Los Alamos, New Mexico); Hari Selvi Viswanathan (Los Alamos, New Mexico); Jeffrey Foering App (Houston, Texas); Gary Michael Hoversten (Lafayette, California); Christopher J. Champeaux (Spring, Texas); Jesus Barraza (Houston, Texas) |
| ABSTRACT | A method for determining placement of MFEIT sensors in a horizontal well for detecting producing stages of the horizontal well. Embodiments involve computationally modeling the underlying physics of a well system and performing inversion to identify the MFEIT parameters (locations and conductivity) from electrical impedance measurements. |
| FILED | Wednesday, December 09, 2020 |
| APPL NO | 17/116163 |
| CURRENT CPC | Earth Drilling, e.g Deep Drilling; Obtaining Oil, Gas, Water, Soluble or Meltable Materials or a Slurry of Minerals From Wells E21B 43/162 (20130101) E21B 47/113 (20200501) E21B 2200/20 (20200501) Electric Digital Data Processing G06F 30/28 (20200101) Original (OR) Class G06F 2113/08 (20200101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220181006 | Bremer et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Lawrence Livermore National Security, LLC (Livermore, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Peer-Timo Bremer (Livermore, California); Rushil Anirudh (Dublin, California); Jayaraman Jayaraman Thiagarajan (Milpitas, California) |
| ABSTRACT | A system for classifying a target image with segments having attributes is provided. The system generates a graph for the target image that includes vertices representing segments of the image and edges representing relationships between the connected vertices. For each vertex, the system generates a subgraph that includes the vertex as a home vertex and neighboring vertices representing segments of the target image within a neighborhood of the segment represented by the home vertex. The system applies an autoencoder to each subgraph to generate latent variables to represent the subgraph. The system applies a machine learning algorithm to a feature vector comprising a universal image representation of the target image that is derived from the generated latent variables of the subgraphs to generate a classification for the target image. |
| FILED | Thursday, September 09, 2021 |
| APPL NO | 17/470331 |
| CURRENT CPC | Computer Systems Based on Specific Computational Models G06N 3/08 (20130101) G06N 20/10 (20190101) Image Data Processing or Generation, in General G06T 7/0014 (20130101) G06T 2207/20081 (20130101) G06T 2207/20084 (20130101) G06T 2207/30024 (20130101) G06T 2207/30236 (20130101) Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 30/20 (20180101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220181566 | Yurke |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Boise State University (Boise, Idaho) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Bernard Yurke (Boise, Idaho) |
| ABSTRACT | An excitonic device comprises an exciton transmission line comprised of a row of molecules. Propagation of excitons is mediated by an exciton exchange interaction. The gate consists of a molecule “a” that interacts with a proximal molecule via a two-body exciton interaction. If the gate molecule is not excited, it does not couple to the transmission line thereby allowing incoming signals to propagate unimpeded. If the gate molecule is excited, signals are back scattered as a result of the two-body interaction between the exciton residing on “a” and the excitons on the transmission line. The ballistic exciton transistor has industrial applications that extend to at least fast optical switching, optical communication, exciton devices, and exciton-based information processing. |
| FILED | Tuesday, December 07, 2021 |
| APPL NO | 17/643080 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 51/428 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220181573 | Forrest et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of Michigan (Ann Arbor, Michigan) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Stephen R . Forrest (Ann Arbor, Michigan); Chan Ho Soh (Ann Arbor, Michigan) |
| ABSTRACT | An optoelectronic device comprises a first electrode; a first host material layer positioned over the first electrode; a second host material layer positioned over the first host material layer; at least one ultrathin dopant layer positioned between the first and second host material layers, the at least one ultrathin dopant layer having a thickness of less than 2 Å; and a second electrode positioned over the second host material layers. Other organic optoelectronic devices are also disclosed. |
| FILED | Friday, November 19, 2021 |
| APPL NO | 17/530817 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 51/5008 (20130101) Original (OR) Class H01L 51/5012 (20130101) H01L 51/5056 (20130101) H01L 2251/558 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220181618 | Manthiram et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Board of Regents, The University of Texas System (Austin, Texas) |
| ASSIGNEE(S) | Board of Regents, The University of Texas System (Austin, Texas) |
| INVENTOR(S) | Arumugam Manthiram (Austin, Texas); Wangda Li (Austin, Texas); Steven Lee (Austin, Texas) |
| ABSTRACT | Described herein are low or no-cobalt materials useful as electrode active materials in a cathode for lithium or lithium-ion batteries. For example, compositions of matter are described herein, such as electrode active materials that can be incorporated into an electrode, such as a cathode. The disclosed electrode active materials exhibit high specific energy and voltage, and can also exhibit high rate capability and/or long operational lifetime. |
| FILED | Monday, January 24, 2022 |
| APPL NO | 17/582896 |
| CURRENT CPC | Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy H01M 4/382 (20130101) H01M 4/386 (20130101) H01M 4/505 (20130101) H01M 4/525 (20130101) Original (OR) Class H01M 4/583 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220181771 | Grando et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Battelle Memorial Institute (Richland, Washington) |
| ASSIGNEE(S) | Battelle Memorial Institute (Richland, Washington) |
| INVENTOR(S) | Maurio B. Grando (Richland, Washington); A. Mark Jones (West Richland, Washington) |
| ABSTRACT | Antenna assemblies and antenna systems are described. According to one aspect, a printed circuit board antenna system includes a dielectric substrate comprising first and second surfaces that are opposite to one another, first electrically conductive material of an antenna element adjacent to the first surface of the dielectric substrate, wherein the antenna element is configured to emit electromagnetic energy, and second electrically conductive material of a ground plane adjacent to the second surface of the dielectric substrate, wherein the ground plane is aligned with the antenna element and configured to reflect some of the electromagnetic energy in a direction towards the antenna element. |
| FILED | Wednesday, December 09, 2020 |
| APPL NO | 17/117005 |
| CURRENT CPC | Antennas, i.e Radio Aerials H01Q 1/38 (20130101) Original (OR) Class H01Q 1/48 (20130101) H01Q 21/0006 (20130101) H01Q 21/061 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220181843 | Patra et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Lawrence Livermore National Security, LLC (Livermore, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Susant Patra (Brentwood, California); Robert J. Deri (Pleasanton, California); John W. Elmer (Danville, California) |
| ABSTRACT | A pyrolytic graphite (PG) substrate and laser diode package includes a substrate body having a PG crystalline structure with a basal plane oriented at a pre-determined orientation angle as measured from a longitudinal axis of a heat generating material, such as a laser diode, mounted on a surface of the PG substrate, so that a coefficient of thermal expansion (CTE) of the PG substrate is substantially matched with a CTE of the material. |
| FILED | Monday, November 15, 2021 |
| APPL NO | 17/526497 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 23/5226 (20130101) H01L 23/53228 (20130101) Devices Using the Process of Light Amplification by Stimulated Emission of Radiation [LASER] to Amplify or Generate Light; Devices Using Stimulated Emission of Electromagnetic Radiation in Wave Ranges Other Than Optical H01S 5/021 (20130101) H01S 5/024 (20130101) H01S 5/0206 (20130101) H01S 5/02469 (20130101) Original (OR) Class H01S 5/4025 (20130101) H01S 5/32316 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220182070 | Fan et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Trustees of the Leland Stanford Junior Univeristy (Stanford, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Shanhui Fan (Stanford, California); Bo Zhao (Menlo Park, California); Sid Assawaworrarit (Redwood City, California); Parthiban Santhanam (Redwood City, California); Meir Orenstein (Haifa, Israel) |
| ABSTRACT | In certain examples, methods and semiconductor structures are directed to an apparatus including a photon emitter such as an LED which operates over an emission wavelength range and a photo-voltaic device arranged relative to the photon emitter to provide index-matched optical coupling between the photo-voltaic device and the photon emitter for an emission wavelength range of the photon emitter. |
| FILED | Friday, December 03, 2021 |
| APPL NO | 17/541521 |
| CURRENT CPC | Coding; Decoding; Code Conversion in General H03M 1/66 (20130101) H03M 7/008 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220182309 | Bataineh et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Hewlett Packard Enterprise Development LP (Houston, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Abdulla M. Bataineh (Vista, California); Edwin L. Froese (Burnaby British Columbia, Canada); Duncan Roweth (Bristol Avon, United Kingdom) |
| ABSTRACT | A switch is provided, which can receive a data communication at an edge of a network. The network may be made up of a plurality of switches. The switch may generate a flow channel based upon an identified source and destination for the data communication. The data communication can be routed across the plurality of switches based on minimizing a number of hops between a subset of the plurality of switches and in accordance with the flow channel. |
| FILED | Monday, March 23, 2020 |
| APPL NO | 17/594649 |
| CURRENT CPC | Transmission of Digital Information, e.g Telegraphic Communication H04L 45/122 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Veterans Affairs (DVA)
| US 20220175560 | Winkler et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | United States Government as Represented by the Department of Veterans Affairs (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sandra L. Winkler (Lithia, Florida); Samuel Phillips (Tampa, Florida); Jemy Delikat (Brandon, Florida) |
| ABSTRACT | A prosthesis system can comprise an upper arm prosthesis comprising a socket, the upper arm prosthesis being positioned on a first side of the prosthesis system proximate a residual limb of a user. A harness that can be coupled to the socket of the upper arm prosthesis. The harness can comprise a front portion that is configured to extend across the chest of the user and receive at least a portion of the breasts of the user therein and a back portion that is configured to extend across the back of the user and couple to opposed lateral sides of the front portion. A first end of a support strap can couple to the socket of the prosthesis at a first anchor point, and a second end can couple to the back portion of the harness on a second side of the prosthesis system opposite the first side. |
| FILED | Monday, December 06, 2021 |
| APPL NO | 17/543251 |
| CURRENT CPC | Corsets; Brassieres A41C 3/0057 (20130101) Filters Implantable into Blood Vessels; Prostheses; Devices Providing Patency To, or Preventing Collapsing Of, Tubular Structures of the Body, e.g Stents; Orthopaedic, Nursing or Contraceptive Devices; Fomentation; Treatment or Protection of Eyes or Ears; Bandages, Dressings or Absorbent Pads; First-aid Kits A61F 2/80 (20130101) Original (OR) Class A61F 2002/7862 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175804 | FARESE et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF SOUTH FLORIDA (Tampa, Florida); UNITED STATES DEPARTMENT OF VETERANS AFFAIRS (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Robert Vito FARESE (St. Petersburg, Florida); Mini Paliyath SAJAN (Wesley Chapel, Florida); Margaret Genevieve HIGGS (St. Petersburg, Florida) |
| ABSTRACT | Provided herein are formulations effective for and methods of treating or preventing a neurodegenerative disorder in a subject in need thereof that can include administering an amount of an aPKC inhibitor to a subject in need thereof. |
| FILED | Friday, December 17, 2021 |
| APPL NO | 17/554924 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/122 (20130101) A61K 31/675 (20130101) Original (OR) Class A61K 33/242 (20190101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/28 (20180101) Enzymes C12Y 304/23046 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177418 | Rettig et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); The United States Government represented by the Department of Veterans Affairs (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Matthew Rettig (Los Angeles, California); Michael E. Jung (Los Angeles, California); D. Elshan Nakath G. Ralalage (Los Angeles, California); Jiabin An (Los Angeles, California) |
| ABSTRACT | The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer. |
| FILED | Friday, March 27, 2020 |
| APPL NO | 17/599083 |
| CURRENT CPC | Acyclic or Carbocyclic Compounds C07C 49/537 (20130101) C07C 49/697 (20130101) C07C 69/618 (20130101) C07C 233/13 (20130101) Original (OR) Class C07C 233/40 (20130101) C07C 233/91 (20130101) C07C 235/76 (20130101) C07C 255/46 (20130101) C07C 307/04 (20130101) C07C 2601/02 (20170501) Heterocyclic Compounds C07D 207/38 (20130101) C07D 207/273 (20130101) C07D 211/70 (20130101) C07D 213/46 (20130101) C07D 263/32 (20130101) C07D 303/32 (20130101) C07D 307/46 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177534 | DUBINETT et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); The United States Government Represented by the Department of Veterans Affairs (Washington, District of Columbia) |
| ASSIGNEE(S) | The Regents of the University of California (Oakland, California); The United States Government Represented by the Department of Veterans Affairs (Washington, District of Columbia) |
| INVENTOR(S) | Steven M. DUBINETT (Los Angeles, California); Jay Moon LEE (Manhattan Beach, California); Bin LIU (Woodland Hills, California); Ramin SALEHI-RAD (Encino, California); Sharvendra SHARMA (Culver City, California) |
| ABSTRACT | The present disclosure relates, in general, to methods for treating cancer comprising administering to a subject in need thereof an effective amount of dendritic cells comprising the human CCL21 gene in combination with an anti-PD-1 antibody. In one aspect, the treatment is amenable to patients with tumors having a high mutational burden. |
| FILED | Friday, May 10, 2019 |
| APPL NO | 17/053872 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/00 (20130101) Peptides C07K 14/521 (20130101) Original (OR) Class C07K 14/70596 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
National Aeronautics and Space Administration (NASA)
| US 20220175870 | Chatterjee et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of Colorado, a body corporate (Denver, Colorado); United States of America as Represented by the Administrator of NASA (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Anushree Chatterjee (Boulder, Colorado); Afshin Beheshti (Medford, Massachusetts); Sylvain Vincent Costes (Albany, California); Thomas R. Aunins (Boulder, Colorado); Prashant Nagpal (Lafayette, Colorado) |
| ABSTRACT | The inventive technology generally relates to systems, methods, and compositions for the treatment of viral infections, as well as novel use of antisense technology to rationally design antiviral compositions that can be applied to clinical cases and human infections. In one preferred aspect, the inventive technology includes methods, and compositions to treat COVID-19 in humans through the targeted inhibition of host-derived miRNAs. |
| FILED | Friday, December 03, 2021 |
| APPL NO | 17/541737 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/04 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220176651 | JUAREZ et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF NASA (WASHINGTON, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | PETER D. JUAREZ (HAMPTON, Virginia); ELIZABETH D. GREGORY (HAMPTON, Virginia) |
| ABSTRACT | Systems, methods, and devices are provided for the creation of predictable and accurate defects in a fiber tow of an Automated Fiber Placement (AFP) process, with such artificial defects being useful to support calibration of an in situ inspection system used in the AFP process. Various embodiments include methods for creating such artificial defects that support calibration of an in situ inspection system of an AFP system or process. Various embodiments may also include a defect stencils for an AFP system or process. |
| FILED | Friday, December 04, 2020 |
| APPL NO | 17/112442 |
| CURRENT CPC | Shaping or Joining of Plastics; Shaping of Material in a Plastic State, Not Otherwise Provided For; After-treatment of the Shaped Products, e.g Repairing B29C 70/382 (20130101) Original (OR) Class B29C 70/545 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/93 (20130101) G01N 21/8851 (20130101) G01N 2021/8472 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177109 | HEFNER et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Bell Textron Inc. (Fort Worth, Texas) |
| ASSIGNEE(S) | Bell Textron Inc. (Fort Worth, Texas) |
| INVENTOR(S) | Levi HEFNER (Dallas, Texas); Maurice Griffin (Boerne, Texas); Jennifer Diana Andrews (North Richland Hills, Texas) |
| ABSTRACT | In an embodiment, an aircraft includes first and second wings. The aircraft also includes a plurality of propulsion assemblies, the plurality of propulsion assemblies including a propulsion assembly connected to each end of each of the first and second wings. The aircraft also includes first and second vertical supports disposed between the first and second wings. The aircraft also includes a storage pod disposed between the first and second vertical supports. The storage pod includes a nose portion that extends forward of the plurality of propulsion assemblies. The nose portion includes at least one radar and at least one camera. Other embodiments of this aspect include corresponding computer systems, apparatus, and computer programs recorded on one or more computer storage devices, each configured to perform the actions of the methods. |
| FILED | Wednesday, December 09, 2020 |
| APPL NO | 17/116778 |
| CURRENT CPC | Aeroplanes; Helicopters B64C 1/36 (20130101) B64C 1/068 (20130101) Original (OR) Class B64C 29/02 (20130101) B64C 39/08 (20130101) Equipment for Fitting in or to Aircraft; Flying Suits; Parachutes; Arrangements or Mounting of Power Plants or Propulsion Transmissions in Aircraft B64D 9/00 (20130101) B64D 47/08 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Small Business Administration (SBA)
| US 20220176377 | Seitter et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Cerillo, LLC (Charlottesville, Virginia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Kevin Seitter (Charlottesville, Virginia); Kristin Schmidt (Charlottesville, Virginia); Thomas Moutinho, Jr. (Charlottesville, Virginia) |
| ABSTRACT | The present invention generally relates to a solid-state, multi-well plate reader including an emitter assembly having a plurality of emitters and a receptor assembly having a plurality of receptors, where the positions of these assemblies are not fixed relative to each other but are temporarily aligned for measurement by way of two alignment trays. |
| FILED | Monday, October 18, 2021 |
| APPL NO | 17/451162 |
| CURRENT CPC | Chemical or Physical Laboratory Apparatus for General Use B01L 3/502715 (20130101) B01L 3/502784 (20130101) Original (OR) Class B01L 2200/10 (20130101) B01L 2200/12 (20130101) B01L 2300/041 (20130101) B01L 2300/0654 (20130101) B01L 2300/0819 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/3563 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220176422 | Quigley et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Loci Controls, Inc. (Wareham, Massachusetts) |
| ASSIGNEE(S) | Loci Controls, Inc. (Wareham, Massachusetts) |
| INVENTOR(S) | Peter Quigley (Duxbury, Massachusetts); Ian Martin (Sharon, Massachusetts); Nicole Neff (Colorado Springs, Colorado); Jack Rowbottom (Swansea, Massachusetts) |
| ABSTRACT | Systems and methods for controlling extraction of landfill gas from a landfill via a gas extraction system comprising a plurality of wells are provided herein. In some embodiments, the method comprises obtaining a concentration of a greenhouse gas measured a distance above a surface of a region comprising the plurality of wells; determining whether the measure of the concentration of the greenhouse gas is greater than a first threshold; and in response to determining that the measure of the concentration of the greenhouse gas is greater than the first threshold, increasing a flow rate of landfill gas being extracted from at least one well of the plurality of wells. |
| FILED | Thursday, December 02, 2021 |
| APPL NO | 17/540833 |
| CURRENT CPC | Disposal of Solid Waste B09B 3/80 (20220101) Original (OR) Class B09B 2101/25 (20220101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220177488 | Ouyang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | SUVALENT THERAPEUTICS, INC. (Thousand Oaks, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Xiaohu Ouyang (Rosemead, California); Miles Kubota (Monrovia, California); Ted Charles Judd (Granada Hills, California); Andrew S. Tasker (Simi Valley, California) |
| ABSTRACT | The present invention relates to compounds and compositions capable of acting as inhibitors of small ubiquitin-like modifier (SUMO) family of proteins. The compounds and compositions may be used in the treatment of cancer. There are disclosed, inter alia, methods of inhibiting an E1 enzyme, and compounds useful for inhibiting an E1 enzyme. |
| FILED | Thursday, March 19, 2020 |
| APPL NO | 17/435855 |
| CURRENT CPC | Heterocyclic Compounds C07D 209/08 (20130101) C07D 217/06 (20130101) C07D 217/14 (20130101) C07D 217/16 (20130101) C07D 333/54 (20130101) C07D 401/04 (20130101) C07D 401/12 (20130101) C07D 405/06 (20130101) C07D 471/04 (20130101) C07D 491/048 (20130101) C07D 495/04 (20130101) Original (OR) Class Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/573 (20130101) G01N 2440/36 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Agriculture (USDA)
| US 20220174962 | Webb et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CORNELL UNIVERSITY (Ithaca, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | James Webb (Ithaca, New York); Jing Chen (Ithaca, New York); Minglin Ma (Ithaca, New York) |
| ABSTRACT | A composition for detoxifying insect pollinators from one or more organophosphate pesticides, the composition containing microparticles comprising: (i) a phosphotriesterase; (ii) nanoparticles; and (iii) a surface active agent. Also disclosed herein is an aqueous suspension comprising the above-described detoxifying microparticles in an external aqueous medium, which may also contain an insect pollinator attractant. Also described herein is a method for detoxifying insect pollinators of one or more organophosphate pesticides, the method comprising placing the detoxifying aqueous suspension in a location accessible to the insect pollinators to permit the insect pollinators to ingest the detoxifying aqueous suspension, wherein the detoxifying aqueous suspension comprises microparticles, as described above, suspended in an external aqueous medium, typically also including an insect pollinator attractant in the external aqueous medium. |
| FILED | Tuesday, December 07, 2021 |
| APPL NO | 17/544375 |
| CURRENT CPC | Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators A01N 25/04 (20130101) A01N 25/08 (20130101) A01N 63/50 (20200101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220175675 | NITIN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Nitin NITIN (Oakland, California); Maha ALSHEHAB (Oakland, California) |
| ABSTRACT | Provided herein are methods of encapsulating molecules in milk fat globules and oleosomes, and compositions and pharmaceutical formulations of compositions with molecules encapsulated in milk fat globules and oleosomes. |
| FILED | Thursday, April 30, 2020 |
| APPL NO | 17/594825 |
| CURRENT CPC | Foods, Foodstuffs, or Non-alcoholic Beverages, Not Covered by Subclasses A23B - A23J; Their Preparation or Treatment, e.g Cooking, Modification of Nutritive Qualities, Physical Treatment; Preservation of Foods or Foodstuffs, in General A23L 27/10 (20160801) A23L 27/72 (20160801) A23L 33/105 (20160801) A23L 33/155 (20160801) Shaping or Working of Foodstuffs, Not Fully Covered by a Single Other Subclass A23P 10/35 (20160801) Indexing Scheme Relating to Foods, Foodstuffs or Non-alcoholic Beverages A23V 2002/00 (20130101) Preparations for Medical, Dental, or Toilet Purposes A61K 9/1276 (20130101) Original (OR) Class A61K 31/12 (20130101) A61K 31/085 (20130101) A61K 31/232 (20130101) A61K 31/353 (20130101) A61K 31/593 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Commerce (DOC)
| US 20220179283 | BURENKOV et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Maryland, College Park (College Park, Maryland); Government of the United States of America, as Represented by the Secretary of Commerce (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ivan A. BURENKOV (Gaithersburg, Maryland); Sergey V. POLYAKOV (Gaithersburg, Maryland) |
| ABSTRACT | A quantum EIT-based optical switch includes a first waveguide, linear or nonlinear, a separate nonlinear waveguide evanescently coupled to the first waveguide, and a pump coupled to the nonlinear waveguide. A quantum STIRAP-based optical transduction device, which includes an auxiliary, intermediate spectral state for the quantum signal that aids efficient transduction of the quantum signal from the input spectral state to the output spectral state in a single device. |
| FILED | Wednesday, December 08, 2021 |
| APPL NO | 17/545451 |
| CURRENT CPC | Devices or Arrangements, the Optical Operation of Which Is Modified by Changing the Optical Properties of the Medium of the Devices or Arrangements for the Control of the Intensity, Colour, Phase, Polarisation or Direction of Light, e.g Switching, Gating, Modulating or Demodulating; Techniques or Procedures for the Operation Thereof; Frequency-changing; Non-linear Optics; Optical Logic Elements; Optical Analogue/digital Converters G02F 1/365 (20130101) G02F 1/3534 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220179285 | Klimov et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Government of the United States of America, as represented by the Secretary of Commerce (Gaithersburg, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Nikolai Nikolaevich Klimov (Ellicott City, Maryland); Joseph Arthur Schneemeyer Hagmann (Falls Church, Virginia); Stefan Cular (Gaithersburg, Maryland); Thomas Eller Lipe, JR. (Richfield, North Carolina) |
| ABSTRACT | A photonic AC-DC voltage and current equivalence converter includes: a photonic chip; a weak thermal link; an isothermal region; a resistive electrode; an isothermal region photonic nanoresonator; an isothermal region waveguide; a chip photonic nanoresonator; and a chip waveguide, such that an ac voltage is determined from matching a temperature rise of the isothermal region due to a primary elevated temperature of the isothermal region when ac voltage is received by the resistive electrode. |
| FILED | Monday, September 27, 2021 |
| APPL NO | 17/486852 |
| CURRENT CPC | Devices or Arrangements, the Optical Operation of Which Is Modified by Changing the Optical Properties of the Medium of the Devices or Arrangements for the Control of the Intensity, Colour, Phase, Polarisation or Direction of Light, e.g Switching, Gating, Modulating or Demodulating; Techniques or Procedures for the Operation Thereof; Frequency-changing; Non-linear Optics; Optical Logic Elements; Optical Analogue/digital Converters G02F 7/00 (20130101) Original (OR) Class Apparatus for Conversion Between AC and AC, Between AC and DC, or Between DC and DC, and for Use With Mains or Similar Power Supply Systems; Conversion of DC or AC Input Power into Surge Output Power; Control or Regulation Thereof H02M 11/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Homeland Security (DHS)
| US 20220178852 | Ashok et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Arizona Board of Regents on Behalf of the University of Arizona (Tucson, Arizona) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Amit Ashok (Tucson, Arizona); Ahmad Masoudi (Tucson, Arizona) |
| ABSTRACT | Methods, system and devices for multiplexed x-ray detection systems are described. The x-ray detection systems are designed using a multiplexed array of x-ray sources that are turned on simultaneously in groups of two or more x-ray sources to form multiple exposures that are detected by a plurality of detectors. The number of exposures, as well as x-ray source characteristics and parameters, such as the number and output energy level associated with each x-ray source are determined to optimize the quality of reconstrued images or maximize the detection/classification accuracy of object(s) and/or material(s) based on a total photon energy budget. The disclosed detection methods and devices improve both the quality and acquisition speed of x-ray images and x-ray measurement data for detection/classification of object(s) and/or material(s). |
| FILED | Monday, April 06, 2020 |
| APPL NO | 17/601274 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 23/046 (20130101) Original (OR) Class G01N 2223/401 (20130101) G01N 2223/419 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Transportation (USDOT)
| US 20220180745 | Banaei-Kashani et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of Colorado, a Body Corporate (Boulder, Colorado) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Farnoush Banaei-Kashani (Centennial, Colorado); Robert Fitzgerald (Arvada, Colorado) |
| ABSTRACT | According to some aspects of the present disclosure, a method for system-optimal traffic routing is disclosed. In one embodiment, the method includes: obtaining a current state of a traffic network, determining a set of active agents in the traffic network that are configured to receive a system optimal route, where each of the active agents corresponds to a vehicle of a set of vehicles, applying a batching function to the set of vehicles to create a batch of vehicles for replanning; creating sub-batches based on a spatial relationship between the vehicles and temporal relationships between the vehicles, generating a plurality of alternative paths for each of the sub-batches, generating a batch assignment for each of the sub-batches, assigning an alternative path to each agent in the set of active agents based on the batch assignment function, and transmitting the assigned alternative paths to the active agents. |
| FILED | Wednesday, October 13, 2021 |
| APPL NO | 17/500567 |
| CURRENT CPC | Traffic Control Systems G08G 1/093 (20130101) G08G 1/0133 (20130101) G08G 1/096725 (20130101) Original (OR) Class G08G 1/096833 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Environmental Protection Agency (EPA)
| US 20220177853 | Ashton et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Wisconsin Alumni Research Foundation (Madison, Wisconsin) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Randolph Scott Ashton (Madison, Wisconsin); Gavin Thomas Knight (Madison, Wisconsin); Benjamin John Knudsen (Menomonee Falls, Wisconsin); Nisha Ramdas Iyer (Madison, Wisconsin); Carlos Marti-Figueroa (Madison, Wisconsin) |
| ABSTRACT | Described herein are methods, compositions, and kits for directed differentiation of human pluripotent stem cells, neuromesodermal progenitors, and neural stem cells into bioengineered elliptical neuroepithelial tissues and bioengineered neuroepithelial tubes that contain a single rosette of polarized neuroepithelial cells and have microscale cellular organization similar to that of an in vivo developing human neural tube. |
| FILED | Wednesday, December 08, 2021 |
| APPL NO | 17/545416 |
| CURRENT CPC | Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 27/3604 (20130101) A61L 27/3675 (20130101) A61L 27/3687 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0618 (20130101) C12N 5/0697 (20130101) Original (OR) Class C12N 2501/41 (20130101) C12N 2501/999 (20130101) C12N 2506/02 (20130101) C12N 2531/00 (20130101) C12N 2533/30 (20130101) C12N 2535/10 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
National Security Agency (NSA)
| US 20220182309 | Bataineh et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Hewlett Packard Enterprise Development LP (Houston, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Abdulla M. Bataineh (Vista, California); Edwin L. Froese (Burnaby British Columbia, Canada); Duncan Roweth (Bristol Avon, United Kingdom) |
| ABSTRACT | A switch is provided, which can receive a data communication at an edge of a network. The network may be made up of a plurality of switches. The switch may generate a flow channel based upon an identified source and destination for the data communication. The data communication can be routed across the plurality of switches based on minimizing a number of hops between a subset of the plurality of switches and in accordance with the flow channel. |
| FILED | Monday, March 23, 2020 |
| APPL NO | 17/594649 |
| CURRENT CPC | Transmission of Digital Information, e.g Telegraphic Communication H04L 45/122 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
U.S. State Government
| US 20220177389 | Chen et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Lamar University (Beaumont, Texas) |
| ASSIGNEE(S) | LAMAR UNIVERSITY, A COMPONENT OF THE TEXAS STATE UNIVERSITY SYSTEM, AN AGENCY OF THE STATE OF TEXAS (Beaumont, Texas) |
| INVENTOR(S) | Daniel H. Chen (Beaumont, Texas); Russel Buss (Beaumont, Texas); Dan P. Fernandes (Beaumont, Texas) |
| ABSTRACT | Disclosed is a boiler may that uses recycled carbon dioxide as a working fluid. Instead of releasing high-purity CO2 into the atmosphere, the bulk of the CO2 is utilized as the working fluid and the produced CO2 is captured and sent to a pipeline for utilization or storage. These systems will minimize heat loss and achieve essentially zero CO2 emission to the air. |
| FILED | Wednesday, January 26, 2022 |
| APPL NO | 17/585277 |
| CURRENT CPC | Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus B01J 6/00 (20130101) Acyclic or Carbocyclic Compounds C07C 4/025 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
United States Postal Service (USPS)
| US 20220180084 | Simpson |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | United States Postal Service (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ryan J. Simpson (Vienna, Virginia) |
| ABSTRACT | The present disclosure relates to a system and a method for extracting a computer readable code from a captured image of a mailpiece or parcel using downsampling and edge detection. The system can include a reader configured to capture an image of an item having a computer readable code positioned thereon and a processor in data communication with the reader. The processor can generate captured image data of the item including the computer readable code, downconvert the captured image data to generate a downconverted image data and detect an edge of the computer readable code. The processor can also identify a position of the computer readable code in the downconverted image data and store or process only the identified computer readable code. |
| FILED | Thursday, December 02, 2021 |
| APPL NO | 17/540801 |
| CURRENT CPC | Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers G06K 7/1413 (20130101) G06K 7/1443 (20130101) Original (OR) Class Image Data Processing or Generation, in General G06T 3/4023 (20130101) G06T 7/13 (20170101) G06T 7/73 (20170101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Government Rights Acknowledged
How To Use This Page
THE FEDINVENT PATENT APPLICATION DETAILS PAGE
Each week, FedInvent analyzes newly granted patents and published patent applications whose origins lead back to funding by the US Federal Government. The FedInvent Patent Details page is a companion to the weekly FedInvents Patents Report.
This week's information is published in the FedInvent Patents report for Thursday, June 09, 2022.
The FedInvent Weekly Patent Details Page contains a subset of patent information to provide a deeper dive into the week's taxpayer-funded patents to help the reader better understand where a patent fits in the federal innovation ecosphere.
HOW IS THE INFORMATION ORGANIZED?
Patents are organized by the funding agency. Within each group, the patents are organized in numeric order. A patent funded by more than one agency will appear in the section of each of the agencies that funded the research and development that resulted in the invention. This approach gives the reader a complete view of the department or agency activity for the week.
WHAT INFORMATION WILL I FIND?
THE PANEL
There is a panel for each patent that contains the patent number and the title of the patent. When you click the panel, it opens to reveal the following information:
FUNDED BY
The agencies that funded the grants, contracts, or other research agreements that resulted in the patent. FedInvent includes as much information on the source of the funding as possible. The information is presented in a hierarchy going from the Federal Department down to the agencies, subagencies, and offices that funded the work. Here are two examples:
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Army Research Office (ARO)
We do our best to provide detailed information about the funding. In some cases, the patent only reports limited information on the origins of the funding. FedInvents presents what it can confirm. We add the patents without the information required by the Bayh-Dole Act to our list of patents worthy of further investigation.
APPLICANT(S) and ASSIGNEES
FedInvent includes both the Applicants and the Assignees because having both provides more information about where the inventive work was done and by what organizations. Many organizations — universities, corporations, and federal agencies — standardize the Assignee/Owner information by the time a patent is granted. In the case of federal patents, many of the patents use the agency headquarters information for patent assignment.
Showing just the headquarters address would make Washington, DC the epicenter of all taxpayer-funded research and development. Providing both the applicant information and the assignee information provides a more accurate picture of where important taxpayer-funded innovation is happening in America. Here are two examples from two different patents:
APPLICANT: U.S. Army Research Laboratory, Adelphi, MD
ASSIGNEE: The United States of America as represented by the Secretary of the Army Washington, DC
APPLICANT: Optech Ventures, LLC (Torrance, California)
ASSIGNEE(S): The Regents of the University of California (Oakland, California); Optech Ventures, LLC (Torrance, California)
INVENTOR(S)
The inventors appear in the same order as they appear on the patent. FedInvents presents the names in first name/last name order because they are easier to read than the last name/first name order of the names on the USPTO patent documents.
ABSTRACT
The abstract is presented as it appears on the patent.
FILED
The date the patent application including the day of the week.
APPL NO
This is the patent application serial number. If you’d like to learn more about how application serial numbers work you can go to the Lists Page.
ART UNIT
Patent data includes the Art Unit where a patent was examined. (The Art Unit isn’t available for published patent applications.) The Art Unit provides insight into what group of patent examiners prosecuted the patent application and the subject matter that the examiners work on. For example:
3793 — Medical Instruments, Diagnostic Equipment, and Treatment Devices
You can learn more about ART UNITS on the FedInvent Patents Weekly panel called About Tech Center or you can find information on the FedInvent Lists Page.
CURRENT CPC
Current CPC provides a list of the Cooperative Patent Classification symbols assigned to the patent. These are the CPC symbols assigned at the time the patent was granted.
The FedInvent Project is a patent classification maximalist endeavor or put another way, we believe that the more you understand about patent classification the more you'll learn about the nature of the invention and the types of work that the federal government is funding.
The symbol presented in BOLD is the symbol identified as the "first" classification which is the most relevant classification on the patent. The date that follows the symbol is the date of the most recent revision to the art classed there.
- A61B 1/149 (20130101)
- A61B 1/71 (20130101)
- A61B 1/105 (20130101)
The CPC symbols match the classifications found on the PDF version of the patent. Over time, the classifications on the full text version of the patent change to reflect how USPTO organizes patent art to support its examiners. The two sets of CPCs don’t always match.
VIEW PATENT
As of June 2021, we include two ways to view a patent at USPTO. FedInvent provides a link to the Full-Text Version of the patent and a link to the PDF version of the patent.
HOW DO I FIND A SPECIFIC PATENT ON A PAGE?
You can use the Command F or Control F to find a specific patent you are interested in.
HOW DO I GET HERE?
You navigate to the details of a patent by clicking the information icon that follows a patent on the FedInvent Patents Weekly Report.
You can also reach this page using the weekly page link that looks like this:
https://wayfinder.digital/fedinvent/patents-2022/fedinvent-applications-20220609.html
Just update the date portion of the URL. Tuesdays for patents. Thursdays for pre-grant publication of patent applications.
Download a copy of the How To Use This Page